From sequence to function: Understanding of genetic risk factors for psoriasis and atopic dermatitis by Niehues, H.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/175295
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
FROM SEQUENCE TO FUNCTION:
Understanding of genetic risk factors 
for psoriasis and atopic dermatitis
FR
O
M
 SEQ
U
EN
C
E TO
 FU
N
CTIO
N
: U
nderstanding of genetic risk factors for psoriasis and atopic derm
atitis
H
anna N
iehues
Hanna Niehues
Graag nodig ik u uit voor de 
openbare verdediging van
 mijn proefschrift:
FROM SEQUENCE TO FUNCTION:
Understanding of genetic risk 
factors for psoriasis and
atopic dermatitis
De verdediging vindt plaats op 
 15 september om 12.30 uur 
in de Aula van de 
Radboud Universiteit Nijmegen, 
Comeniuslaan 2 te Nijmegen.
Aansluitend bent u van harte 
welkom op de receptie ter plaatse.
Hanna Niehues
Hanna.Niehues@radboudumc.nl
Paranimfen 
Diana Rodijk-Olthuis 
Diana.Rodijk-Olthuis@radboudumc.nl 
Ivonne van Vlijmen-Willems 
Ivonne.vanVlijmen-Willems@radboudumc.nl
UITNODIGING
FROM SEQUENCE TO FUNCTION:
Understanding of genetic risk factors  
for psoriasis and atopic dermatitis
Hanna Niehues
The research presented in this thesis was performed at the Department of Dermatology of the 
Radboud university medical center, Nijmegen, The Netherlands.
This research was funded by the Netherlands Organization for Health Research and Development 
(ZonMw).
Printing of this thesis was financially supported by the Radboud university medical center, 
Proefdiervrij, AnimalfreeResearch and Greiner Bio-One.
ISBN 
978-94-6295-696-4
Design/lay-out 
Bregje Jaspers, ProefschriftOntwerp.nl, Nijmegen 
Print 
ProefschiftMaken.nl, Nijmegen
© Hanna Niehues, 2017 
All rights are reserved. No part of this book may be reproduced, distributed, stored in a retrieval 
system, or transmitted in any form or by any means, without prior written permission of the author.
FROM SEQUENCE TO FUNCTION:
Understanding of genetic risk factors  
for psoriasis and atopic dermatitis
Proefschrift
ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken,
volgens besluit van het college van decanen
in het openbaar te verdedigen op
vrijdag 15 september 2017,
om 12.30 uur precies
door
Hanna Niehues
geboren op 5 november 1987
te Coesfeld (Duitsland)
Promotor
Prof. dr. J. Schalkwijk
Co-promotoren
Dr. P.L.J.M. Zeeuwen
Dr. E.H.J. van den Bogaard
Manuscriptcommissie
Prof. dr. I.J.M. de Vries (voorzitter)
Prof. dr. J.M.J. Kremer
Dr. C.M.P. Backendorf (Universiteit Leiden) 
 „So eine Arbeit wird eigentlich nie fertig, man muss sie für fertig erklären, wenn man 
nach der Zeit und den Umständen das Möglichste getan hat.“
 (Johann Wolfgang von Goethe)

Table of contents
Chapter 1 General introduction and thesis outline
PART I 
Keratinocyte models to test the effect of soluble disease-associated factors on 
epidermal formation and differentiation
Chapter 2  Antibiotics in cell culture: friend or foe? Suppression of keratinocyte 
growth and differentiation in monolayer cultures and 3D skin 
models. 
  Exp Dermatol. 2015 Dec;24(12):964-5
Chapter 3  Keratinocyte proliferation and differentiation upon IL-9 
stimulation: an explorative in vitro study. 
  Acta Derm Venereol. 2017 Jun 9;97(6):741-742 
Chapter 4  The “Alarmins” HMBG1 and IL-33 Downregulate Structural Skin  
Barrier Proteins and Impair Epidermal Growth. 
  Acta Derm Venereol. 2017 Mar 10;97(3):305-312
PART II
Filaggrin mutations and atopic dermatitis
Chapter 5  Epidermal equivalents of filaggrin null keratinocytes do not show 
impaired skin barrier function. 
  J Allergy Clin Immunol. 2017 Jun;139(6):1979-1981.e13
Chapter 6  Gram-positive anaerobe cocci are underrepresented in the 
microbiome of filaggrin-deficient human skin. 
  J Allergy Clin Immunol. 2017 Apr;139(4):1368-1371
 
 
11
29
31
43
57
77
79
99
PART III
Late Cornified Envelope 3B/C deletion (LCE3B/C-del) and psoriasis
Chapter 7  Late cornified envelope (LCE) proteins: distinct expression 
patterns of LCE2 and LCE3 members suggest nonredundant 
roles in human epidermis and other epithelia. 
  Br J Dermatol. 2016 Apr;174(4):795-802
Chapter 8  Psoriasis-associated Late Cornified Envelope (LCE) proteins 
have antibacterial activity
  J Invest Dermatol. 2017 Jun
Chapter 9 Summary
  General discussion and future outlook 
Chapter 10 List of references
Chapter 11 Nederlandse samenvatting
  Deutsche Zusammenfassung
Chapter 12 Curriculum vitae
  Dankwoord
  Portfolio
  List of publications
   Research data stewardship and accessibility  
according to the FAIR principles
  List of abbreviations 
131
133
153
181
185
197
223
229
235
237
247
249
251
253


General introduction and thesis outline
1
12
113
General introduction
The skin is one of the largest organs of the human body. It covers our body to keep the inside 
in and the outside out. The main functions of the skin are to maintain our body temperature, 
to be our touch sensing organ, minimize water loss and protect us against various kinds of 
pathogenic microbes and other environmental insults. Furthermore, it is the habitat of our skin 
microbiome and contributes to innate as well as adaptive immunity. To properly fulfill all its 
tasks, the composition, functioning and maintenance of all skin components have to be tightly 
regulated. For an extensive review of skin morphology, appendages and function I refer to an 
excellent textbook on this subject1.
In this introduction, I will briefly outline general epidermal stratification and differentiation and 
focus on the formation, functioning and malfunctioning of the epidermal barrier.
Epidermal structure and differentiation
The skin is composed of two main compartments, the dermis and the epidermis (Figure 1). The 
dermis largely consists of connective tissue and is connected to the overlying epidermis by the 
lamina basalis, or basal membrane. The epidermis is a keratinized stratified epithelium formed 
by the major population of skin resident cells, the keratinocytes. 
Figure 1. Human skin layers. 
The left panel schematically shows all different layers of the skin and the right panel shows these in a 
haematoxylin-eosin staining of in vivo normal human skin.
The epidermis is subdivided into several layers (“strata”), starting with the stratum basale at 
the bottom, where the epidermal stem cells are located that proliferate and thereby contribute 
to constant skin renewal. Solely this subset of keratinocytes is capable of cell division. After 
the “birth” of a new keratinocyte, its journey of differentiation and movement to the skin 
surface begins. During the movement towards the next epidermal layer, the stratum spinosum, 
keratinocytes switch the expression of their keratin protein profile from keratin 5 (K5) and 
K14 to a new subset of keratins, K1 and K10. These keratins contribute to cell stiffness and 
mechanical strength of this cell layer. From there, the keratinocytes are transiting to the stratum 
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granulosum (SG), the last viable layer of the epidermis. Like its name indicates, this layer is 
characterized by clearly visible keratohyalin granules within the keratinocytes. In this layer, the 
transition from living keratinocytes into terminally differentiated dead corneocytes that will form 
the uppermost epidermal layer, the stratum corneum (SC), takes place. Terminal differentiation 
leads to influx of calcium, which in turns activates transglutaminases (TGases) which will cross-
link the keratinocyte cell envelopes to form the highly insoluble cornified envelope (CE). Finally, 
at the end of this journey the corneocytes will be shed from our skin. The entire process from cell 
division to cell shedding takes about 30 days to complete.
There are a few proteins in the epidermis that make up the majority of structural proteins of 
the CE. First, involucrin (IVL), a 68kDa protein, is present in all types of stratified epithelia. In 
the epidermis, it is synthesized from the upper stratum spinosum upwards and is finally cross-
linked into the CE by TGases2. Next to its function as a structural CE protein it also functions 
as attachment side for the lipid bilayer in the SC3. The most prominent protein in the cornified 
epidermis is loricrin (LOR). Its size is 26kDa and it makes up about 70% of the total protein mass 
of the CE4. This insoluble protein is expressed in the SG and is also cross-linked into the CE by 
TGases, linking to additional loricrin protein or other proteins like involucrin or small-proline-rich 
repeat (SPPR) proteins5,6. Another structural late differentiation protein is filaggrin (FLG), whose 
name is derived from filament aggregating protein. This protein is synthesized in the SG as 
profilaggrin. At later stages during keratinocyte differentiation it is further cleaved into filaggrin 
monomers. Free filaggrin binds to keratin intermediates to form strong macrofibrils, thereby 
increasing cell stiffness and serving as anchor for cross-linking of late differentiation proteins 
into the CE7. Filaggrin belongs to the S100-like fused-type proteins, a group that also comprises 
the late differentiation proteins filaggrin-2, hornerin, trichohyalin and repetin8-11.
Another large group of keratinocyte-expressed proteins is the late cornified envelope (LCE) 
protein family, consisting of six subgroups, LCE1-6. LCE proteins are small-sized molecules (9-
12 kDa) of which the function is largely unknown. Mice studies suggest that their expression in 
the epidermis starts rather late in the differentiation cascade10 and that they are also cross-linked 
into the CE by TGases12. Despite their high sequence homology, mRNA expression patterns of 
the individual LCE subgroups appear different in the epidermis and other keratinized epithelia 
suggesting specific individual functions that remain to be elucidated13. 
In this thesis, I have focused my investigations on the LCE gene family and filaggrin. For this 
reason, I will give a general background on structural skin proteins and provide more detailed 
information on these genes and encoded proteins.
Genomics of the epidermal differentiation complex
The majority of structural genes described above are found in one locus on human chromosome 
1 (Chr.1q21). This cluster is called the epidermal differentiation complex (EDC) and comprises 
about two megabases (Mbp) of DNA. Basically, there are three clusters within this locus: (1) the 
CE precursors, (2) the S100 family and (3) the S100-like fused-type gene family (Figure 2). 
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Loricrin, involucrin and SPPR’s are the main precursors of the CE and share substantial sequence 
homology in their glutamine and lysine-rich amino and carboxy-terminal domains. There are ten 
SPRR genes, subdivided into four groups (SPRR1, 2, 3 and 4)6. These are characterized by 
high sequence homology and have been described to be most likely evolved from a common 
ancestral gene14. Within the group of CE precursors there is a large gene family, the late cornified 
envelope (LCE) genes, which comprise about 32kb of DNA. Initially, Zhao and Elder found the 
forerunner of this family in healthy and psoriatic skin, and called it XP58. Another alias for the LCE 
genes is late envelope protein (LEP) genes10. The in total eighteen LCE genes can be subdivided 
into six groups (LCE1, LCE2, LCE3, LCE4, LCE5 and LCE6) which each consist of one or more 
members. LCE proteins are highly homologous and are characterized by high cysteine content 
(Figure 3). Expression of the LCE genes is restricted to stratifying epithelia, including internal 
epithelia and the skin13,15. Within the LCE locus there are some non-LCE genes. Located between 
LCE1F and LCE4A, keratinocyte proline-rich protein (KPRP), a highly proline-rich protein is present 
which is expressed in stratified squamous epithelia16. 
Figure 2. The epidermal differentiation complex. 
Schematic overview of the different groups of keratinocyte-expressed proteins encoded within the EDC, with 
filaggrin and the eighteen LCE genes highlighted in red.
Directly neighbouring KPRP, a gene of unknown function, chromosome 1 open reading frame 68 
(c1orf68) is located. In transcriptome analysis, however, it has recently been found to be highly 
expressed in the skin17. Another poorly studied member of the EDC gene cluster is chromosome 
1 open reading frame 46 (c1orf46), which is positioned between LCE2D and LCE3A. It was found 
to be expressed in suprabasal epidermal keratinocytes, however specific expression patterns 
or protein function are yet unknown18. In between LCE3E and LCE5A there is one other non-LCE 
gene located and that is cysteine rich C-terminal 1 (CRCT1), which is also poorly characterized. 
Although LCE6A is annotated as an LCE gene, its sequence homology to the other 17 LCE genes 
is so low that it might be considered as a non-LCE gene within the LCE locus. The S100 family, 
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consisting of more than twenty members19,20 is split into two segments flanking the LCE region 
(Figure 2). Finally, the last group of genes to be distinguished within the EDC, is the group of 
S100-like fused type genes, which comprises well-known genes such as filaggrin and hornerin. 
Figure 3. Sequence alignment of the LCE proteins. 
The LCE proteins are subdivided into 6 groups (LCE1- 6, blue boxes) based on their sequence alignment. All LCE 
proteins contain several low complexity amino acid clusters (red lines indicate most abundant amino acids of these 
clusters). The amino acids are abbreviated as follows: Q, glutamine; P, proline; K, lysine; C, cysteine; G, glycine; S, 
serine; H, histidine; R, arginine. The alignment was conducted using the UniProt Clustal Omega tool at http://www.
uniprot.org/align/.
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Epidermal barrier 
Our skin is a two-way protection layer, it has an outside-in as well as inside-out barrier function. 
I will describe both by subdividing the epidermal barrier into three main shields of protection, 
namely the physical, chemical and microbial barrier (Figure 4).
Figure 4. Compartments of the epidermal barrier. 
The human epidermal barrier can be divided into four compartments, the physical, chemical, immunological 
and microbial barrier. The schemes show the most important cells, molecules or microorganisms that 
contribute to each particular barrier function.
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Physical barrier
The physical barrier is mainly located in the SC, the outer shield of the epidermis, which consists 
of about 15 to 20 stacked layers of corneocytes with intermediate lipid bilayers. This insoluble 
barrier withstands mechanical forces and prevents penetration of chemical or microbial 
substances to reach the more fragile underlying viable keratinocytes. Furthermore, it retains 
water and thereby protects us against so-called transepidermal water loss (TEWL)21 and keeps 
our skin hydrated.
Corneocytes
During terminal differentiation, viable keratinocytes transform into non-living corneocytes, a 
process called cornification. At the initiation of terminal differentiation, keratin filaments are tightly 
bundled by filaggrin protein, causing the cells to collapse and become typically flattened22. 
Meanwhile, TGase activity transforms the cells into a protein scaffolding cell envelope, the 
CE23. TGase activity will cross-link two proteins by formation of a peptide bond between their 
glutamine and lysine side chains. The main protein being cross-linked is loricrin, which is 
released from the keratohyalin granules together with filaggrin. Amongst others, loricrin is cross-
linked to involucrin24 and SPRR proteins25,26. Finally, this protein network of keratin filaments and 
late differentiation proteins replaces the cell membrane, forming the CE27.
After bundling of keratin filaments, filaggrin is released from the keratin scaffold. Thereafter it is no 
longer part of the cytoskeleton, but it still contributes to the epidermal barrier function. Filaggrin 
is proteolytically degraded into a pool of free amino acids including histidine and glutamine 
which are further converted to, respectively, urocanic acid (UCA) and 2-pyrrolidone-5-carboxylic 
acid (PCA). These so-called natural moisturizing factor (NMF) molecules are highly hygroscopic, 
thereby contributing to water retention of the epidermis.
The SC also forms the main barrier against UV radiation from sunlight. Solar UV-light is essential 
for vitamin-D production28, but UV exposure is also an important risk factor for developing skin 
cancer29. The dead corneocytes of the SC are the first shield against UV radiation to protect the 
underlying living keratinocytes. The corneocytes provide photoprotection by light reflectance 
and the lower situated melanocytes additionally provide photoprotection by transferring melanin 
to the keratinocytes30,31.
Lipids
The CE is not only formed by the corneocytes but the surrounding intercellular lipids are another 
important component. To secrete lipids, keratinocytes release lamellar bodies from the Golgi-
apparatus in the granular layer of the epidermis. These organelles are uniquely present in the 
epidermis. During cornification and upon certain cell signalling events, like increasing calcium 
concentrations, these lamellar bodies move towards and fuse with the plasma membrane to 
release its lipids into the intercellular space32. These are ceramides (50%), cholesterol (25%) 
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and fatty acids (15%) and they are metabolized and organized in a lamellar-like structure, also 
referred to as lateral-lipid organization33.
Metabolism of SC lipids also contributes to barrier function in another way. Glycerol derived from 
phospholipids and phospholipases serves as a water retention molecule to hydrate the SC, 
thereby preventing epidermal water loss and contributing to epidermal elasticity.
Cell adhesion molecules
Additionally, to the SC, the viable epidermis also contributes to the skin barrier function. 
Herein important cell adhesion molecules are present which form tight connections between 
keratinocytes. Adherens junctions mainly consist of cadherin proteins tightly connecting 
keratinocytes within the epidermis. Their membrane anchors reach the cell internal cytoskeleton, 
thereby drawing two neighbouring cells together34. Another cell-adhesion molecule in the 
epidermis that contributes to the integrity of the epidermal skin compartment is the desmosome. 
It is composed of the transmembrane glycoproteins desmoglein and desmocollin. Several 
isoforms of the desmosomal cadherins are expressed in different layers of the epidermis. For 
example, desmoglein-1 (Dsg-1) is expressed throughout all living layers, whereas Dsg-3 is only 
found in the lower viable keratinocytes35. To strengthen cell-cell contact they aggregate with 
intracellular keratin filaments of the keratinocytes34. Thereby, desmosomes tightly clamp cells 
together, or clamp cells to the underlying basal membrane. For the latter, the junction is formed 
by a so-called hemidesmosome (or half a desmosome)36. The next group of proteins described, 
the tight junction proteins, are directly linked to skin barrier function. Tight junctions are cell-cell 
contacts that connect neighbouring keratinocytes, thereby controlling the paracellular pathway 
of molecules through the epidermal tissue. These junctions are the main players in the inside-
out epidermal barrier function and are formed by several proteins including occludin, claudins, 
JAM-1 and zonula occludens-1 (ZO-1)37. All are expressed at specific layers of the epidermis, 
indicating the complexity of the barrier formation: Claudin-1 (Cldn-1), is expressed in all living 
cell layers, whereas Cldn-7 is almost absent in basal keratinocytes. ZO-1 and Cldn-4 proteins are 
expressed in the upper spinal layer and in the SG, and occluding (Ocln) and Cldn-3 are solely 
present in the SG38,39. These membrane-spanning proteins form adhesions between two cells, 
separating the intercellular spaces and withhold paracellular diffusion40.
Chemical barrier
In addition to the physical barrier, the skin also has chemical barrier properties, which will be 
described in the following paragraphs. 
Antimicrobial peptides
Being a surface tissue, the skin is exposed to loads of microbial and chemical stimuli. Our 
skin is equipped with so-called antimicrobial peptides (AMPs) to stay healthy and protect us 
against bacterial infection. AMPs are either constitutively expressed or may be induced when 
General introduction and thesis outline
20
required. Common features of AMPs are that they have a cationic charge, and consist of many 
hydrophobic amino acids to interact with the bacterial membrane41,42. The most well-known 
keratinocyte-derived AMPs are defensins, S100 proteins and the human cathelicidin LL-37. The 
latter is antimicrobial and can recruit T-cells mast cells, thereby providing antimicrobial defense 
in several ways43. LL-37 is highly effective against Streptococcus pyogenes. The human defensin 
family can be subdivided into two major groups, α- and β-defensins, the latter being expressed 
by keratinocytes. Expression levels vary between the four different β-defensins (hBD1-4). Their 
role in host defense is represented by their strong antimicrobial activity and their inducibility upon 
inflammatory skin conditions by immune stimulants or bacterial components44,45. Other skin 
AMPs are dermicidin46, S100 proteins47, SKALP/elafin48 and secretory leukoprotease inhibitor 
(SLPI)49. Most of these AMP’s are absent or expressed at low levels in skin homeostasis, and the 
physical skin barrier protects against pathogen invasion. In more vulnerable areas like the hair 
follicles (port d’entrée) these AMPs are expressed at higher levels to contribute to host defense50. 
ROS detoxifiers
Another part of the chemical skin barrier is provided by the release of reactive oxygen species 
(ROS). ROS are beneficial for antimicrobial killing and these are produced, amongst others, by 
keratinocytes. However, ROS may also be toxic molecules to the host, e.g. when produced by 
excessive UV radiation. For protection, the skin has two groups of defense molecules: enzymes 
that can scavenge ROS (e.g. superoxide dismutase, catalase, peroxidase) and low-molecular 
weight antioxidants that are able to directly detoxify ROS (e.g. Vitamin C and E, glutathione)51-53. 
Additionally, some other proteins in the epidermis contribute to ROS detoxification. Like it was 
shown that SPRR proteins are highly effective in quenching ROS in the CE, thereby contributing 
to epidermal protection54. 
Immunological barrier
Besides the physical and chemical barrier, the skin is also equipped with another defense 
mechanism, the cellular immunological barrier. Mainly in the dermis but also in the epidermis, cells 
and molecules from either the innate or adaptive immune system are present to protect against a 
large variety of pathogens. Innate reactions are typically rapid and poorly discriminating. Adaptive 
responses, in contrast, show a high degree of specificity as well as memory but need a protracted 
time for their development. Not only immune cells contribute to epidermal immune response, but 
also the keratinocytes themselves produce soluble immunomodulatory factors, like cytokines 
and chemokines that lead to or dampen inflammation, or can modulate T-cells and dendritic 
cells55. Several host-defense pathways are activated by toll-like receptors (TLRs) and pattern 
recognition receptors that are present on keratinocytes and immunocytes56-58. Another cellular 
component of the epidermal immune system are epidermal dendritic cells, or Langerhans cells. 
These antigen-presenting major histocompatibility complex II-positive cells make up about 2-4% 
of the epidermal cells. Their main function is to process and present antigens to T-lymphocytes, 
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but Langerhans cells can also modulate immune response by cytokine secretion59. Another 
group of epidermal defense cells are CD4+ or CD8+ memory T-cells, also including regulatory 
T-cells60. In the skin, there are twice as much T-cells present than in the bloodstream61! Some 
of these cells passage the skin whereas others constantly remain in the dermal or epidermal 
compartment and function as long-term tissue-resident memory cell population61,62. Dependent 
on the type of infection or inflammation, different subpopulations of CD4+ T-cell are present, 
e.g. T helper (Th) 1, Th2, Th17 or Th22 that in turn can activate more T-cells or induce antibody 
production by B-cells.
Microbial barrier 
The fourth skin barrier mechanism is non-human, and is formed by the commensal skin 
microbiome. The skin microbiome is defined as all microbiota that are present on our skin, 
mainly consisting of bacteria but also including fungi, viruses and mites. In and on our body, 
microbial cells outnumber human cells by a factor of 10. Colonization by commensal organisms 
is normally present on the skin surface and can be influenced by various factors including the 
human innate and adaptive immunity63. Generally, the four dominant phyla of bacteria residing 
on the skin are Actinobacteria, Proteobacteria, Firmicutes, and Bacteroidetes. The dominant 
types of bacteria that reside on the skin appear to be relatively stable, with the more rare, less 
abundant types of bacteria accounting for the variability. These dominant types of bacteria, 
primarily Staphylococcus, Propionibacterium, and Corynebacterium, are differentially abundant 
depending on the skin site64-67. Our skin commensals serve as a skin barrier as they dominate 
the skin microbiome and thereby prevent pathogenic microbes to take over. A well-balanced 
microbiome contributes to our health and it is shown that imbalance, with a shift towards 
pathogenic microbiota, is related to disease66. However, microbes participating in (inflammatory) 
diseases yet may not cause infections but infection might rather be a secondary phenomenon 
of disease68. The complex host–microbe and microbe–microbe interactions on the surface of 
human skin, in health and disease, are still not very well understood.
Genetically determined skin disorders
A large number of monogenic (Mendelian) skin disorders have been elucidated over the last 
decades by means of linkage analysis and positional cloning. Mutations in structural proteins 
(e.g. keratins or SC proteins) lead to blistering skin diseases or hyperkeratotic scaling conditions 
(ichthyoses). I will not discuss these diseases here in depth, as this is beyond the scope 
of my thesis. One example of such a monogenic disease is ichthyosis vulgaris, a condition 
characterized by dry flaky skin, which is caused by homozygosity or (more rarely) heterozygosity 
for null mutations in the filaggrin (FLG) gene69. This is one of the few monogenic diseases that 
has contributed to our insight of polygenic, complex diseases, and will be discussed hereafter. 
Most of these genodermatoses are rare diseases, as opposed to the polygenic, inflammatory 
skin diseases psoriasis and atopic dermatitis (AD). Although psoriasis and AD have a strong 
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genetic component, they are not caused by a single gene but were found to be associated with 
a large number of genetic risk factors. In the next two sections I aim to provide a background 
on psoriasis and AD, and discuss the known genetic polymorphisms in keratinocyte-expressed 
genes associated with these two diseases.
Atopic dermatitis and filaggrin null mutations
AD, or eczema, is a very common inflammatory skin disorder with a complex etiology. About 15-
20% of all children and approximately 1%-5% of all adults is affected and the prevalence is still 
increasing70. AD lesions are mainly located in the flexural lesions of the arms and legs and they 
appear as red and scaly skin which is often very itchy for the patient (Figure 5). Acute lesions 
of AD are characterized by T-helper 2 driven inflammation. Skin resident T-cells predominantly 
secrete interleukin-4 (IL-4) and IL-13, but also IL-5, IL-12 and interferon-γ (IFNγ) are present at 
high levels in the inflammatory milieu of the skin lesion71.
Figure 5. Atopic dermatitis. 
Lesional AD skin is characterized by erythema and vesicles. The skin can generally be affected all over the 
body (left) but the most prevalent sites are the flexural sites of the knees and elbows (middle). In children, 
the face is most often affected (right). 
Thirty years ago, filaggrin was already suggested to play a role in the genetically inherited skin 
disease, ichthyosis vulgaris72. Twenty years later, in 2006 two prevalent FLG mutations (R501X 
and 2282del4) were found to be the underlying genetic risk factors for ichthyosis vulgaris in 
West-European populations69. These mutations in the FLG gene lead to truncated, non-
functional protein and the absence of SG in ichthyosis vulgaris. Moreover, heterozygous FLG 
loss-of-function mutations have been discovered to also be a very strong genetic predisposing 
factor for AD73,74. Besides these two variants, which are the most common ones in the Western 
population, until today about fifty mutations within the FLG gene have been found that contribute 
to AD (Figure 6)75. Important to mention is that FLG mutations per se are not sufficient to develop 
AD, as these also frequently occur in the healthy population. Moreover, there are several other 
genetic variations linked to AD that encode proteins important in immune signalling, such as IL-4, 
IL-4RA and IL-1376. In the Western population about 30-40% of AD patients carry a FLG null allele, 
whereas this is found in about 8-10% of the general population73,77,78.
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Figure 6. FLG mutations. 
Variation of mutations in the European (upper panel) and Asian population (lower panel). These variants have 
been predicted to result in partial or complete loss of FLG protein and all lead to loss of protein function. The 
red arrow indicates the two mutations 2282del4 and R501X which are the most frequently occurring variants 
located at the N-terminus of the FLG gene. Figure adapted from Irvine et al.75 
Besides the (partial) loss of filaggrin protein, there are more defects in the epidermis of 
AD skin79. Histopathological hallmarks of AD skin are acanthosis (epidermal thickening), 
intraepidermal oedema (spongiosis) and T-cell infiltration into the dermis and epidermis. Late 
differentiation proteins like filaggrin, loricrin and involucrin are expressed at lower levels than in 
healthy epidermis80 whereas proliferation of keratinocytes is highly induced. The decrease of 
the epidermal differentiation proteins is due to the Th2-cytokine milieu present in AD lesional 
skin and is irrespective of the genotype-dependent FLG expression. Many studies have also 
showed decreased expression of tight junction proteins81-83 and abnormal ceramide and general 
lipid composition and organization84,85. Collectively, these abnormalities are considered to be 
responsible for the impaired barrier function of AD skin.
AD pathogenesis is also known to have a microbial component. More than 90% of all chronic AD 
patients are carriers of Staphylococcus aureus (S. aureus)86,87. Besides their increased numbers 
within AD lesions, it was found that colonization of this microbe is also elevated in unaffected 
skin and the nasal cavity of these patients. S. aureus can release toxins that act as so-called 
superantigens and these can stimulate local inflammation and therefore contribute to disease 
severity. More recent studies have shown that there are shifts in the microbiome composition 
between AD patients and healthy controls, and that disease status and epidermal barrier 
function are linked to specific bacterial profiles67,88,89. However, the exact cause for shifts in the 
AD microbiome and the ensuing host-microbe interactions still needs to be unravelled.
General introduction and thesis outline
24
Psoriasis and the LCE3B/C deletion
Psoriasis is a common chronic inflammatory disease affecting about 1-2% of today’s Western 
population90. Phenotypically, psoriasis is characterized by sharply demarcated plaques with white 
scaling predominantly located at the knees and outer elbows and the scalp, although it can also affect 
other areas of the body (Figure 7). About 10-30% of all patients additionally develop psoriatic arthritis91.
Figure 7. Psoriasis. 
Lesional psoriatic skin shows sharply demarcated red and scaly plaques that can occur all over the body 
(left). The most often affected body sites are the extensor site of the knees and elbows (middle) and the 
scalp (right).
Lesional psoriasis skin has several histological features. The epidermis is thickened (acanthosis), 
caused by abnormal increase in keratinocyte turnover. Normally, it takes about 30 days to reach 
the skin surface for a keratinocyte starting its journey in the basal layer. In psoriasis, this process 
takes about 6-8 days. Scaling is caused by premature keratinocyte differentiation and incomplete 
cornification of the keratinocytes, which results in parakeratosis: the retention of nuclei in the cells of 
the SC. The T-cell infiltrate in the dermis and epidermis is another typical feature of a psoriatic lesion. 
These cells are mainly CD4+ Th-cells and CD8+ cytotoxic T-cells. In psoriasis Th1, Th17 and Th22 
cells are involved, leading to a cytokine milieu of IFNγ, TNFα, IL-17, IL-22 and IL-2392.
The pathogenesis of psoriasis is complex and exact mechanisms of disease onset and manifestation 
remain unknown. However, it is known that psoriasis cannot be attributed to a single risk factor or 
insult but is likely caused by the interaction of environmental and genetic factors. Although psoriasis 
has been regarded as an (auto) immune disease for a long time, more and more evidence points to 
a combined role for innate and adaptive immunity and tissue specific epidermal factors. 
Besides the genetic risk factors for psoriasis, other non-specific triggers can initiate psoriasis 
onset. Examples are skin trauma, chemical irritation or microbial infection. It has been shown that 
exacerbation of psoriasis often follows streptococcal throat infection93,94. 
Many studies have shown that psoriasis has a substantial genetic basis95-97. About 33% of all 
patients with psoriasis report a positive family history98. Moreover, twin studies have shown that 
psoriasis risk is at least twice as high among monozygotic twins compared to dizygotic twins99. 
The first discovered, strongest and most replicated genetic variant is the presence of the major 
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histocompatibility gene HLA-C*06:02 on chromosome 6p21.3100, implicating a major role for 
the adaptive immune system in psoriasis pathophysiology. During the last years, genome wide 
association studies have identified additional psoriasis risk gene loci (>60). Polymorphisms, 
like copy number variation of the DEFB4 gene on chromosome 8p23.1101 and single nucleotide 
polymorphisms (SNPs) in genes related to the innate or adaptive immune system have been 
found: IL12B, IL23A, TNFAIP3, TNIP1, REL, NFKBIA, IL4 and IL13102.
In addition to the aforementioned risk factors, there is one widely replicated risk factor that I will 
discuss in more detail here. This involves the deletion of two LCE genes (LCE3B and LCE3C), further 
referred to as LCE3B/C-del (Figure 8). In a case control study comprising more than 1400 psoriasis 
patients from different European countries, the deletion of a 32.2 kB segment on chromosome 
1q21, comprising LCE3B and LCE3C, was found to be present at higher frequency in the diseased 
group compared to the controls (OR = 1.3-1.5)103,104. LCE3B/C-del has a population attributable 
risk of 23% indicating that this mutation explains a sizable proportion of the genetic contribution. 
The association of the LCE3B/C-del and psoriasis has been replicated in several cohorts with 
different ethnic backgrounds105-109. The deletion of LCE3B/C can either be heterozygous (indicated 
as LCE3B/C wt/del) or homozygous (indicated as LCE3B/C del/del). Recent studies have shown 
that the deletion is a derived state and that the ancestral chromosome contained the LCE3B and 3C 
genes110,111. The original wild type (wt) genotype is referred to as LCE3B/C wt/wt. Interestingly, the 
frequency of the LCE3B/C risk allele is higher than the wild type allele in most populations (only 10% 
carries the wt/wt genotype in the Western population). LCE3B/C-del is a rather ancient mutation, 
whose frequency has increased particularly in out-of-Africa populations, possibly as a result of 
balancing selection110,111. The deletion is not present in non-human primates or Neanderthals, but 
is present in Denisovans, and may have arisen more than 50.000 years ago.
Figure 8. LCE3B/C deletion. 
Illustration of the wild type genotype of the LCE3 region and the deletion genotype where 32kB of DNA is 
lost comprising the two genes, LCE3B and LCE3C. The LCE3B/C deletion can either occur on one allele 
(heterozygous deletion) or on both alleles (homozygous deletion).
General introduction and thesis outline
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Keratinocyte culture models
Experimental skin research relies on in vitro keratinocyte culture models as not all experiments 
can be performed on human subjects or animal models. For decades, monolayer keratinocyte 
cultures were the main technique to work with in dermatological research. Cells, varying from 
primary adult or foreskin keratinocytes to different types of keratinocyte cell lines have been used. 
Simplicity, high-throughput and reproducibility are major advantages of monolayer keratinocyte 
cultures and this is therefore a valuable model to use. However, many features of a fully stratified 
epidermis are lacking in this model. To study cell-cell interactions, regulation of proliferation and 
differentiation, wound healing, skin barrier function and skin-microbiome interactions, models 
are required that better resemble the natural architecture and functions of the skin. Therefore, 
various three-dimensional (3D) skin models have been developed during the last years112-114. 
Models vary from keratinocyte-only, to whole-skin models and can also include other cells 
than keratinocytes, like fibroblasts, melanocytes, immune cells or others80,115-123. In the studies 
performed for this thesis, keratinocyte-only 3D epidermal equivalents were used in addition to 
the conventional keratinocyte monolayers. Full stratification and cornification make this model 
very useful for differentiation and functional barrier analyses. Moreover, the possibility to use 
genetically defined keratinocytes of diverse donors makes this an elegant model to functionally 
study the effects of disease-specific gene polymorphisms on epidermal structure and function.
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Thesis aim and outline
The general aim of my thesis is to use in vitro reconstructed skin models for normal and diseased 
skin to study pathogenetic factors of common skin diseases. More specifically, as described in 
part I, I have optimized the 3D human epidermal equivalent model and used it to study the role 
of disease-associated cytokines; in part II and III, which comprise the most challenging and 
exciting investigations, I have studied the functional consequences of genetic polymorphisms in 
keratinocyte expressed proteins that contribute to the risk of AD and psoriasis.
For experimental dermatological research, the use of keratinocyte models is the gold standard. 
In the first experimental part of my thesis I have described the optimization of our primary 
keratinocyte culture model. To prevent infection and increase experimental success, the use of 
antibiotics has become common practice. To address their effect on keratinocyte proliferation 
and differentiation, we have tested antibiotics in monolayer and 3D keratinocyte cultures and 
evaluated cell behaviour, morphology and gene/protein expression (Chapter 2). Next, we have 
tested the effect of soluble factors on differentiation and epidermal structure, which have been 
described to be important players in AD. We have studied whether IL-9 (Chapter 3) and high-
mobility group 1 protein (HMGB1) and IL-33 (Chapter 4) affect the expression of structural 
proteins in the epidermis under normal and AD-like conditions. 
The third part aimed to address the question how filaggrin mutations are related to AD disease 
phenotype. FLG loss-of-function mutations are causative for ichthyosis vulgaris and strongly 
linked to AD. However, the exact relation between protein loss and disease onset or disease 
mechanism is still unknown. Here we investigated if loss of filaggrin has any consequences for 
skin barrier function (Chapter 5) and/or cutaneous microbiome alterations (Chapter 6).
The final studies of this thesis focused on the late cornified envelope proteins, a protein family of 
which it is known that a mutation in this locus, LCE3B/C-del, is associated with psoriasis. We first 
investigated the expression of this family of structural keratinocyte proteins in the epidermis and 
other epithelia (Chapter 7). Next, we analysed the impact of the LCE3B/C deletion in the skin 
concerning gene expression of LCE family members and other keratinocyte expressed genes. 
Additionally, we studied whether members of the LCE3 family are involved in the physical or 
antimicrobial skin barrier function (Chapter 8).
In the final chapter of this thesis, the results of all presented studies are summarized and 
discussed and future perspectives are outlined (Chapter 9).
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Abstract
Normal human keratinocytes (NHKs) are widely used in the field of basic research, and 
conventional monolayer cultures have been a modality for almost 30 years. One common trade 
in the standard protocols is the use of antibiotics in the culture medium to reduce infection 
rates. Protocols have been optimized over the last decades regarding type of medium, 
supplements, Ca2+ levels and pH124,125. In contrast, few studies have investigated the effect of 
the most commonly used antibiotics: gentamycin (genta) and the combination of penicillin and 
streptomycin (pen-strep) on keratinocyte growth and differentiation126. Instead, focus has been 
directed at cytotoxicity of topically used antiseptics and antibiotics in the context of burn wounds, 
allograft and wound healing127,128. In embryonic stem cell cultures, however, it is known that genta 
and pen-strep have a capacity to reduce growth rate and differentiation129. In our laboratory, we 
have been optimizing cell culture conditions for both conventional submerged cultures and 3D 
human epidermal equivalents (HEEs), and we now conclude that antibiotics should be omitted 
whenever possible to achieve optimal culture conditions and reproducible results.
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Question addressed
We aimed to evaluate the effects of commonly used antibiotics on keratinocyte growth and 
differentiation in both conventional cultures and HEE development.
Experimental design
We herein examined the effects of genta and pen-strep on conventional NHK monolayer cultures 
by evaluating cell viability, cell culture confluence rates and keratinocyte gene expression levels.
Epidermal morphology of HEEs was evaluated by haematoxylin and eosin staining. For detailed 
methods, see Supplemental Methods.
Materials and Methods
Primary keratinocyte isolation 
Primary NHKs were obtained from skin explants after abdominoplasty. Isolation and cell culture 
were performed as previously described130.
Submerged keratinocyte culture
Keratinocytes were cultured in 24-wells plates using keratinocyte growth medium (Lonza) and 
differentiated by depletion of growth factors, as previously described131. During the entire cell 
culture, the medium was either supplemented with penicillin/streptomycin (Gibco), gentamycin 
(Lonza) or was left antibiotics free. Cells were harvested for RNA isolation from day 3 of 
proliferation until 48 hours after 100% confluency was reached.
Click-iT EdU cell proliferation assay
Keratinocytes on 24-well coverslips (Thermo Scientific) were supplied with EdU in keratinocyte 
growth medium for 1 hour at different time points of submerged cell culture to allow incorporation 
into newly synthesised DNA during S-phase of cell cycle. Staining of EdU was performed with 
a Click-it EdU kit (Life Technologies) using an Alexa-Fluor-594 label and it was combined with 
4',6-diamidino-2-fenylindool (DAPI) staining of all nuclei.
Human epidermal equivalent development
Normal human keratinocytes (1x105) were seeded onto microporous membrane of polycarbonate 
culture inserts (Thincert, Greiner bio-one) in proliferation medium (CellnTec, CnT-Prime) After 2 
days the medium was changed to differentiation medium (CellnTec, 3D barrier) complemented 
with DMEM (Gibco). On day 3 the HEEs were exposed to the air–liquid interface to induce 
differentiation and stratification. The medium was refreshed every other day until harvesting on 
day 8. During the entire culture period the medium was supplemented with either pen-strep 
(Gibco), gentamycin (Lonza) or left unhampered.
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Histology 
HSEs were fixed in 4% buffered formalin and processed for routine histology. 6 µm paraffin 
sections were stained with haematoxylin and eosin. 
Immunohistochemistry
Indirect immunoperoxidase technique with avidin-biotin complex enhancement (Vectastain 
Laboratories) was used to analyse epidermal differentiation. Antibodies against filaggrin (1:200; 
NCL-FLG, Novocastra), loricrin (1:500; BabCO, Covance), and keratin 10 (1:100 DE-K10, 
Eurodiagnostics) were used and detected with 3-amino-9-ethylcarbazole (AEC).
Gene expression analyses
RNA was isolated according to manufacturer’s recommendation (Favorgen) while cDNA synthesis 
and qPCR analysis was performed according to manufactures recommendation (Biorad). Target 
gene expression was normalized to the expression of the house keeping gene human acidic 
ribosomal phosphoprotein P0 (RPLP0) and relative expression levels were calculated by the ΔΔCt 
method according to Livak et al132. Primer sequences are depicted in Supplemental Table 1. 
Results
Antibiotics suppress keratinocyte proliferation and differentiation 
To study the effect of pen-strep and genta on keratinocyte proliferation, we cultured keratinocytes 
and determined the NHK confluency in time. Pen-strep significantly stalled the proliferation 
during the first phase (days 3–6) of the culture period (Figure 1a, open squares). Genta (closed 
squares) showed an intermediate inhibitory effect with significantly reduced cell confluency at 
day 5 of the culture period as compared to the antibiotic-free NHK cultures (closed circles). EdU 
incorporation into newly synthesized DNA during the S-phase of dividing cells was reduced in 
cultures with pen-strep or genta (Supplemental Figure 1a, b). In these proliferating cultures, we 
found no differences in Ki67, filaggrin (FLG), keratin 10 (KRT10) or KRT16 mRNA expression 
levels due to pen-strep or genta (Supplemental Figure 2a). However, expression of the terminal 
differentiation genes, FLG and loricrin (LOR), was nearly completely inhibited by pen-strep and 
genta after 24 and 48 h of differentiation. Expression of the early differentiation marker keratin 
10 (KRT10) was unaffected by antibiotic use (Figure 1b). Similarly, no statistically significant 
differences were found for Ki67, KRT16, involucrin (IVL), transglutaminase 1 (TGM-1) and late 
cornified envelope 1 (LCE1) expression (Supplemental Figure 2b). 
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Figure 1. Growth rate and differentiation of keratinocytes are affected by antibiotics. 
(a) Proliferation rate of submerged cultured NHKs (three different donors) influenced by pen-strep or 
gentamycin as compared to antibiotic-free cultures (control). (b) mRNA expression of terminal differentiation 
genes, LOR and FLG, in NHKs during keratinocyte differentiation for 24 h and 48 h after 100% confluency is 
reached (indicated as 0 h). N=3 donors, *P < 0.05.
Development of a fully differentiated epidermis fails when using antibiotics.
The attachment of keratinocytes after seeding, their proliferation and subsequent formation of a 
monolayer prior to air exposure are vital in the development of fully differentiated and stratified 
HEEs. Due to the profound effects on NHK growth, we postulated that the antibiotics would have 
similar effects in 3D skin cultures thereby leading to disturbed epidermal morphogenesis during 
the HEE development. Antibiotic-free HEEs showed a multi-layered and fully differentiated 
epidermis (Figure 2, control). Pen-strep severely impaired epidermal development as shown by the 
almost total absence of epidermis in donor 3 (95% reduction in epidermal thickness). Epidermal 
thickness was also reduced in HEEs generated with NHKs from donor 1 (65% reduction) and 
donor 2 (75% reduction). The absence of a stratum granulosum and stratum corneum in HEEs 
cultured with pen-strep indicates the disturbed epidermal differentiation as shown by the lack 
of protein expression of early (keratin 10) and late (filaggrin and loricrin) differentiation markers 
(Supplemental Figure 3). Genta also interfered with normal HEE development as indicated by the 
randomly distributed cells and complete lack of stratification (Figure 2b). Notably, the addition of 
pen-strep during the final days of the HEE culture (from day 5 of the air–liquid interface culture 
onwards) did not alter the epidermal morphology (Supplemental Figure 4).
(a)
(b)
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Figure 2. Pen-strep severely affects epidermal morphology in epidermal equivalents. 
(a) Three keratinocyte donors (D1, D2 and D3) were cultured with a combination of penicillin and streptomycin 
(pen-strep) in the culture medium or cultured free of antibiotics (control). (b) Representative picture of N=2 
keratinocyte donors treated with gentamycin (genta) or cultured free of antibiotics (control). After 8 days of 
air–liquid interface culture, the HEEs were harvested, processed and stained with haematoxylin and eosin. 
Experiment was performed in quadruplicate and repeated twice. Scale bar = 100 µm.
(a)
(b)
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Discussion
In this study, we have shown a strong negative effect of commonly used antibiotics on NHK 
growth and differentiation in conventional NHK cultures, with an even more pronounced impact 
on HEE cultures. Although the conventional submerged NHK cultures do reach 100% confluency, 
albeit a few days later than antibiotic-free NHK cultures, and their gene expression is not altered 
in the proliferating phase, we strongly suggest to avoid antibiotics as the induction of epidermal 
differentiation in these cultures was hampered due to pen-strep and genta. As pen-strep did 
not alter the HEE morphology when added during the last days of culture, the profound effects 
on HEE development are most likely caused by growth inhibition during the first days of the 
culture period, where optimal cell adhesion and proliferation is a necessity for proper monolayer 
formation prior to lifting the HEEs to the air–liquid interface. However, as we found epidermal 
differentiation defects in both our submerged cultures and HEEs by pen-strep and genta, 
these antibiotics may also directly interfere with the epidermal differentiation program leading 
to cessation of stratification. Already in 1996, a review on the prophylactic use of antibiotics in 
cell culture summarized the inhibition of  protein biosynthesis and morphological changes by 
aminoglycosides (e.g. streptomycin) and other adverse effects of commonly used antibiotics 
on various cell cultures133. In addition, minoglycosides are known to affect cells from both the 
kidney and cochlea in vivo134. Facing methodological problems in the laboratory when culturing 
keratinocytes, one should consider the use of antibiotics as a potential culprit. Influencing 
some of the keystone biological hallmarks of cell biology gives rise to the question whether 
the common use of antibiotics might do more harm than good and hence should be avoided 
whenever possible. 
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Supplemental Figures
Supplemental Figure 1. Lower proliferation rate of keratinocytes by antibiotics. 
(a) The number of proliferating cells represented by EdU positive cells (red) in relation to the total number 
of cells represented with DAPI (blue) upon treatment with pen-strep or genta, 4 days after seeding. (b) 
Quantification of the percentage of EdU positive cells. Scale bar = 100 µm, N=2 -3 donors.
(a)
(b)
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Supplemental Figure 2. Gene expression of keratinocyte proliferation and differentiation markers 
influenced by antibiotics. 
(a) mRNA expression of proliferation (Ki67), differentiation (FLG, KRT10) and keratinocyte activation 
(KRT16) markers during the proliferation phase. (b) mRNA expression of Ki67, IVL, TGM-1 and LCE1A during 
keratinocyte differentiation for 24h and 48h after 100% confluency is reached (indicated as 0h). 
(a)
(b)
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Supplemental Figure 3. Disturbed epidermal differentiation protein expression by pen-strep. 
Paraffin sections were stained for the early (Keratin 10, K10) and late differentiation markers (Filaggrin, FLG 
and Loricrin, LOR). 3D epidermal equivalents cultured in presence of pen-strep are compared to antibiotics 
free control equivalents. Scale bar = 100 µm, N=3 donors.
Supplemental Figure 4. Epidermal morphology of HSE cultures treated with pen-strep. 
At day 5 or culture at the air-liquid interface, HSEs were switched from antibiotic free to pen-strep.  From 
day 5 till day 8 cultures were supplemented with pen-strep and harvested on day 8. Paraffin sections were 
stained with haematoxylin & eosin. Scale bar = 100 µm
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Supplemental Tables
Supplemental Table 1: Primer sequences of all genes examined by real-time quantitative 
polymerase chain reaction
HUGO 
gene 
symbol
Description of  
gene/protein Forward primer Reverse primer
KRT10 Keratin 10, KRT10 tggttcaatgaaaagagcaagga gggattgtttcaaggccagtt
KRT16 Keratin 16, KRT16 gatcattgcggccaccat tgctcatacttggtcctgaagtca
MKI67 Ki-67, Ki67 aaaccaacaaagaggaacacaaatt gtctggagcgcagggatattc
IVL Involucrin, IVL acttatttcgggtccgctaggt gagacatgtagagggacagagtcaag
TGM1 Transglutaminase 1, TGM1 cccccgcaatgagatctaca atcctcatggtccacgtacaca
LOR Loricrin, LOR aggttaagacatgaaggatttgcaa ggcaccgatgggcttagag
FLG Filaggrin, FLG acttcactgagtttcttctgatggtatt tccagacttgagggtctttttctg
LCE1A Late cornified envelope 1A, 
LCE1A
tgcaagagtggctgagatgc agacaacacagttggtgtcagg
RPLP0 Ribosomal phosphoprotein 
P0, RPLP0
caccattgaaatcctgagtgatgt tgaccagcccaaaggagaag
Niehues H, Smits JPH, Rodijk-Olthuis D, Schalkwijk J and van den Bogaard EH
Affiliations
Department of Dermatology, Radboud Institute for Molecular Life Sciences, Radboud university 
medical center, Nijmegen, The Netherlands
Published in:
Acta Derm Venereol. 2017 Jun 9;97(6):741-742 
Keratinocyte proliferation and 
differentiation upon IL-9 stimulation: 
an explorative in vitro study
3
44
345
Background
Recent studies have indicated the significance of Th9 cells in a variety of inflammatory and 
allergy-related diseases (recently reviewed by Kaplan et al.135). Th9 cells are a distinct subset of 
CD4+ T cells present in the skin that secrete IL-9136-138. IL-9 is transiently expressed by skin tropic 
and skin resident Th9 cells to regulate the production of inflammatory cytokines139. IL-9 is like 
IL-4 associated with predominantly type 2 immune responses, and aberrant IL-9 expression or 
signalling in skin is implicated in allergic contact dermatitis (ACD)140, atopic dermatitis (AD)141,142, 
and psoriasis139,143. Targeting of IL-9 or its receptor may therefore be an interesting new therapeutic 
avenue to be explored. Although the IL-9 receptor (IL9R) is expressed by immune cells as well 
as epithelial cells  144, the majority of research focuses on the Th9/IL-9 axis in immune cells. 
Recent in vitro studies, however, showed the regulation of IL9R expression in keratinocytes by 
IL-4145 and increased IL9R expression in basal keratinocytes of psoriatic lesions143. Furthermore, 
IL-9 increased IL-8 (CXCL8) and VEGF secretion by keratinocytes in vitro140,141. The effects of IL-9 
on human keratinocytes with regard to epidermal proliferation, differentiation and host defence 
are still poorly understood, yet vital to explore the potential pathogenic role of the Th9/IL-9 axis 
in mediating skin inflammation. We here examined the effects of IL-9 on epidermal morphology, 
proliferation, differentiation and host defence, we studied cytokine-mediated regulation of IL9R 
expression on keratinocytes, and we investigated the potential additive or synergistic effects by 
IL-9 in Th2-cytokine mediated epidermal responses. 
Material and Methods 
Primary keratinocyte culture 
Primary human keratinocytes were obtained from skin derived from patients undergoing 
abdominal skin reconstruction. Isolation and cell culture was performed as described earlier146. 
3D human epidermal equivalent (HEE) culture
Primary human keratinocytes were seeded into a transwell system (Greiner Bio-One, 0.4um pore 
size) in PCT epidermal keratinocyte medium (CellNTec) at a density of 100.000 cells per insert. 
After 2 days medium was changed to 3D barrier/DMEM medium (60:40 ratio). At day three the 
constructs were lifted to the air-liquid interface for another 10 days; the medium was changed 
every other day. For details see Niehues et al147. HEEs were stimulated with cytokines from day 
5 till day 8 of the air-liquid interface at depicted concentrations and harvested at day 8 for further 
analysis. Cytokines were all purchased from Preprotech. 
Immunohistochemistry
HEEs were fixed in 4% buffered formalin solution, processed and embedded in paraffin. 6 µm 
sections were stained with haematoxylin and eosin or processed for immunohistochemistry using 
an indirect immunoperoxidase technique with avidin-biotin complex enhancement (Vectastain 
Laboratories). For antibodies and dilutions see Supplemental Table 1. See Supplemental Figure 
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7 for isotype control staining’s of all used antibodies. Images of immunohistochemical staining 
were taken using the Axiokop 2 MOT microscope (Zeiss) at a magnification of ×40, Axiocam 
MRc5 digital camera and AxioVision software rel. 4.8 (Zeiss).
Quantitative real-time PCR
RNA was isolated using an RNA isolation kit (Favorgen) followed by DNase treatment of 1 µg 
of RNA. First-strand cDNA was generated with the iScriptTM Reverse Transcriptase kit (Biorad) 
and the reverse transcriptase reaction products were used for quantitative real-time PCR 
amplification which was performed with the MyiQ Single-Colour Real-Time Detection System for 
quantification with Sybr Green and melting curve analysis (BioRad, Hercules, California). Primers 
(Supplemental Table 2) were designed using PRIMER EXPRESS 1.0 software package (Applied 
Biosystems, Foster City, CA, USA) and the primers were designed to produce an amplicon 
length between 50 and 200 base pairs. Primes were produced by Biolegio (Nijmegen, The 
Netherlands). Primer validation, PCR amplification conditions, and calculation of relative mRNA 
expression was performed as previously described148. The qPCR program used contained the 
following steps: 2 min at 50°C and 10 min at 90°C followed by 40 cycles of 15 s at 95°C and 1 min 
at 60°C, with data collection during the last 30 s. mRNA expression levels were normalized using 
the household gene RPLP0 and relative quantities were calculated according to the method of 
Livak and Schmittgen132.
Statistics
Data are depicted as mean ± SD of at least three biological replicates. Statistical analysis of 
qPCR data was performed on ΔCt values using commercially available software (IBM, SPSS 
Statistics 22). One-way analysis of variance, followed by Bonferroni post hoc testing (in case of 
more than 2 groups), and two-sided paired t-tests were performed (comparison of two groups). 
P < 0.05 was considered statistically significant. 
Results
We first tested a dose range of IL-9 on differentiating submerged keratinocyte monolayer cultures 
and did not observe an effect on cell morphology and viability, even at the highest concentration 
of 500 ng/ml (data not shown). For further in-depth analysis of keratinocyte proliferation and 
differentiation, HEEs were exposed to 50 ng/mL of human recombinant IL-9, being a biologically 
relevant concentration as shown by the induction of CXCL8 expression143 (Supplemental Figure 
1). After 72 hours of IL-9 stimulation, HEEs showed normal epidermal morphology with a 
fully stratified epidermis and a well-developed stratum corneum (Figure 1a). The number of 
proliferating cells, measured with Ki67 staining, and the epidermal thickness was similar to that 
of control HEEs (Figure 1a, Supplemental Figure 2). Next, we analysed the expression of the 
major epidermal differentiation proteins, keratin 10 (K10), involucrin (IVL), filaggrin (FLG) and 
loricrin (LOR) (Figure 1b). For all markers, IL-9 did not alter protein localisation or expression 
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levels, nor did it change the expression of epidermal differentiation genes (Supplemental Figure 
3). Also, marker expression for keratinocyte activation or host defence, namely keratin 16 (K16) 
and SKALP remained unaffected. Human beta defensin 2 (hBD2) is absent in unstimulated 
HEEs and is also not induced by IL-9 (Figure 1c). This in contrast to the classical Th2 cytokines, 
IL-4 and IL-13 which downregulated FLG, LOR and IVL expression (Supplemental Figure 4a) and 
induced K16 and SKALP expression (Supplemental Figure 4b). 
Figure 1. Normal epidermal proliferation and differentiation upon IL-9 stimulation. 
HEEs were stimulated with IL-9 [50 ng/mL) for 72 hours and stained for (a) Haematoxylin Eosin (HE) and 
Ki67 protein by immunohistochemistry. Immunohistochemistry of (b) filaggrin (FLG), involucrin (IVL), loricrin 
(LOR) and keratin 10 (K10), and (c) Keratin 16 (K16), SKALP and human beta defensin-2 (hBD2). Images are 
representative of N=3 keratinocyte donors. Scale bar=100 µm.
(a)
(b)
(c)
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Figure 2. No effects of IL-9 on HEEs upon induced expression levels of IL9R. 
(a) IL9R mRNA expression of submerged keratinocytes stimulated for 48h with single cytokines or mixes 
thereof:  Th1: IL-1a [30 ng/mL], TNF-α [30 ng/mL], IFN-γ [500 U/mL], Th2: IL-4 [50 ng/mL], IL-13 [50 ng/mL), 
Th17: IL-17 [30 ng/mL], IL-22 [30 ng/mL). Bars represent mean+/-SD, N=3 keratinocyte donors, * P<0.05. 
mRNA expression analysis of (b) IL9R and (c) epidermal differentiation or pro-inflammatory genes of HEEs 
stimulated with IFN-γ [500 U/mL) for 6 hours or in combination with IL-9 [50 ng/mL) for 72 hours. Bars 
represent mean +/-SD, N=3 keratinocyte donors, * P<0.05. (d) Immunohistochemistry of Ki67, keratin 10 
(K10), involucrin (IVL), loricrin (LOR), filaggrin (FLG), SKALP and human beta defensin-2 (hBD2). HEEs were 
stimulated with IFN-γ [500 U/mL) alone for 6 hours or subsequently stimulated with IL-9 [50 ng/mL) for 72 
hours. Images are representative of N=4 keratinocyte donors. Scale bar=100 µm.
(a)
(c)
(d)
(b)
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The suggested role of IL-9 in atopic diseases, which are largely Th2 driven, led us to investigate 
the interaction of IL-9 with IL-4 and/or IL-13. Co-stimulation with IL-9 did not alter the effect of Th2 
cytokines on downregulation of epidermal differentiation proteins (Supplemental Figure 5a) or 
the induction of inflammatory epidermal markers, K16 and SKALP (Supplemental Figure 5b and 
Supplemental Figure 6).
We hypothesised that the absence of significant effects by IL-9 in our study could be due to 
low IL9R expression (average Ct value 34) under the conditions used above. IL9R expression 
appears to be induced in inflammatory processes, and we therefore stimulated keratinocyte 
monolayers and HEEs with various cytokine combinations and found IFN-γ to be the main inducer 
of IL9R expression (Figure 2a). We determined the minimal but effective IFN- γ exposure time 
and observed significantly induced IL9R expression after 6 hours of IFN-γ stimulation (Figure 2b). 
Thereafter HEEs were exposed to IL-9 for 72 hours. IFN-γ alone induced the mRNA expression 
of IVL, and the chemokines CCL5 and CXLC10, yet no additional effect of IL-9 stimulation was 
observed on these or other genes analysed (Figure 2c). Similar to previous experiments, IL-9 did 
not alter epidermal morphology or differentiation protein expression (K10, IVL, LOR and FLG) 
even under conditions of high IL9R expression due to 6h IFN-γ pre-stimulation (Figure 2d). 
Discussion
We herein explored the potential effects of IL-9 on keratinocytes and investigated its potential role in 
multiple biological processes involved in epidermal homeostasis like proliferation, differentiation, 
host defence and inflammatory responses. Even after the induction of IL9R in keratinocytes we 
did not detect any effect of IL-9 on any of the aforementioned processes, besides the induction 
of CXCL8 mRNA expression, which has been previously reported145. Induced expression of this 
chemokine may potentially aid in the inflammatory process mediated by Th9 cells and cytokines. 
Our data indicate that IL9R expression in human keratinocytes is constitutively low but highly 
inducible upon inflammatory conditions and that this regulation is mainly due to IFN-γ. This 
finding is in line with the upregulated expression of this receptor as found in psoriasis and allergic 
contact dermatitis136,137,139, where IFN-γ levels prevail and contribute to disease pathogenesis. In 
contrast, Hong et al145. found IL9R to be upregulated by IL-4. We did not detect Th2-cytokine 
mediated induction of IL9R mRNA expression in HEEs (Figure 2a) or monolayer cultures (data 
not shown). The differences in cell source or post-transcriptional regulation may explain this 
discrepancy since Hong et al. studied IL9R protein expression in foreskin keratinocytes. 
The limitation of the current study is that we have examined a selection of genes. Genome wide 
transcriptomic analysis may reveal additional IL-9 responsive genes in epidermal keratinocytes, 
other than CXCL8 reported here, but this is outside the scope of the current study. Based on our 
data we conclude that IL-9 does not affect important keratinocyte functions as proliferation or 
transcription of major differentiation related genes involved in skin barrier function. 
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Supplemental Figures
Supplemental Figure 1. IL-9 induces epidermal CXCL8 expression. 
CXCL8 mRNA expression of HEEs stimulated with IL-9 [50 ng/mL] for 72 hours. Bars represent mean +/- SD, 
N=3 keratinocyte donors, *P<0.05
Supplemental Figure 2. IL-9 has no effect on epidermal proliferation. 
Quantification of epidermal thickness and Ki67 positive cells (percentage of total basal cells) of HEEs 
stimulated with IL-9 [50 ng/mL] for 72 hours. Figures represent mean +/- SD, N=3 keratinocyte donors.
(a) (b)
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Supplemental Figure 3. Epidermal differentiation gene expression is unaffected by IL-9. 
Keratin10 (K10), involucrin (IVL), loricrin (LOR), filaggrin (FLG) and late cornified envelope 3A (LCE3A) mRNA 
expression of HEES stimulated with IL-9 [50 ng/mL] for 72 hours or unstimulated (control) HEEs. Figures 
represent mean +/- SD, N=3 keratinocyte donors.
Supplemental Figure 4. IL-4/IL-13 mimic Th2-mediated inflammation in HEES. 
Immunohistochemistry of (a) late differentiation proteins filaggrin (FGL), involucrin (IVL) and loricrin (LOR) 
and (b) of inflammatory markers keratin 16 (K16) and SKALP of HEEs stimulated for 72 hours with IL-4/IL-13 
[50 ng/mL). Images are representative of N=4 keratinocyte donors. Scale bar = 100 µm.
(a) (b)
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Supplemental Figure 5. IL-9 has no additive or synergistic effects on Th2-cytokine mediated 
changes on differentiation and inflammation markers. 
HEEs were stimulated simultaneously with IL-4 and/or IL-13 [50 ng/mL] and IL-9 [50 ng/mL] for 72 hours. 
Immunohistochemistry of (a) epidermal differentiation proteins filaggrin (FLG), involucrin (IVL), and loricrin 
(LOR) and (b) inflammatory markers keratin 16 (K16) and SKALP. Images are representative of N=4 
keratinocyte donors. Scale bar = 100 µm. 
Supplemental Figure 6. Quantification of SKALP/Elafin and K16 staining. 
Staining’s of epidermal activation markers SKALP/Elafin and K16 were quantified with ImageJ software 
to analyse if there were differences in the amount of protein expression dependent on IL-9, IL-4 and IL-
13 cytokine stimulation. Data are presented a fold difference compared to the unstimulated control HEEs 
represented by the red line. One-way ANOVA was performed to statistically test for significant differences. 
*** P < 0.001. ns = not significant. N= 3. 
(a) (b)
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Supplemental Figure 7. Isotype control staining’s for all used antibodies. 
For validation of staining specificity, we present isotype control staining’s of all antibodies used in this study 
on a control HEE: keratin 10 (K10), involucrin (IVL), filaggrin (FLG), loricrin (LOR), Ki67, Keratin 16 (K16), 
SKALP/Elafin and human beta defensin 2 (hBD2). As both markers are not always expressed in normal skin/
HEEs, SKALP and hBD2 are additionally stained in psoriatic skin as positive control tissue is performed to 
show the staining and for protein localization. Scale bar = 100 µm.
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Supplemental Tables
Supplemental Table 1. Antibodies used for immunohistochemistry.
Antibody clone Manufacturer Host Dilution
Filaggrin; 15C10 Novocastra, Newcastle-On Tyne, UK mouse 1:200
Loricrin; 145P-100 Biolegend, San Diego, USA rabbit 1:4000
Involucrin; Mon150 Generated by our own group149 mouse 1:10
Ki-67; MIB-1 DAKO, Heverlee, Belgium mouse 1:50
pAb to beta 2 defensin Abcam, Cambridge, UK goat 1:200
SKALP/Elafin; 92-1 Generated by our own group150 rabbit 1:500
Keratin-10; DE-K10 LifeSpan Biosciences, Seattle, USA mouse 1:100
Keratin-16; LL025 Novocastra, Newcastle-On Tyne, UK mouse 1:50
Biotinylated horse anti-mouse IgG Vectastain, Vector Laboratories, Burlingame, UK horse 1:200
Biotinylated goat anti-rabbit IgG Vectastain, Vector Laboratories, Burlingame, UK goat 1:200
Biotinylated rabbit anti-goat IgG Vectastain, Vector Laboratories, Burlingame, UK rabbit 1:200
HRP linked swine anti-rabbit DAKO, Heverlee, Belgium swine 1:50
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Supplemental Table 2. Primers used for qPCR.
HUGO Alias gene name Forward primer 5’-3’ Reverse primer 3’-5’ E*
CCL2 chemokine  
(C-C motif) ligand 2
gaagaatcaccagcagcaagtg gatctccttggccacaatgg 2,1
CCL5 chemokine  
(C-C motif) ligand 5
tctgcgctcctgcatctg gggcaatgtaggcaaagca 1,9
CXCL8 C-X-C motif  
chemokine 10,  
interleukin-8
cttggcagccttcctgattt ttctttagcactccttggcaaaa 2,1
CXCL10 C-X-C motif  
chemokine 10
ttcctgcaagccaattttgtc tcttctcacccttctttttcattgt 2,0
DEFB4 human beta  
defensin 2
gatgcctcttccaggtgttttt ggatgacatatggctccactctt 2,0
FLG filaggrin acttcactgagtttcttctgatggtatt tccagacttgagggtctttttctg 1,9
HRNR hornerin tacaaggcgtcatcactgtcatc atctggatcgtttggattcttcag 2,1
IL9R Interleukin 9  
receptor
tggaggatgatgtggtagag agtcagcaggagaaagatgg 2,1
IL33 interleukin 33 ggaggcctgttactttaggagaga aggcagcgagtaccagatgtc 1,9
IVL involucrin acttatttcgggtccgctaggt gagacatgtagagggacagagtcaag 1,9
K10 cytokeratin-10 tggttcaatgaaaagagcaagga gggattgtttcaaggccagtt 1,9
LCE3A late cornified  
envelope 3A
gagtcaccacagatgcc cttgctgaccacttccc 2,0
LOR loricrin aggttaagacatgaaggatttgcaa ggcaccgatgggcttagag 2,1
PI3 Skalp/elafin catgagggccagcagctt tttaacaggaactcccgtgaca 2,0
RPLP0 hARP, 
60S acidic  
ribosomal  
protein P0
caccattgaaatcctgagtgatgt tgaccagcccaaaggagaag 2,0
*E is the efficiency as the fold increase in fluorescence per PCR cycle.
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Abstract
The epidermal-derived “alarmins” high-mobility group box 1 (HMGB1) protein and interleukin-33 
(IL-33) are upregulated in patients with atopic dermatitis (AD). However, their capacity as pro-
inflammatory cytokines and their derived effects on skin barrier regulation are poorly elucidated. 
We investigated the impact of HMGB1 and IL-33 on gene transcription, protein expression and 
epidermal differentiation across three distinct keratinocyte in vitro models. Primary keratinocytes 
from healthy donors were used in submerged monolayer cultures, 3D human epidermis equivalents 
and 3D human skin equivalents. All keratinocyte models underwent 96-hour stimulation with 
HMGB1 (100 µM) or IL-33 (100 ng/ml) using IL-4 (50 ng/mL) as positive control of regulation 
and vehicle as negative control. We found that HMGB1 and IL-33 downregulated transcription 
of several genes from members of the epidermal differentiation complex, including filaggrin. 
Furthermore, HMGB1 downregulated the expression of the encoded proteins in the upper 
epidermis. Finally, IL-33 and HMGB1 ultimately led to impaired epidermal growth and maturation. 
In conclusion, HMGB1 and IL-33 could play a significant role in the AD pathophysiology due to 
negative regulation of structural proteins, stratum corneum formation and epidermal growth. 
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Introduction
The skin is a vital first line of defence between the environment and the human body. Studies 
indicate that defects in epidermal barrier function contribute to triggering and perpetuating skin 
inflammation in atopic dermatitis (AD)151-155.  Furthermore, disease activity and barrier function 
seem to be intimately related, and fluctuations in either can drive the disease156. The role of skin 
barrier dysfunction as an important contributing factor in AD is further substantiated by loss-
of-function mutations seen in the filaggrin gene which is a major risk factor for development of 
AD73,153,157. Filaggrin is a key protein in epidermal homeostasis and barrier integrity; and through 
its processing to free amino acids, it facilitates retention of water in the stratum corneum (natural 
moisturising factor)153,158. In conjunction with filaggrin, other proteins encoded by genes in the 
epidermal differentiation complex, including loricrin and involucrin, are indispensable elements of 
the epidermal barrier153,159. Skin alterations in AD are characterised by increased transepidermal 
water loss (TEWL) and a defective terminal keratinocyte differentiation entailing reduced levels of 
filaggrin, involucrin and loricrin160-162.
Loss-of-function mutations in the filaggrin gene are found in approximately one third of all AD 
patients and are considered responsible for the decreased skin barrier function, the increased 
TEWL and increased disease severity. Yet, all patients with AD display a reduced expression of 
filaggrin and also involucrin and loricrin. This phenomenon is explained in part by the impact of 
cytokines, e.g. interleukin (IL)-4, IL-13 and IL-25 that reduce the expression of barrier proteins161-163. 
The cytokine IL-33 is a member of the IL-1-family. IL-33 is constitutively expressed in healthy 
skin and is upregulated in skin of AD patients and in AD-like lesions in mice164-167. Furthermore, 
we recently found elevated IL-33 serum levels in children with AD168,169. IL-33 is classified as 
an alarmin due to the passive release upon cellular stress like allergen stimulation, scratching 
or non-apoptotic cell death, though these mechanisms are still to be fully elucidated165,170,171. 
It displays Th2 immunomodulatory effects by inducing IL-5 and IL-13. It also displays a Th1 
response via upregulation of IFN-γ172. Keratinocytes produce IL-33 and also express its receptor 
complex consisting of ST2 and IL-1RAcP on their surface165,173. Moreover, IL-33 appears to exert 
receptor-independent transcriptional effects in the nucleus of epithelial cells174, thereby operating 
as a dual-function immune mediator similarly to high-mobility group box 1 (HMGB1)175. HMGB1 
is localised in the nucleus in almost all cells and is rapidly mobilised to other sites within the 
cell, and into the extracellular space in response to a variety of stimuli175,176. Through RAGE 
and TLR4 signalling, HMGB1 mediates immune responses in non-infectious inflammation and 
shows upregulation in the skin and serum of AD patients177,178. HMGB1 sustains a long-term 
inflammatory state under stress similar to IL-33 by activating both keratinocytes and a range of 
immune-competent cells (e.g., macrophages, monocytes and dendritic cells) which, in turn, form 
a positive feedback loop that causes the release of additional cytokines and chemokines179-182. 
Although we have in-depth understanding of the systemic actions of IL-33 and HMGB1, little is 
known about the direct intraepidermal effects of IL-33 and HMGB1on skin barrier integrity and 
homeostasis. In the present report, we investigate the impact of IL-33 and HMGB1 on primary 
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human keratinocyte monolayer cultures and two different three-dimensional (3D) skin models. 
Our results demonstrate that HMGB1, and to a lesser extent IL-33, impair the gene transcription 
and protein expression of a range of pivotal barrier and epidermal differentiation proteins. 
Moreover, they reduce the epidermal growth and thereby hamper the formation of a normal, 
fully stratified epidermis. These results indicate that HMGB1 and IL-33 may impair skin barrier 
function and that they may be new targets in the intraepidermal pathophysiology of AD.
Materials and methods
Monolayer primary human keratinocyte culture (KMC)
Primary human keratinocytes were collected and cultured as described previously183. All KMCs 
and stimulations were performed in duplicate. For the analysis of IL-33 and HMGB1 synthesis, 
primary keratinocytes (N=4) were grown to about 60% confluency, stimulated with IFN-γ (5 ng/
ml, #285-IF, R&D Systems, Oxon, UK), IL-25 (10 ng/ml or 100 ng/ml, #1258-IL, R&D Systems, 
Oxon, UK) or combinations of IFN-γ (5 ng/ml) and IL-25 (10 ng/ml or 100 ng/ml) for 24 hours and 
collected in a lysis buffer for protein analysis. 
For the evaluation of filaggrin, loricrin, involucrin, hornerin, SPINK5 and matriptase mRNA 
levels, cells (N=5) cultured in growth medium supplemented with 1.3 mM calcium to increase 
differentiation were stimulated for 4 days at 70-80% confluency with recombinant human 
IL-25 (10 or 100 ng/ml), IL-33 (2, 10 or 100 ng/ml, #3625-IL, R&D Systems, Oxon, UK),) or 
disulphide HMGB1 (100 µM, #HM-121, HMGBiotech, Milano, Italy). After 48 hours, the medium 
supplemented with cytokine was refreshed. The cells were collected on day 4, washed in ice-cold 
phosphate-buffered saline (PBS) and total RNA was isolated using the SV Total RNA Isolation 
System (Promega, Madison, USA) as previously described184.
Western blot analysis of IL-33 and HMGB1 synthesis in keratinocytes was performed as 
previously described185. The following antibodies were used for evaluation of the protein 
expression: polyclonal goat anti-IL-33 (#AF3625; R&D Systems, Oxon, UK),), polyclonal rabbit 
anti-HMGB1 (#ab18256, Abcam, Cambridge, UK) and horseradish peroxidase-conjugated 
mouse anti-human β-actin (Clone c4; Santa Cruz Biotechnology, Dallas, USA). Primary 
antibodies were visualised using horseradish peroxidase-conjugated polyclonal antibodies 
(p0449; DAKO, Glostrup, Denmark), (#7074, Cell Signalling Technology) and (p0447; DAKO, 
Glostrup, Denmark). All samples were analysed in duplicate.
For RT-qPCR analysis, cDNA synthesis was performed using TaqMan reverse transcription 
reagents (Applied Biosystems, Waltham, USA). RPLP0 (Ribosomal protein, large, P0) was used 
as reference gene. PCR master mix and primers and probes for filaggrin, involucrin, loricrin, 
hornerin, matriptase, SPINK5 and RPLP0 were all commercially available (Taqman Master Mix 
#4369016, Taqman IDs: Hs00856927_g1, Hs00846307_s1, Hs01894962_s1, Hs02340614_
m1, Hs01058386_m1, Hs00928575_m1 and Hs99999902_m1; all from Applied Biosystems, 
Waltham, USA). The probe was a FAM-labelled MGB probe with a non-fluorescent quencher. 
Each gene was run in triplicate on a StepOnePlus PCR system PCR platform (Applied Biosystems, 
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Waltham, USA). The target gene expression level was normalised to the reference gene (RPLP0). 
The average of non-stimulated controls was set to 1, and the relative gene expression levels in 
comparison with the control were determined.
Human epidermal equivalent (HEE) 
Primary keratinocytes were acquired from skin explants after abdominoplasty (N=7). Isolation 
was done as described previously130.
Keratinocytes (1x105) were seeded onto polystyrene inserts (Thincert, Greiner bio-one, 
Kremsmünster, Austria) in proliferation medium (CnT-Prime, CellnTec, Bern, Switzerland). 
On day 2, the medium was replaced by a differentiation medium (3D barrier, CellnTec, Bern, 
Switzerland) complemented with DMEM (Gibco, Waltham, USA). HEEs were exposed to the air-
liquid interface on day 3 to stimulate differentiation and stratification. The medium was refreshed 
every other day. HEEs were stimulated with IL-4 (50 ng/ml, #204-IL, R&D Systems, Oxon, 
UK), IL-33 (100 ng/ml) and disulphide HMGB1 (100 µM) on day 8. After 48 hours, the medium 
supplemented with cytokine was changed. The HEEs were harvested for subsequent analysis 
on day 11. All cultures were antibiotics-free and handled with aseptic techniques in accordance 
with recommendations168.
HEEs were fixated in a 4% buffered formalin solution and processed for routine histology. 
Paraffin sections of 6 µm were stained with haematoxylin and eosin to assess histology, while 
immunohistochemistry with indirect immunoperoxidase technique using avidin-biotin complex 
enhancement (Vectastain Laboratories, Burlingame, USA) was prepared to analyse epidermal 
differentiation. Antibodies against filaggrin (1:200; NCL-FLG, Leica Biosystems, Nussloch, 
Germany), loricrin (1:2000; BabCO, Covance, Princeton, USA), involucrin (1:20; Mon 150, custom 
made), keratin 10 (1:100; DE-K10, Eurodiagnostics, Apeldoorn, The Netherlands), keratin 14 
(1:50; DE-K14, Eurodiagnostics, Apeldoorn, The Netherlands), late cornified envelope 2 (1:1000; 
pan-anti-LCE2, custom made) and Ki67 (1:50; MIB-1; DAKO, Glostrup, Denmark) were used 
and detected with 3-amino-9-ethylcarbazole (AEC). All immunohistochemical staining’s were 
performed with a strict time protocol to avoid intra-analysis variance. Fixed software settings 
were used during histopathological imaging to ensure minimal slide-to-slide variability. An 
experienced technician blindly evaluated epidermal thickness and the number of Ki67-positive 
cell nuclei.  
RNA from duplicates was isolated in accordance with the manufacturer’s protocol (RLT buffer, 
QIAGEN, Valencia, USA). Likewise, cDNA synthesis and RT-qPCR analyses were performed 
according to the manufacturer’s recommendation (Biorad, Hercules, USA). Target gene 
expression was normalised to the expression of RPLP0, and relative expression levels were 
calculated by the ΔΔCt method132. SYBR Green primer sequences are depicted in Supplemental 
Table 1.
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Human skin equivalent (HSE)
In-depth description of the development, culturing and handling of the HSE is provided in 
detail in previous publications121,146. HSEs (N=6) were stimulated on day 8 with IL-4 (50 ng/ml), 
IL-33 (100 ng/ml), disulphide HMGB1 (100 µM) or left unhampered. On day 10, the medium 
supplemented with cytokine was changed. The HSEs were harvested on day 11. Tissue fixation, 
processing for HE staining, RNA extraction and RT-qPCR analysis were performed similarly to 
the HEE procedures after dispase-facilitated isolation of epidermis121. 
Statistical analysis
The distribution of dependent data was assessed by histograms and Q-Q plots, which were 
supported by skewness and kurtosis tests for normality. Data that passed the normality test were 
analysed with unpaired t-test, paired t-test or one-way ANOVA, as appropriate. P-values < 0.05 
were considered significant (*P < 0.05, **P < 0.01, ***P < 0.001). Statistics were performed 
using STATA version 12.0 (StataCorp, College Station, USA) Graphs were prepared in GraphPad 
Prism version 6 (GraphPad software, La Jolla, USA).
Figure 1. IL-33 and HMGB1 protein levels in KMCs. 
(a) Densitometric band analysis of the Western blots showed significant IL-33 upregulation in all IFN-γ 
stimulations when compared with unstimulated control. (b) Representative IL-33 Western blots. (c) Quantified 
HMGB1 protein levels displayed no significant alterations. (d) Representative HMGB1 Western blots. Graphs 
show the relative (to unstimulated control) mean + SD of measured protein levels. *P < 0.05 compared with 
control. IL-33 = interleukin-33, HMGB1 = high-mobility group box 1, IFN-γ = interferon gamma, IL-25 = 
interleukin-25, SD = standard deviation. (N=4).
(a)
(b) (d)
(c)
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Results
IL-33 and HMGB1 protein levels in KMCs
Our study revealed a significant relative increase in the IL-33 protein level when KCs were 
stimulated with IFN-γ compared with unstimulated controls. However, co-stimulation with IL-
25 had no significant additive effect; nor did IL-25 alone affect IL-33 production (Figure 1a, b). 
Studies of HMGB1 protein levels revealed only non-significant changes (Figure 1c, d).
mRNA expression profiles in KMCs
IL-33 was tested in a dose-response study with 2, 20 and 100 ng/ml. This test revealed a 
significant concentration-dependent downregulation of involucrin (P = 0.016), while the other 
targets were non-significant (data not shown). HMGB1 showed non-significant changes in a 
comparison time-response study (24 vs. 96 hours) (data not shown).
KMCs were hence stimulated for 96 hours with IL-25 (100 ng/ml), IL-33 (100ng/ml) and HMGB1 
(100 mM) which revealed a significant downregulation of filaggrin mRNA and involucrin mRNA 
and a non-significant regulation of loricrin, SPINK5 and matriptase mRNA compared with the 
relevant controls (+calcium) (Figure 2). Controls without added calcium showed significantly 
lower mRNA levels of filaggrin, involucrin and SPINK5 than controls with added calcium. 
Figure 2. mRNA expression profiles in keratinocyte monolayer cultures measured by quantitative 
RT-PCR. 
Filaggrin and involucrin mRNA levels were significantly downregulated following addition of IL-33 or HMGB1. 
Graphs show the relative (to unstimulated control (Ca)) mean + SD of measured mRNA levels. *P < 0.05, 
**P < 0.01 compared with control (+Ca). Ca = calcium, IL-25 = interleukin-25, IL-33 = interleukin-33, 
HMGB1 = high-mobility group box 1, SD = standard deviation. (N=5)
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mRNA expression profiles in HEEs
Knowing that IL-33 and HMGB1 downregulated filaggrin and involucrin in KMCs, we wanted 
to interrogate the same hypothesis in an organotypic human epidermis model. We included 
the archetypical Th2 cytokine IL-4 as a positive control. Compared with the KMC studies, we 
excluded SPINK5 and matriptase due to an only modest sign of regulation from target cytokines, 
and included a wide range of other epidermal differentiation genes. 
Our studies in HEEs revealed that stimulation with HMGB1 or IL-4 significantly downregulated the 
mRNA expression of filaggrin, involucrin, loricrin, LCE2A and KLK5. Furthermore, we found that 
IL-4 mediated a significant downregulation on the majority of additional targets (Table 1). Most 
interestingly was the strong downregulation of residual structural protein genes, of kallikrein 5 
and 7 and the highly significant upregulation of IL-33. Besides LCE2A mRNA, IL-33 produced 
no significant regulation of any of the examined differentiation genes, which is in contrast to the 
results obtained in the KMCs (Table 1). Details on mRNA expression in individual genes are 
presented in the Supplemental Figure 1.
mRNA expression profiles in HSEs
Concentrations and gene targets identical to those used in the HEE experiments were applied 
in the HSE study (Table 2). HMGB1 produced downregulations paralleling those in the HEE 
model, in addition to hornerin, K10, and IL-18, and, interestingly, an increase in the IL-33 mRNA 
expression. Among other gene targets, IL-4 showed a consistent downregulation of all structural 
protein genes apart from loricrin. Similarly, to the HEE analysis, a very significant upregulation 
of IL-33 mRNA 
was observed. IL-33 stimulation showed no significant regulation in the HSE model. Details on 
mRNA expression in individual genes are presented in Supplemental Figure 2.
Histology and immunohistochemistry in HEEs
As PCR analysis suggested a potential impact of the target cytokines on cell proliferation and 
differentiation, we consequently performed HE and Ki67 staining’s to evaluate HEE growth 
parameters, and Ki67-positive nuclei. 
The total epidermal thickness of the HEEs was significantly reduced in all stimulations (Figure 
3a). The thickness of the nucleated epidermal layers (NEL, total epidermal thickness without 
the stratum corneum (SC)) was reduced by IL-33 and HMGB1 stimulation, while the isolated 
SC thickness was significantly reduced by HMGB1 and IL-4 (Figure 3b, c).  The Ki67 analysis 
revealed a significant increase in the number of Ki67-positive nuclei in all three stimulations 
(Figure 4). Supplemental
Fig s3 displays representative Ki67 and HE staining’s. 
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Table 1. mRNA expression profiles in human epidermis equivalents (N=7)
HUGO gene symbol
FLG IVL LOR HRNR LCE2A KRT10 KRT14 FLG2
IL-33 (100 ng/ml) - - - - * - - -
HMGB1 (100 μM) * * * - - - - -
IL-4 (50 ng/ml) *** *** ** * *** ** * *
TLR4 CA2 KLK5 KLK7 IL-33 IL-18 IL1RL1 CCL26
IL-33 (100 ng/ml) - - - - - - - -
HMGB1 (100 μM) - - * - - - - -
IL-4 (50 ng/ml) - *** ** *** *** *** ** *
The arrow direction indicates whether an up- or downregulation was disclosed. Non-significant regulation is 
indicated with (-). IL-33 = interleukin-33; HMBG1 = high mobility group box 1 protein; IL-4 = interleukin-4; 
FLG = filaggrin; IVL = involucrin; LOR = loricrin; HRNR = hornerin; LCE2A = late cornified envelope 2A; 
KRT10 = keratin 10; KRT14 = keratin 14; FLG2 = filaggrin 2; TLR4 = toll-like receptor 4; CA2 = carbonic 
anhydrase II; KLK5 = kallikrein 5; KLK7 = kallikrein 7; IL-18 = interleukin-18; IL1RL1 = interleukin-1 receptor-
like 1 (ST2); CCL26 = chemokine (C-C motif) ligand 26. *P < 0.05, **P < 0.01, ***P < 0.001 compared 
with control. 
Table 2.  mRNA expression profiles in human skin equivalents (N=6).
HUGO gene symbol
FLG IVL LOR HRNR LCE2A KRT10 KRT14 FLG2
IL-33 (100 ng/ml) - - - - - - - -
HMGB1 (100 μM) ** ** ** ** ** ** - -
IL-4 (50 ng/ml) * ** - * * * * *
TLR4 CA2 KLK5 KLK7 IL-33 IL-18 IL1RL1 CCL26
IL-33 (100 ng/ml) - - - - - - - -
HMGB1 (100 μM) - - - - ** * - -
IL-4 (50 ng/ml) - - * - *** - *** *
The arrow direction indicates whether an up- or downregulation was disclosed. Non-significant regulation is 
indicated with (-). IL-33 = interleukin-33; HMBG1 = high mobility group box 1 protein; IL-4 = interleukin-4; 
FLG = filaggrin; IVL = involucrin; LOR = loricrin; HRNR = hornerin; LCE2A = late cornified envelope 2A; 
KRT10 = keratin 10; KRT14 = keratin 14; FLG2 = filaggrin 2; TLR4 = toll-like receptor 4; CA2 = carbonic 
anhydrase II; KLK5 = kallikrein 5; KLK7 = kallikrein 7; IL-18 = interleukin-18; IL1RL1 = interleukin-1 receptor-
like 1 (ST2); CCL26 = chemokine (C-C motif) ligand 26. *P < 0.05, **P < 0.01, ***P < 0.001 compared 
with control.
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Figure 3. Human epidermis equivalents display significant morphological changes upon IL-33 
(100 ng/ml), HMGB1 (100 μM) and IL-4 (50 ng/ml) stimulation. 
(a) The total epidermal thickness of the HEEs was significantly reduced in all stimulations. (b) IL-33 and 
HMGB1 significantly reduced the thickness of NEL. (c) HMGB1 and IL-4 significantly reduced the thickness 
of SC. Graphs display the mean + SD of measured thickness. *P < 0.05, **P < 0.01, ***P < 0.001 
compared with control. NEL = nucleated epidermal layers (total epidermal thickness without the stratum 
corneum (SC)), SC = stratum corneum, IL-33 = interleukin-33 = HMBG1, high mobility group box 1 protein, 
IL-4 = interleukin-4, SD = standard deviation. (N=7).
The protein expression of filaggrin in the upper epidermis was distinctly diminished by HMGB1 
and IL-4 stimulation, while the supplement of IL-33 exhibited no apparent changes. Involucrin 
staining was markedly decreased by IL-4, while HMGB1 produced a minor reduction and IL-33 
no evident regulation. HMGB1 and IL-4 stimulation reduced the protein expression of loricrin; 
conversely, IL-33 stimulation increased the expression (Figure 5). Despite downregulation 
of LCE2A mRNA by all stimulations, immunohistochemical staining did not support a 
corresponding reduction of protein expression, which may, in part, be explained by the difficulty 
of LCE2 immunohistochemical interpretation. IL-4 stimulation resulted in a clear reduction of 
K10 expression in the HEE model, whereas other K10 and K14 staining’s were inconclusive 
compared with unstimulated controls (Supplemental Figure 4).
Histology and immunohistochemistry in HSEs
HSE growth and differentiation were validated from HE staining presented in the online 
supplement (Supplemental Figure 5). Immunohistochemical staining’s of HSEs were of little 
value because they displayed lesser upper epidermal differentiation than HEEs which made the 
staining weaker and challenging to interpret (staining’s not shown).
(a) (b) (c)
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Figure 4. Ki67-positive nuclei cell count in human epidermis equivalents is increased following 
IL-33, HMGB1 or IL-4 stimulation. 
IL-33 (100 ng/ml), HMGB1 (100 µM) and IL-4 (50 ng/ml) all produced a significant increase in the quantity of 
Ki67-positive nuclei. The graph displays the mean + SD of Ki67-positive nuclei cell count. **P < 0.01, ***P 
< 0.001 compared with control. IL-33 = interleukin-33, HMBG1 = high mobility group box 1 protein, IL-4 = 
interleukin-4, SD = standard deviation. (N=7).
Figure 5. The protein expression of filaggrin, involucrin and loricrin in the upper epidermis of 
human epidermis equivalents is significantly regulated by IL-33, HMGB1 or IL-4 stimulation. 
Representative immunohistochemical staining’s of filaggrin, involucrin and loricrin upon IL-33 (100 ng/ml), 
HMGB1 (100 µM) or IL-4 (50 ng/ml) stimulation. The protein expression of filaggrin in the upper epidermis 
was distinctly diminished by HMGB1 and IL-4 stimulation. Involucrin staining was markedly decreased by 
IL-4, while HMGB1 produced a minor reduction. HMGB1 and IL-4 stimulation reduced the protein expression 
of loricrin; conversely, IL-33 stimulation increased the expression. Scale bar = 100 µm. IL-33 = interleukin-33, 
HMBG1 = high mobility group box 1 protein, IL-4 = interleukin-4. (N=7).
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Discussion
AD is characterised by a dysregulation of several cytokines, and it has been suggested that these 
cytokines participate in disease pathophysiology186,187. Two of the effector cytokines possibly 
implicated in AD are the alarmins IL-33 and HMGB1. Other well-described cytokines, including 
IL-4, IL-13 and IL-25161-163,165,177, may also be implicated. Here, we demonstrate for the first time 
that HMGB1 and IL-33 downregulate transcription of genes from members of the epidermal 
differentiation complex. Furthermore, HMGB1 downregulates the expression of several of the 
encoded proteins in the upper epidermis. Finally, we show that IL-33 and HMGB1 stimulation 
ultimately leads to impaired epidermal growth and maturation. While HMGB1 shows uniform 
effects across three keratinocyte models, the impact of IL-33 is less pronounced. 
The inflammatory response mediated by HMGB1 is well characterised across a broad palette 
of cells and tissues175. However, the role of HMGB1 in skin barrier homeostasis and AD is 
poorly elucidated. HMGB1 expression is chronically augmented during various types of skin 
inflammation, including AD177,178,188-191. Our results give us reason to believe that constant HMGB1 
stimulation of keratinocytes within AD lesions can impair natural barrier formation. Keeping in 
mind that the HMGB1 concentrations used in our study could enhance any effects compared 
with the pathophysiological situation, we show that HMGB1 heavily impacts the gene products 
of pivotal skin barrier differentiation genes, e.g. filaggrin, involucrin and loricrin. Consequently, 
HMGB1 has deleterious effects on protein expression, epidermal growth and SC formation. This 
is in line with the effects of HMGB1 in lung and intestinal endothelia cells where HMGB1 gives 
rise to cytoskeletal rearrangement and barrier disruption192,193. We show an upregulation of Ki67 
in the basal cell layer in HMGB1-stimulated cells that does not, as would be expected, result 
in increased epidermal growth and barrier maturation; in fact, we observe the opposite. These 
results are in concert with previous in vitro studies of HMGB1 as increased Ki67 expression 
and cell proliferation of adult and embryonic mesoangioblasts disrupt the barrier function of 
endothelial monolayers194. Whether the impact of HMGB1 in the AD in vivo setting might mimic 
that seen in psoriasis need further exploration190. 
IL-4 and HMGB1 experiments revealed a recurrent downregulation of kallikrein 5 mRNA. 
This regulation may hint at a meaningful counter response to the deterioration of skin barrier 
formation as it is recognised that increased levels and activity of kallikrein 5 are important to 
the development and maintenance of AD. However, these possible dual functions need further 
study195,196. Additionally, in the 3D models HMGB1, in union with IL-4 showed a highly significant 
upregulation of the IL-33 mRNA product that parallels results reported in studies of other 
epithelial cells197. This could indicate the existence of a damaging feedback loop enhancing any 
IL-33 properties, e.g. systemic Th2 skewing TSLP and IL-13 upregulation in the skin, augmenting 
ongoing immunomodulation, diminishing barrier function and possibly reducing the effect of 
topical glucocorticosteroid treatment in AD patients172,198-201. 
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IL-33 is reported to be elevated in both the blood and epidermis of AD patients165,167,169. Our 
study verified the IL-33 production from keratinocytes under IFN-γ exposure. It also revealed an 
IL-33 upregulation after HMGB1 or IL-4 stimulation, and it disclosed a downregulation of filaggrin 
and involucrin mRNA in the KMCs upon IL-33 stimulation, although no regulation was observed 
in either of the 3D models. These findings are partly in line with those of a previous study 
investigating similar causality202. Seltmann et al. showed significant downregulation of filaggrin 
mRNA in lesional AD keratinocytes upon IL-33 stimulation. Still, they did not reproduce these 
results in normal human KMCs, AD skin biopsies or in a HEE model, data mirrored in our study. 
Lastly, and in contrast to our results, they reported a reduction in filaggrin protein expression by 
IHC staining of HEEs. The fact that we disclosed a no effect of IL-33 on isolated SC thickness 
is supports our mRNA data, as neither of the eight gene targets representing the bulk mass of 
protein in the SC, was not significantly regulated in either the HEE- or HSE mRNA profile. Together 
these findings give little reason to believe that IL-33 heavily impacts structural skin barrier protein 
expression and translation. However, the question remains unanswered whether IL-33 does, in 
fact, negatively impact production and maturation of filaggrin, involucrin and other structural 
barrier proteins. Our studies of HEE thickness support the evidence of an intraepidermal role of 
IL-33. We show a clear reduction of epidermal growth upon IL-33 stimulation despite an increased 
Ki67-positive cell count. This is possibly due to mechanisms mimicking those of HMGB1 where 
significant upregulation of Ki67 and cell proliferation do not translate into increased growth, but 
instead hamper epidermal development194. This causality is further supported by the increased 
production of IL-33 from lung epithelial cells causing a reduced alveolar diffusion capacity and 
aggravation of chronic obstructive lung disease203. 
Several papers describe the downregulatory effects of IL-4/IL-13 concerning keratinocyte 
proliferation, differentiation and filaggrin expression80,161,162,202,204,205. Our present report offers a 
consolidation of the isolated impact of IL-4 on filaggrin, involucrin and loricrin gene and protein 
expression. Additionally, it is also the first study exploring the effect of IL-4 in HEEs supported 
by two additional models; and it furthermore shows impaired HEE growth and SC formation, 
thereby accentuating the prospect of the ongoing studies of AD patients treated with dupilumab, 
a fully human monoclonal antibody that blocks the IL-4 receptor subunit IL-4Rα, hence modulates 
signalling of both the IL-4 and IL-13 pathway206,207.
In the present study, we provide a triple in vitro study of the impact of HMGB1, IL-33 and IL-4 on 
the most pivotal epidermal differentiation genes, the protein expression in a HEE model and the 
evaluation of HEE growth and SC formation. Furthermore, we report a consistent and convincing 
reduction of hallmark skin barrier gene and protein products upon stimulation with HMGB1 and 
IL-4. We speculate that HMGB1 has primary regulatory effects on keratinocyte homeostasis and 
could be a major target for future research into barrier dysfunction in AD. IL-33 has only discrete 
gene and protein regulatory effects; however, its capacity to decelerate normal epidermal 
growth might turn out to be an important part of the negative feedback loop of the intraepidermal 
pathophysiology of AD.
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Supplemental Figure 3. Epidermal morphology and Ki67-positivity of human epidermis 
equivalents.
Representative immunohistochemical Ki67 and haematoxylin & eosin staining’s upon IL-33 (100 ng/ml), 
HMGB1 (100 µM) or IL-4 (50 ng/ml) stimulation. Scale bar = 100 µm. IL-33 = interleukin-33, HMBG1 = high 
mobility group box 1 protein, IL-4 = interleukin-4, HE = haematoxylin & eosin. (N=7).
Supplemental Figure 4. The protein expression of late cornified envelope 2A protein, keratin 10 
and keratin 14 in the upper epidermis of human epidermis equivalents. 
Representative LCE2A, keratin 10 and keratin 14 immunohistochemical staining’s upon IL-33 (100 ng/ml), 
HMGB1 (100 µM) or IL-4 (50 ng/ml) stimulation. No convincing reduction of LCE2A protein expression was 
observed from either stimulation. IL-4 stimulation resulted in a clear reduction of keratin 10 staining intensity 
in the HEE model, whereas keratin 10 and keratin 14 staining’s in IL-33 and HGBM1 stimulated equivalents 
were inconclusive compared with unstimulated controls. Scale bar = 100 µm. IL-33 = interleukin-33, HMBG1 
= high mobility group box 1 protein, IL-4 = interleukin-4. (N=7).
473
 
Supplemental Figure 5. Epidermal morphology of human skin equivalents. 
Representative haematoxylin & eosin staining’s upon IL-33 (100 ng/ml), HMGB1 (100 µM) or IL-4 (50 ng/ml) 
stimulation. Scale bar = 100 µm. IL-33 = interleukin-33, HMBG1 = high mobility group box 1 protein, IL-4 = 
interleukin-4. (N=6).
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Supplemental Table
Supplemental Table 1. Primer sequences of all genes examined by real-time quantitative 
polymerase chain reaction
HUGO 
gene 
symbol
Description of gene/protein Forward primer Reverse primer
KRT10 Keratin 10 tggttcaatgaaaagagcaagga gggattgtttcaaggccagtt
KRT14 Keratin 14 ggcctgctgagatcaaagactac cactgtggctgtgagaatcttgtt
MKI67 Ki-67 aaaccaacaaagaggaacacaaatt gtctggagcgcagggatattc
IVL Involucrin acttatttcgggtccgctaggt gagacatgtagagggacagagtcaag
LOR Loricrin aggttaagacatgaaggatttgcaa ggcaccgatgggcttagag
FLG Pro-filaggrin acttcactgagtttcttctgatggtatt tccagacttgagggtctttttctg
FLG2 Filaggrin-2 accaggttcacttaaacttgca atgacatccactgtgtctggatc
HRNR Hornerin tacaaggcgtcatcactgtcatc atctggatcgtttggattcttcag
TLR4 Toll-like receptor 4 ggtgagtaattccatggtgcacta ttccctctgcactggaagct
LCE2A Late cornified envelope 2A ggacctgtcccagagtgatg gatccaggatgggctcttg
RPLP0 Ribosomal phosphoprotein P0 caccattgaaatcctgagtgatgt tgaccagcccaaaggagaag
CA2 Carbonic anhydrase II aacaatggtcatgctttcaacg tgtccatcaagtgaaccccag
KLK5 Kallikrein 5 tgctctgatcacagccttgct gggtggtcacaggaaacatcat
KLK7 Kallikrein 7 gcatccccgactccaagaa cagggtacctctgcacaccaa
IL-33 Interleukin 33 ggaggcctgttactttaggagaga aggcagcgagtaccagatgtc
IL-18 Interleukin 18 atcgcttcctctcgcaaca cattgccacaaagttgatgca
IL1RL1 Interleukin-1 receptor-like 1 (ST2) tggtttaagaattgtcaggctcttc gcgtcctcagtcatcacattatca
CCL26 Chemokine (C-C motif) ligand 26 cctgggtgcgaagctatgaa ttgcctcttttggtagtgaatatcac
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Abstract
Filaggrin (FLG) loss-of-function mutations and the T helper 2 (Th2) dominated cytokine milieu 
are assumed to cause an impaired skin barrier function in atopic dermatitis (AD). Previous 
studies have used in vitro skin equivalents to provide experimental evidence for the role of FLG 
deficiency but different experimental setups and knockdown approaches make these data 
difficult to compare and interpret. Here we addressed the question if complete FLG deficiency 
alters skin barrier function in epidermal equivalents derived from keratinocytes of ichthyosis 
vulgaris patients that innately carry homozygous FLG loss-of-function mutations. This approach 
uses genetically defined cells without detectable filaggrin protein and avoids potential off-target 
effects of knockdown approaches. FLG deficiency marginally altered the constitutive or Th2 
cytokine dependent expression of differentiation-associated proteins or antimicrobial proteins. 
Additionally, we observed a decrease of tight junction protein expression. No alteration of the 
outside-in barrier was observed, as measured by the permeability for low molecular weight tracers 
(Lucifer Yellow or biotin). Although these findings do not rule out alterations of FLG deficient 
epidermis with respect to inside-out barrier function or outside-in permeability for molecules with 
other biophysical properties, our study contradicts previous work that suggests an increased 
permeability for low molecular weight polar solutes.
581
Introduction
The skin barrier protects us from the environment and prevents dehydration. Most of these 
functions lie within the stratum corneum (SC), where terminally differentiated keratinocytes are 
embedded in a lipid-rich extracellular matrix and form stable and insoluble cornified envelopes 
(CE). One very important and intensively studied protein of keratinocyte differentiation is (pro-) 
filaggrin (FLG). FLG is a large (>400kDa), insoluble protein that forms the major component 
of the keratohyalin granules. Upon dephosphorylation and degradation, monomeric FLG 
is proteolyzed to release its component amino acids. FLG monomers are vital for proper CE 
formation7 and degraded FLG forms a mixture of hygroscopic amino acids, the so-called ‘natural 
moisturizing factors’ (NMF)208. NMF contributes to epidermal barrier function and hydration, and 
regulates the skin pH. Acidic pH modulates serine protease activity209, which is necessary for 
coordinated epidermal differentiation, CE formation and desquamation. In addition, the ‘acid 
mantle’ of the SC has a well-known antimicrobial effect210.
In 2006, the McLean group discovered that homozygous loss-of-function mutations in the FLG 
gene cause ichthyosis vulgaris (IV), a skin disease characterized by a dry skin211 and increased 
trans epidermal water loss (TEWL) indicating a poor inside-out skin barrier function. In a second 
study, the same authors found that 30% of European patients with atopic dermatitis (AD) carry 
a FLG loss-of-function mutation73. AD is, like IV, characterized by a poor skin barrier with high 
TEWL in both lesional and non-lesional skin212,213. These results were replicated in other cohorts 
throughout the world214-216. Furthermore, across large populations217, it was revealed that each 
additional FLG repeat gained, decreased the odds ratio for AD by 0.88. Thus, both FLG genomic 
copy number and intragenic FLG repeat number variation makes a significant, dose-dependent 
contribution to AD risk.
Murine models of FLG haploinsufficiency, showing barrier impairment and enhanced percutaneous 
allergen sensitization, exemplify the detrimental effect of having less FLG expression on skin 
barrier function218. The barrier integrity phenotype associated with FLG-null mutations in human 
skin is emerging, with evidence of reduced NMF in the SC84,219,220, and SC integrity and cohesion 
impairment221,222. FLG knockdown approaches using in vitro three-dimensional (3D) skin models 
have recently emerged as tools to dissect the role of FLG in skin barrier function. Conflicting 
outcomes of studies that have addressed this question during the last years (Table 1) may be 
caused by differences in experimental setup or the lack of proper controls. Insufficient numbers 
of biological replicates, and off-target effects, a well-known phenomenon in knockdown studies, 
may have played a role. Most of these studies obtained a significant reduction in FLG mRNA or 
protein expression (70% to 90%), but none of them reached complete absence of expression. 
We here used genetically defined keratinocytes, completely deficient of FLG protein, in a 3D 
human epidermal equivalent (HEE) model. This provided a unique possibility to study the role of 
FLG in skin barrier defects, reported for both IV and AD. Thereby, knockdown-derived off-target 
effects were excluded, while potential compensatory mechanisms by naturally occurring FLG 
deficiency were taken into account.
Filaggrin-deficiency does not directly lead to skin barrier impairment
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Materials and methods
Primary keratinocyte isolation
Primary human keratinocytes were obtained from four 4-mm diameter punch biopsies of 
genotyped healthy volunteers (FLG+/+) and patients with IV (FLG−/−), which were taken at the 
upper buttock by a dermatologist. All volunteers (aged between 25 and 65 years) signed 
informed consent for this study. Keratinocytes were isolated and expanded according to the 
Rheinwald-Green protocol223 and stored in liquid nitrogen.
Filaggrin genotyping
FLG mutation analysis for the 2 most common mutations, R501X and 2282del4, was performed 
as described previously80. 
HEE development
For the generation of HEEs, 300,000 primary human keratinocytes were seeded onto 0.4 µm 
pore size transwell filters (Thincerts, Greiner Bio-One GmbH, Frickenhausen, Germany). Before 
seeding, these transwells were incubated with 100 µg/mL rat-tail collagen (BD Biosciences, 
Breda, The Netherlands) diluted in sterile cold PBS at 4°C for 1 hour, or with 100 µg/mL fibrinogen, 
10% FCS (HyClone), or 100 µg/mL poly-d-lysine at room temperature for 1 hour. Afterward, 
excessive coating solutions were carefully aspirated and filters were washed once with cold, 
sterile PBS. First, the primary keratinocytes were cultured in a submerged manner in proliferation 
medium (CnT-prime, CELLnTEC) for 2 days to form a homogeneously distributed monolayer. 
One day later, medium was changed to differentiation medium (60% 3D barrier, CELLnTEC 
complemented with 40% Dulbecco modified Eagle medium, Gibco, Life Technologies, Thermo 
Scientific, Bleiswijk, The Netherlands). On the third day, the transwell inserts were lifted to the 
air-liquid interface to induce differentiation and stratification of the epidermis. From now on, cells 
were cultured in differentiation medium until the end of the culture and they were refreshed with 
differentiation medium every other day. This HEE culture schedule is depicted in Figure 1.
Th2 cytokine stimulation of HEEs
For Th2 cytokine stimulation, a mixture of 50 ng/mL IL-4 (Preprotech) and 50 ng/mL IL-13 
(Preprotech, Rocky Hill, NJ) in HEE differentiation medium containing 0.05% BSA (Sigma-
Aldrich, Zwijndrecht, The Netherlands) was added from day 1 of air-liquid interface culture until 
the end of the culture of the HEEs.
In vitro outside-in epidermal permeability assay
LY (1 mM) (Sigma-Aldrich, Zwijndrecht, The Netherlands) or EZ-Link Sulfo-NHS-LC-LC-
Biotin (Life Technologies) was added epicutaneously onto the HEE for 60 minutes, followed 
by formalin fixation and processing for histology. Sections (6 µm) were counterstained with 
4′,6-diamidino-2-phenylindole (Boehringer Mannheim, Mannheim, Germany) and assessed 
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with fluorescence microscopy for LY penetration or stained with an indirect immunoperoxidase 
technique (Vectastain, Vector Laboratories, Burlingame, Calif) for EZ-Link Sulfo-NHS-LC-LC-
Biotin penetration.
To show LY penetration on impaired skin barrier function in vitro, HEEs were topically treated with 
0.5% SDS in PBS (Sigma-Aldrich) for 90 minutes followed by a 60-minute incubation with 1 mM 
LY as described above.
In vitro inside-out epidermal permeability assay
Fully differentiated HEEs residing in the transwell were placed upside-down. EZ-Link Sulfo-
NHS-LC-LC-Biotin (Life Technologies, Thermo Scientific, Bleiswijk, The Netherlands) in HEE 
differentiation medium was applied to the basal layer side of the HEE for 60 minutes, followed 
by formalin fixation and processing for histology. For visualization, 6-µm sections were stained 
with streptavidin Alexa Fluor 594 (Life Technologies, Thermo Scientific) and counterstained 
with 4′,6-diamidino-2-phenylindole (Boehringer Mannheim) and assessed with fluorescence 
microscopy dye penetration.
Transepidermal water loss (TEWL) analysis
Permeability barrier function was evaluated by measurement of TEWL with a condenser-chamber 
method (Aquaflux AF200, Biox Systems, London, United Kingdom). The HEEs, maintained in 
tissue culture exerts along with their medium, were first acclimatized to the ambient conditions 
of temperature and humidity for at least 30 minutes. The measurement head of the instrument 
was equipped with a stainless-steel extension tube (5-mm bore diameter) to reach down into the 
transwell inserts. A gentle and controlled contact pressure of the tube onto the sample surface 
was achieved by mounting the measurement head on a purpose-designed probe holder with 
precise control of the vertical position of the probe. The same investigator performed all TEWL 
measurements. For each HEE, TEWL measurements were performed in triplicate and then 
averaged.
Immunohistochemistry
HEEs were fixed in formalin and processed for routine histology. Paraffin sections (6 µm) were 
stained with antibodies using an indirect immunoperoxidase technique (Vectastain, Vector 
Laboratories, Burlingame, Calif) or immunofluorescence technique according to Gruber et al224. 
An overview of all used antibodies is presented in Supplemental Table 1.
Quantitative real-time PCR
RNA isolation, cDNA synthesis, and quantitative PCR analysis were performed as described 
earlier13. All primers were designed and used as described previously225. Target gene expression 
was normalized to the expression of the house keeping gene human acidic ribosomal 
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phosphoprotein P0 (RPLP0). The ΔΔCt method was used to calculate relative mRNA expression 
levels132 (see Supplemental Table 2 for primer sequences).
Quantitative PCR data were analysed using 2-way ANOVA to test the effect of both FLG genotype 
and Th2 cytokine stimulation on mRNA expression. For this, we used the ΔCt values of N=11 
HEEs (N=6 FLG+/+, N=5 FLG−/−).
Results
All experiments were performed using fully differentiated HEEs, based on collagen coated 
transwell system with keratinocytes only. Eight days of air-liquid interface culture resulted in a 
fully stratified human epidermis expressing all proliferation and differentiation markers of normal 
skin (Figure 1). For the natural FLG knockout HEEs (FLG-/-) we used primary human keratinocytes 
isolated from two IV patients. The IV keratinocytes were analysed for the two most frequent 
mutations of the FLG gene R501X and 2282del4 located at the 5’end of the FLG gene (Figure 
1a). All patients were found to be compound heterozygous for the two prevalent FLG null alleles. 
In vivo morphology and absence of FLG protein in IV patients skin is shown in Figure 2. Healthy 
controls, who were negative for these mutations and are designated FLG+/+ were used as donors 
for control keratinocytes.
FLG loss-of-function mutations are the main predisposing risk factor for AD, a Th2 cytokine-
mediated inflammatory skin disease characterized by skin barrier defects. We therefore 
hypothesized that the FLG genotype may drive skin barrier defects depending on a concomitant 
Th2 cytokine milieu. We added Th2 cytokines, IL-4 and IL-13, to the FLG+/+ and FLG-/- HEEs to 
mimic AD-like inflammation in vitro as previously described by our group80,123. As the first SC 
layers of our HEEs were already formed at the time point of standard Th2 cytokine stimulation 
(day 5-8) we hypothesized that earlier exposure or a pulse stimulation of IL-4 and IL-13 during a 
longer time period would result in stronger barrier defects and potential differences in epidermal 
differentiation between FLG+/+ and FLG-/- HEEs. Exposure of the HEEs to IL-4 and IL-13 from 
the start of the air-liquid interface (day 1 to day 8) did not hamper epidermal stratification and 
morphology. However, the expression of major skin barrier proteins like FLG and LOR was 
strongly downregulated or even absent (Supplemental Figure 1). The observed downregulation 
was comparable between the pulse and continuous exposure to Th2 cytokines during the HEE 
culture. For all following analyses Th2 cytokine stimulation was performed during the entire 
epidermal differentiation phase (day 1 to day 8). 
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Figure 1. Development of the 3D human epidermal equivalent model. 
(a) Keratinocytes are seeded into proliferation medium (PM), submerged in a transwell system to form a 
confluent monolayer. After two days, the medium is exchanged to differentiation medium (DM) and after 
one more day the inserts are lifted to the air-liquid interface to grow for another eight days in DM. (b) H&E 
staining of the keratinocyte monolayer on the insert at day 0, comparing rat tail collagen coated transwells 
to uncoated ones (left panel). The arrow indicates keratinocyte colonies whereas the circle depicts empty 
filter spaces. Corresponding HE staining of the epidermal equivalents at the end of air-liquid interface culture 
(day 8, right panel). (c) H&E staining of epidermal equivalents cultured 6, 8 or 11 days at the air-liquid 
interface shows that optimal stratification of an epidermis is reached after 8 days. (d) Protein expression of 
proliferation (Ki67) and differentiation (K10, IVL, FLG) markers show that these HEEs exhibit normal protein 
expression comparable to human epidermis in vivo. Scale bar = 100 µm.
(a)
(b)
(c)
(d)
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Figure 2. Filaggrin null-mutation. 
(a) H&E staining of a 4mm skin biopsy punch of one of the IV patients from whom keratinocytes were isolated 
for this study. General morphology and stratification of the epidermis is normal, except for absence of the 
FLG-containing keratohyalin granules that are normally present in the stratum granulosum. (b) FLG protein 
staining is negative, revealing complete loss of the FLG expression in this patient. Scale bar = 100 µm. (c) 
Keratinocytes from IV patients used in this study carry the two most frequently occurring mutations R501X 
and 2282del4 located on the first repeat of the FLG gene. (d) FLG mRNA expression analysis of FLG-/- and 
FLG+/+ epidermal equivalents. Bars represent mean, N =2 for both groups.
We compared FLG−/− and FLG+/+ HEEs with and without stimulation by Th2 cytokines IL-4 
and IL-13 during the entire air-liquid interface culture (Figure 3). Overall, despite the absence 
of keratohyalin granules and FLG protein in FLG−/− HEEs, we found no major differences 
between FLG−/− and FLG+/+ HEEs concerning general epidermal development, stratification, 
and morphology. The stratum corneum (SC) of FLG−/− HEEs was found to be marginally thinner 
but this was not significant (Supplemental Figure 2). Th2 cytokines induced thickening of the 
viable epidermis, spongiosis, and apoptosis, as we have described previously80. Differentiation 
proteins were strongly downregulated by Th2 cytokine treatment as reported before161; however, 
expression levels were equal for both FLG genotypes (Figure 3a). Quantitative PCR analysis 
revealed that Th2 cytokine stimulation caused a significant decrease in the expression of many 
genes that encode structural SC proteins (Figure 4). However, these were, with the exception of 
loricrin, hornerin and caspase 14, not significantly different between the 2 FLG genotypes (Figure 
5). And the effect sizes of the significantly different expressed genes were only small (about 
2-fold difference).  
(a) (b)
(c) (d)
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Figure 3. Comparison of epidermal proliferation, differentiation, and epidermal barrier between 
FLG+/+ and FLG-/- HEEs under normal or Th2 cytokine-stimulated condition. 
(a) Morphological analysis and protein analysis by immunohistochemistry for markers of epidermal proliferation 
(Ki67) and differentiation (FLG, K10, IVL, LOR, LCE3, and TGM-1). (b) Immunofluorescence staining of HEE 
shows TJ proteins Cldn-4 (green) and Cldn-1 (red) at the left part and Ocln (green) at the right part combined 
with nuclear DAPI staining (blue). Among areas with normal TJ protein expression, there are some areas 
with patchy or almost absent expression of Cldn-4 and Ocln in the FLG2/2 HEEs; these are represented in 
the photographs. The arrows indicate the specific location of staining. (c) Outside-in SC permeability assay 
by LY penetration (green) combined with nuclear DAPI staining (blue). (d) TEWL analysis of unstimulated 
HEEs. (e) Inside-out SC permeability assay by EZ-Link Sulfo-NHS-LC-LC-Biotin penetration (red) combined 
with nuclear DAPI staining (blue). Pictures show combination of fluorescence and light microscopy images. 
White bars indicate the SC layer. All scale bars 5 100 mm. N=11 (N=6 FLG+/+ and N=5 FLG-/- HEEs). DAPI, 
49-6-Diamidino-2-phenylindole, dihydrochloride.
(a)
(b)
(c)
(e)
(d)
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Figure 4. mRNA expression changes on Th2 stimulation of HEEs. 
HEEs of 11 primary keratinocyte donors (N=6 FLG+/+, N=6 FLG-/-) were stimulated with Th2 cytokines 
IL-4 and IL-13 during air-liquid interface culture. Epidermal differentiation and TJ genes were significantly 
downregulated on Th2 stimulation. Two-way ANOVA statistical analysis was performed to test the influence 
of the Th2 stimulation. Data are represented as mean 6 SEM. *P < .05, **P < .001, and ***P < .0001. 
Because tight junctions (TJs) are important in epidermal barrier formation, we analysed the 
expression of TJ proteins of our HEEs. Occasionally, we observed a patchy expression of claudin-4 
(Cldn-4) and occludin (Ocln) in FLG−/− HEEs compared with the continuous expression in FLG+/+ 
HEEs (Figure 3b). A previous study in mice, however, reported that the epidermal TJ barrier is not 
affected by the loss of fi laggrin226. In vitro epidermal barrier function of the HEEs described above 
was assessed by outside-in and inside-out tracer penetration assays (Lucifer Yellow [LY] and EZ-
Link Sulfo-NHS-LC-LC-Biotin). To validate the LY penetration assay for the detection of SC defects 
in our system, we used the detergent SDS as a positive control to compromise the HEE barrier 
capacity. We found LY penetration through the SC reaching the keratinocytes of the living epidermis 
following SDS treatment (Supplemental Figure 3). Interestingly, under normal conditions as well as 
in a Th2 cytokine milieu, where expression of most structural proteins was strongly diminished, both 
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SC of FLG+/+ and FLG−/− HEEs appeared impermeable for LY (Figure 3C) and EZ-Link Sulfo-NHS-
LC-LC-Biotin (Supplemental Figure 4) when applied at the SC side of the HEE. The inside-out barrier 
with respect to water evaporation across the SC was measured by TEWL determination of FLG+/+ 
and FLG−/− HEEs. No differences were found between the groups (Figure 1d). In addition, we used 
EZ-Link Sulfo-NHS-LC-LC-Biotin inside-out diffusion to investigate SC permeability in HEEs of both 
genotypes (Figure 1e). Again, no differences were found depending on the FLG genotype.
a. epidermal differentiation
591
b. tight junction
Figure 5. mRNA expression data of FLG+/+ and FLG-/- HEEs. 
Relative mRNA expression levels of genes concerning (a) epidermal differentiation and (b) tight junctions. 
The figures present qPCR expression data of HEEs of 11 primary keratinocyte donors (N=6 FLG+/+, N=5 
FLG-/-) unstimulated (control) or with Th2 stimulation. The house keeping gene ribosomal phosphoprotein 
P0 (RPLP0) was used for normalization. Two-way ANOVA was performed to determine significant changes in 
expression levels between FLG+/+and FLG-/- HEEs.
Discussion
FLG null alleles are by far the strongest and most widely replicated genetic risk factor for AD. 
As sensitization against common environmental antigens is a hallmark of AD, it has been 
tempting to postulate a leaky skin barrier as the most plausible mechanism that links genetic 
alterations to the disease phenotype. Several in vitro studies have been published to provide 
experimental evidence for this contention. To our knowledge, our current investigations are the 
first using genetically defined keratinocytes that are completely deficient for FLG protein, in a 
3D reconstructed epidermal model  This approach provides a unique possibility to study the 
role of FLG in skin barrier defects, reported for both IV and AD. Possible off-target effects due to 
experimental knockdown strategies are excluded by this approach, while potential compensatory 
mechanisms by naturally occurring FLG deficiency are taken into account. We could not 
demonstrate increased SC permeability for low molecular polar solutes in FLG deficient HEEs, 
neither under conditions that mimicked normal skin, nor under conditions that mimicked AD.
Most studies on the role of FLG in the skin barrier function used FLG knockdown strategies 
in 3D skin models, based on the model first described by Mildner et al.227. This model uses 
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neonatal human foreskin keratinocytes, which are known to significantly differ from human adult 
keratinocytes. From our previous studies, we know that foreskin-derived skin equivalents show 
an activated phenotype as witnessed by parakeratosis and expression of psoriasis markers146. 
In addition, the aberrant TGM-1 expression and activity in these models (unpublished data) may 
lead to disturbed cross-linking of CE proteins and therefore an altered SC formation, resulting 
in higher barrier permeability. Similar to our study, van Drongelen et al. reported normal SC 
permeability upon FLG deficiency, although still 20% FLG protein remained after their lentiviral 
transduction strategy, which may have been sufficient for a normal skin barrier function228. Our 
HEE model is most similar to that described by Pendaries et al. as they also make use of human 
adult keratinocytes from different donors and cultured in absence of a fibroblast-populated 
collagen matrix229. Stable FLG knockdown by lentiviral delivery resulted in altered SC formation 
and increased permeability, less epidermal proliferation and altered epidermal differentiation 
marker gene and protein expression, less NMF levels and increased UV sensitivity. All of these 
features very well fit with the main dogma that FLG loss-of-function mutations result in skin barrier 
defects in IV, and that concomitant exposure to environmental triggers results in inflammation 
leading to AD. However, the epidermal morphology of the FLG deficient epidermis presented in 
this study is very different from the mock transfected epidermis, showing only a few epidermal 
cell layers and a SC appears absent229. In vivo absence of FLG protein in AD or IV skin alters 
integrity and intracellular organization of the corneocytes, but general epidermal morphology 
remains normal222, supporting our findings of normal formation and protein expression of FLG-/- 
HEEs. In the same paper, reduced expression of occludin indicating impaired TJ formation was 
found in FLG deficient skin in vivo. This is consistent with our data on reduced expression of TJ 
components in our FLG-/- HEEs. The increased barrier permeability and differentiation defects 
due to FLG knockdown shown in the study by Pendaries et al. may not faithfully represent the 
effect of FLG deficiency but might rather be due to disturbed epidermal morphology caused by 
the knockdown procedure itself. Another drawback of these siRNA/shRNA approaches is that 
they do not reach more than 80-90% FLG protein knockdown. The remaining protein might still 
be sufficient to fulfil its function in the epidermis and compensate for the protein loss.
It has been suggested that reduced levels of FLG may alter lipid organization within the SC and 
thereby affecting SC and skin barrier integrity, as found in AD75. Van Drongelen et al. investigated 
lipid composition in their FLG knockdown model but did not find any changes in lamellar lipid 
organization228. In our study, we did not investigate lipid composition or structure, but even if 
there were any alterations present they obviously did not influence epidermal barrier function of 
FLG-/- HEEs since we did not find any increased SC permeability of our tracers.
In our study, barrier function was tested by the polar solutes LY and biotin as these are commonly 
used in comparable studies. Although alteration of the permeability for these low molecular 
weight tracers was not observed, this does not completely rule out alterations of FLG-deficient 
epidermis with respect to permeability for environmental molecules with other biophysical 
properties such as microbial or airborne antigens, or fragments thereof. As microbiome 
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alterations (e.g. Staphylococcus aureus colonization) may play a role in AD, the penetration of 
environmental stimuli may be the result of an interaction between microorganisms and genetic 
factors such as FLG mutations, as suggested in a recent study230. Clearly, this is an interesting 
area for future research.
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Supplemental Figures
Supplemental Figure 1. Long-term Th2 cytokine stimulation of epidermal equivalents. 
HEEs were stimulated with Th2 cytokines IL-4 and IL-13 for different time periods during air-liquid interface 
culture. Stimulation started between day 1 and day 5 and was prolonged until the endpoint of the 3D culture 
on day 8 (of which the photos are depicted here). We performed two types of stimulation schedules, either 
continuous stimulation with refreshing of the cytokine mix every other day or a 6-hour pulse stimulation every 
other day, where cultures were put back on cytokine-free culture medium in between stimulation periods. 
The figure shows the morphology with HE staining (a), Ki67 staining (b) to show hyperproliferation upon Th2 
treatment and FLG (c) and LOR (d) staining to show the effect of the cytokines on epidermal differentiation. 
Scale bar = 100 µm.
(a)
(b)
(c)
(d)
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Supplemental Figure 2. Epidermal thickness of FLG +/+ and FLG -/- HEEs. 
Thickness of the viable epidermal layers (stratum basale, stratum spinosum, stratum granulosum) as well as 
the entire epidermal thickness were measured in unstimulated (control) and Th2 cytokine stimulated HEEs. 
Measurements were performed using AxioVison software. Two-way ANOVA was performed to determine 
significant changes in epidermal thickness.
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Supplemental Figure 3. SDS application disrupts the epidermal barrier in vitro. 
(a) Representative H&E staining of a HEE after 90 minutes topical application of 0.5% sodium dodecyl 
sulphate (SDS) to disrupt the epidermal barrier. (b) Immunofluorescence detection of LY (green), which was 
incubated for 60 minutes after SDS application, in combination with DAPI staining for cell nuclei (blue). Scale 
bar = 100 µm. N=3.
Supplemental Figure 4. Normal barrier function of FLG-/- HEEs. 
(a) H&E staining of FLG+/+ and FLG-/- HEEs which were used for barrier permeability assays after 8 days of 
air-liquid interface culture. (b) Staining of biotin, which was incubated apically on the HEEs for 60 minutes, 
shows equal epidermal barrier function in both genotypes as the dye remained on top of the SC, not reaching 
the viable cell layers of the epidermis. Scale bar = 100 µm.
(a)
(a)
(b)
(b)
(c)
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Supplemental Tables
Supplemental Table 2. Antibodies for immunohistochemistry and immunofluorescence.
Target protein Antibody clone, manufacturer Dilution
Cytokeratin-10 DE-K10, Euro Diagnostics 1:100
Filaggrin NCL-Filaggrin, Novocastra 1:200
Loricrin PRB145P, Covance 1:2000
Transglutaminase-1 H-87, Santa Cruz 1:100
Involucrin MON-150, generated by our group149 1:20
Late cornified envelope 3 Generated by our group231 1:5000
4',6-diamidino-2-phenylindole Boehringer Mannheim 1:3000
Streptavidin Alexa Fluor 594 Life Technologies 1:200
Claudin-1 JAY.8, Thermo Fisher Scientific 1:1500
Claudin-4 3E2C1, Thermo Fisher Scientific 1:700
Occludin N19, Santa Cruz 1:250
Supplemental Table 3. Primers used for qPCR.
HUGO  
symbol
alias gene name forward primer 5’-3’ reverse primer 3’-5’ E*
CASP14 Caspase 14 acaaaccatcccaacatacac gatatgtcctttcctcttcgt 2,12
CLDN1 Claudin 1 ccagtcaatgccaggtacga ttggatagggccttggtgtt 1,78
CLDN4 Claudin 4 gctgtaaacaggtttgggca tcagaggggatcagtctcca 1,85
FLG Filaggrin acttcactgagtttcttctgatggtatt tccagacttgagggtctttttctg 1,89
FLG2 Filaggrin 2 accaggttcacttaaacttgca atgacatccactgtgtctggatc 1,96
HRNR Hornerin tacaaggcgtcatcactgtcatc atctggatcgtttggattcttcag 2,12
IVL Involucrin acttatttcgggtccgctaggt gagacatgtagagggacagagtcaag 1,93
LCE2A Late cornified envelope 2A ggacctgtcccagagtgatg gatccaggatgggctcttg 2,10
LOR Loricrin aggttaagacatgaaggatttgcaa ggcaccgatgggcttagag 2,08
OCLN Occludin attggtcaccgagggagga taaaccaatctgctgcgtccta 1,86
RPLP0 hARP caccattgaaatcctgagtgatgt tgaccagcccaaaggagaag 2,02
TGM1 Transglutaminase 1 cccccgcaatgagatctaca atcctcatggtccacgtacaca 1,99
*E is efficiency as fold increase in fluorescence per PCR cycle.
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Abstract
Genetic deficiency or haploinsufficiency of the histidine-rich epidermal protein filaggrin (FLG) is 
associated with ichthyosis vulgaris (IV) and atopic dermatitis (AD). We investigated if the FLG 
genotype affects the microbiota composition of human skin and the cutaneous host response. 
FLG-/- individuals had a low abundance of proteolytic Gram-positive anaerobic cocci (e.g. 
Finegoldia magna), which use peptides as nutrient sources. Furthermore, genes involved in 
histidine utilization were underrepresented in FLG-/- microbiota. An in vitro survival disadvantage 
of F. magna on FLG-deficient stratum corneum supported the in vivo findings. In co-cultures 
with primary human keratinocytes, F. magna induced a stronger antimicrobial peptide response 
than Staphylococcus aureus, whereas S. aureus caused a stronger proinflammatory cytokine 
response than F. magna. Our data indicate that a common genetic defect can shape the 
cutaneous microbiome based on metabolic requirements of certain taxa, and may alter the host 
response to pathogens.
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Introduction
Next Generation Sequencing technologies and powerful bioinformatics tools have enabled 
comprehensive analysis of microbiota of human tissues. Large scale studies of the composition 
of microbial communities on skin of healthy volunteers have revealed that the four most abundant 
phyla of human skin bacteria are Actinobacteria, Firmicutes, Proteobacteria and Bacteroidetes. In 
addition, these studies found that the diversity of microorganisms on our skin is much larger than 
was previously assumed from culture-based methods232,233, and that diversity and composition 
of the skin microbiota strongly depends on the topographical location on the body and has 
a high degree of interpersonal variation. Nevertheless, the dominant types of bacteria remain 
relatively stable over time, and specific bacteria are associated with dry, moist and/or sebaceous 
microenvironments64,65,234. Microbial communities, genetic host factors and the environmental 
factors at a particular moment, constitute a complex relationship that is essential for skin barrier 
homeostasis235-237. The first reports on the human skin microbiota were of healthy volunteers, but 
more recent studies have also focused on the microbiota of diseased and injured skin67,88.
There are numerous monogenic human skin conditions (ichthyoses, blistering skin diseases) 
that alter the properties of the stratum corneum (SC) in such a way that it could affect the 
SC microbial ecology, directly or indirectly. However, none of these have been studied at the 
microbiome level, to date. Here, we selected ichthyosis vulgaris (IV) as a model disease to 
investigate if genetic polymorphisms resulting in altered SC composition and structure could 
lead to distinct changes in skin microbiome makeup. IV is caused by loss-of-function (LOF) 
mutations in the filaggrin (FLG) gene, which are quite common in the general population69. FLG 
LOF mutations are also a strong genetic risk factor for atopic dermatitis (AD)73. FLG is a histidine-
rich structural skin protein that is abundantly expressed in the outer layers of human epidermis, 
where it acts as a glue-like protein that facilitates dense packing of keratin filaments in terminally 
differentiating keratinocytes7. Furthermore, upon degradation, FLG serves as the main source of 
so-called natural moisturizing factors (NMFs), which includes free amino acids like histidine and 
metabolites such as urocanic acid (UCA) and pyrrolidone carboxylic acid (PCA), that allow the 
outermost layers of the SC to remain hydrated238. IV is characterized by a dry and scaly skin75 and 
is associated with abnormalities in epidermal structure and function222, but no microbiological 
abnormalities have been reported.
Here, we analysed the skin microbiota of IV patients of the lower leg, which is typically a location 
where the ichthyotic skin alterations are most prominent. Our data indicated that Gram-positive 
anaerobic cocci (GPAC) such as Finegoldia magna (F. magna), are strongly decreased in the 
skin microbiome of IV patients. Gene expression analysis of epidermal keratinocytes in vitro 
exposed to F. magna or the AD-associated bacterium Staphylococcus aureus (S. aureus), 
revealed distinct early host defense responses depending on the microbial stimulation.
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Material and Methods
Study approval
All volunteers in this study were selected according to the inclusion/exclusion criteria as 
approved by a protocol from the National Institutes of Health (NIH) Human Microbiome Project. 
The exact inclusion/exclusion criteria and study procedures that we presented to the volunteers 
can be found in Supplemental methods. In advance, medical ethical committee (Commissie 
Mensgebonden Onderzoek Arnhem-Nijmegen) approval and individual written informed consent 
were obtained. The study was conducted according to the Declaration of Helsinki principles.
Study participants and skin microbiome samples
Prior to microbiome sample collection, IV patients and healthy controls were all genotyped for 
FLG mutations and checked for FLG protein expression in skin biopsies. Samples were collected 
from the lower leg and obtained by swabbing 4 cm2 skin area using Sterile Catch-All™ Sample 
Collection Swabs (Epicentre Biotechnologies) soaked in sterile SCF-1 solution (50 mM Tris buffer 
[pH8], 1 mM EDTA, and 0.5% Tween-20) as previously described67. As negative controls, we took 
two mock swabs, which were only exposed to ambient air. DNA was extracted from the swabs by 
using the Mobio Ultraclean Microbial DNA Isolation Kit (Mobio laboratories) with modifications as 
described previously67. DNA samples were stored at -20°C until further processing.
Mutation analysis and immunohistochemistry 
Genomic DNA was extracted from saliva samples using the Oragene kit (DNA Genotek Inc.) 
according to the manufacturer’s protocol. FLG mutation analysis (for R501X and 2282del4) 
was performed as described previously80. Skin biopsies (3 mm) were immediately fixed in a 
10% formalin solution (Baker Mallinckrodt) for 4 hours and subsequently embedded in paraffin. 
6 µm paraffin sections were stained with an antibody against filaggrin (1:200, NCL-filaggrin, 
Novocastra) using an indirect immunoperoxidase technique (Vectastain, Vector Laboratories).
PCR amplification and sample preparation
For amplification of the V3-V6 region of the 16S rRNA gene we used the universal forward and 
reverse primers 67.  Forward primer:
5’-CCATCTCATCCCTGCGTGTCTCCGACTCAGNNNNNNACTCCTACGGGA GGCAGCAG-3’ 
(italicized sequence is 454 Life Sciences primer A, bold sequence is the broadly conserved bacterial 
primer 338F; NNNNNN designates the sample-specific 6-base barcode used to tag each PCR 
product), reverse primer: 5’-CCTATCCCCTGTGTGCCTTGGCAGTCTCAGCRRCACGAGCTGAC 
GAC–3’ (the italicized sequence is 454 Life Sciences primer B, and the bold sequence is the 
broadly conserved bacterial primer 1061R). We recently described that skin samples contain 
only small numbers of microorganisms. Therefore, we have introduced a pre-amplification 
step with the same primers as described above excluding the barcodes and flag sequences. 
We established that this additional PCR step did not affect the results compared to a single 
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amplification step with bar-coded primers, in other words, we observed no distortion or skewing 
of the taxa distribution67. PCR amplification protocols of step 1 and step 2 were performed as 
described previously67. The purified PCR products were submitted for pyrosequencing of the 
V3-V4 region of the 16S rRNA gene on the 454 Life Sciences GS-FLX platform using Titanium 
sequencing chemistry at DNAvision, Charleroi, Belgium. 
16S rRNA gene pyrosequencing data analysis
The pyrosequencing data were analysed with a workflow based on QIIME v1.2239 and as 
applied and described previously67, using pipeline settings recommended in the QIIME 
v1.2 tutorial, with the following exceptions: (i) sequencing reads were filtered for chimeric 
sequences using UCHIME240, (ii) OTU clustering was performed with settings as recommended 
in the QIIME newsletter of December 17, 2010 (http://qiime.wordpress.com/2010/12/17/new-
default-parameters-for-uclust-otu-pickers/), using an identity threshold of 97%. In short, (i) 
raw sequencing reads are quality filtered based on length and quality scores, (ii) reads are 
demultiplexed (that is, multiplexed reads are assigned to samples based on their nucleotide 
barcode), (iii) chimeric 16S rRNA gene sequence reads are identified and removed, (iv) reads are 
clustered into OTUs, and representative OTU sequences are selected, (v) OTUs are assigned to 
taxonomy (Greengenes 16S rRNA database version ‘6 October 2010’, as default in QIIME v1.2; 
with QIIME default RDP classifier minimum confidence score of 0.80), and finally, (vi) relative 
abundance per taxon per sample (or per sample group) is calculated based on (total) number of 
reads assigned to that taxon. Alpha diversity metrics were calculated as implemented in QIIME 
v1.2, by bootstrapping 800 reads per sample, and taking the average over four bootstrap trials. 
Hierarchical clustering of samples was performed using UPGMA with weighted UniFrac as a 
distance measure, as implemented in QIIME v1.2. The Ribosomal Database Project classifier 
version 2.0 was applied for taxonomic classification241. Visualization of differences in relative 
abundance of taxa between the study contrast (Figure 3) was done in Cytoscape242. Taxa (i.e. 
nodes) were included in the visualization if they met the following criteria: (i) all samples together 
have at least 10 reads assigned to the taxon, and (ii) the sample groups have a fold-difference of 
at least 0.1 for the taxon, or the taxon has a child (that is, more specific taxonomic classification) 
meeting the first criterion. The significance of the difference in relative abundance of specific taxa 
between sample groups was calculated using the Mann-Whitney U test (see section Statistics). 
After pyrosequencing and applying our QC filtering pipeline, we ended up with a small number 
of 16S sequencing reads for the two air control samples. Based on further (in parallel to the 
skin samples) clustering and composition analysis, combined with the very low number of 16S 
sequencing reads retrieved, we concluded that the negative control samples are of expected 
and sufficient quality (not shown).
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Biophysical measurements and instruments
 In vivo measurements were performed on the outer lower leg. None of the samples regions 
had obvious eczematous signs. The published guidelines for TEWL, SC hydration and skin 
surface pH assessments were followed243-245. TEWL was measured with a condenser-chamber 
method (Aquaflux AF200, Biox Systems), SC hydration with a capacitance-based method 
(Corneometer CM825, Courage and Khazaka) and skin surface pH with a planar pH electrode 
and meter (InLab426, Mettler Toledo and Portamess 913 pH, Knick GmbH & Co. KG). Prior to 
measurements, volunteers acclimatized for at least 15 minutes in a temperature-controlled room 
(22±1°C, relative humidity 55±5%) with the body site to be assessed uncovered. Instruments 
were equilibrated in the same room for at least 30 minutes. The average of three, five and two 
readings taken in close proximity was calculated for TEWL, SC hydration and skin surface pH, 
respectively. The tip of the pH electrode was dipped in distilled water prior application on the skin 
and readings were recorded after stabilizing. The same researcher performed all measurements 
of skin surface pH, while TEWL and SC hydration were measured by another researcher. 
Volunteers were not allowed to apply any cream, soap or shower gel on the lower leg skin from 
the day before the experiments; moreover, they were asked to avoid any contact with water on 
the test site from 3 hours before the measurements.
In vitro model for the human cutaneous microbial ecosystem
We recently developed an in vitro system that mimics human SC for bacterial growth, in which 
human callus serves as substrate and nutrient source for bacteria246. Human callus from the heel 
of six healthy volunteers (FLG+/+) and four FLG deficient IV patients (FLG-/-) was collected using 
a callus rasp (Ped Eggtm). This callus was frozen in liquid nitrogen and subsequently grounded 
using a Micro Dismembrator U (B. Braun Biotech International). Phosphate buffered saline (PBS) 
was added to the callus powder to create a 2% suspension, which was sterilized by exposure 
to gamma radiation (16.2 kGray/63 hours). To prepare the model, one mL of sterile agar (2% 
in PBS) was added in wells of 24-well cell culture plates. On top of this agar, 100 µL of sterile 
callus suspension (2% in PBS) was pipetted (Supplemental Figure 4). The plate was allowed to 
dry for 24 hours at 37°C, and stored at 4°C until further use. Bacteria (F. magna) were incubated 
on the model at 32°C in anaerobic conditions for seven days. The entire model (agar + callus 
+ bacteria) was lifted out of the 24-wells plate and transferred to a 50-mL tube containing 5 mL 
PBS. The tubes were vortexed at maximum speed for one minute to detach the bacteria from 
the model. The aqueous solution containing the bacteria (including callus particles, but without 
the agar) was transferred to a new tube. These samples were serially diluted in steps of 5. Ten 
µL of each dilution was placed on sheep blood agar plates and incubated at 37°C in anaerobic 
conditions. Next days, colonies visible on the plate were counted for each dilution.
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Finegoldia magna growth on the in vitro stratum corneum model 
Finegoldia magna type strain 2974 (DSM nr. 20470, ATCC nr. 15794) was inoculated on Columbia 
agar with 5% sheep blood (Dickinson and Company, BD) and grown for four days at 37°C in 
anaerobic conditions. One single colony of the plate was picked and cultured in Brain Heart 
Infusion medium (Mediaproducts BV) for four days at 37°C (anaerobic conditions). Hereafter, the 
bacteria were collected by centrifugation, washed two times with PBS and finally resuspended in 
PBS resulting in bacterial concentrations of 105 CFU/mL. Portions of 20 µL bacteria (2x103 CFU) 
suspension were added to each well of the SC model (with callus derived from FLG+/+ and FLG-/- 
individuals as described above). The bacteria on the model were incubated at 32°C in anaerobic 
conditions for seven days.
Determination of FLG degradation products in callus
The FLG degradation products in callus have been determined by a slightly adapted HPLC 
method reported previously247. 1 mg of callus sample was extracted with 0.5 mL of 25% (w=w) 
ammonia solution by vigorous shaking using IKA-Vibrax-VXR Model 2200 (IKA-works Inc.). 
Ammonia extracts were evaporated to dryness, resolved in 0.5 mL of water, and subsequently 
filtered through a 0.2 mm PVDF membrane filter (Grace Davison Discovery Science). Before 
HPLC analysis, the aliquots were diluted 1:1 with the mobile phase.
Microbiota derived functional prediction by PICRUSt 
For each of the sequencing samples, bacterial 16S profiles of the skin microbiota were 
obtained as described above. Based on these profiles, we predicted the presence of KEGG 
Orthologs (K numbers) and subsequent functional and metabolic pathways for IV patients (FLG-
/- and FLG+/-) and healthy controls (FLG+/+) using PICRUSt (version 1.0.0)248. The Phylogenetic 
Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) method248 
allow for computationally predicting microbiota (i.e. single microbial entities or, as presented 
in this manuscript, complete communities) their function potential, based on interring 16S 
marker-gene sequencing-derived information. PICRUSt requires closed-reference OTU picking 
in QIIME239, which was done to the Greengenes249 reference collection (version 13.5, May 2013). 
For this step, the same sequencing reads were used as those provided for the QIIME workflow, 
as described above. Thereafter, for analysis in PICRUSt, the total skin makeup of microbiota 
for each FLG genotypic group (as derived from QIIME, after OTU clustering and identification) 
was considered; in other words, no OTUs were sub-selected or excluded from analysis. The 
default (and author advised) workflow of PICRUSt was followed: (i) OTUs were normalized by 
dividing each OTU by the known or predicted 16S copy number abundance of its Greengenes 
reference, (ii) a (metagenome) functional predictions table was generated by multiplying each 
normalized OTU abundance by each predicted functional trait abundance, which was input 
for our further downstream analysis (for any additional detail, or for more information about 
the PICRUSt workflow we refer to the PICRUSt website: http://picrust.github.io). The PICRUSt 
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downstream analysis was focused on candidate genes only (KEGG Orthologs; K numbers), 
by applying in-house Perl scripts that filtered-out the required KEGG Orthologs. The candidate 
genes were selected from the Hut pathway based on a review250, and are listed in Supplemental 
Table 4. For additional calculation of relative abundances of pathways and KEGG Orthologs, 
and for downstream statistics, in-house Python scripts were used (see section Statistics). Based 
on the KEGG pathway (http://www.genome.jp/kegg/) for ‘histidine metabolism’ (ko00340), a 
map was constructed in the Cytoscape network interaction visualization program242 with use 
of the KEGGScape app/plugin251 in order to visualize the differential (relative) abundance and 
metabolic context of candidate Hut genes between the study contrast.
Keratinocyte cultures and bacterial stimulations 
Primary human keratinocytes obtained from abdominal plastic skin surgery were isolated and 
expanded according to the Rheinwald-Green protocol223 and stored in liquid nitrogen. Primary 
human keratinocytes were cultured in keratinocyte growth medium (KGM bullet kit, Lonza) 
without antibiotics as described earlier168. Staphylococcus aureus (ATCC 29213) was obtained 
from the department of Medical Microbiology of the Radboudumc. F. magna (DSM 20470) was 
purchased from DMSZ, Braunschweig, Germany. Bacteria were inoculated on Columbia agar 
with 5% sheep blood (Dickinson and Company (BD), Sparks, MD) overnight (S. aureus) or for 
four days (F. magna) at 37°C. One single colony of each plate was picked and cultured in Brain 
Heart Infusion medium (Mediaproducts BV, Groningen, The Netherlands). F. magna was cultured 
under strict anaerobic conditions. S. aureus and F. magna were collected by centrifugation, 
washed two times with PBS and finally resuspended in PBS resulting in bacterial concentrations 
of 107 CFU/mL. A portion of the bacterial suspensions was exposed to 85°C for 25 minutes to 
heat-kill the bacteria. To determine the amount of S. aureus and F. magna that was brought on 
the keratinocyte cultures, bacterial suspensions were serially diluted in steps of 5. Ten µL of each 
dilution was placed on sheep blood agar plates and incubated overnight (S. aureus) or for four 
days (F. magna) at 37°C in aerobic or anaerobic conditions, respectively. Visible colonies on 
the plate were counted for each dilution. The number of CFU was calculated: counted CFU x 
dilution factor. Confluent submerged keratinocyte cultures (plastic surgery controls, N=10) were 
inoculated with 3.5x105 viable and heat-killed bacteria and incubated for 10 hours. Cells were 
washed after 6 hours and incubated for another 4 hours in fresh medium before the keratinocytes 
were collected (t=10 hours). Afterwards, the bacteria were washed away and the keratinocytes 
were harvested and processed for RNA isolation and qPCR analysis.
RNA isolation and qPCR analysis
RNA isolation, cDNA synthesis and qPCR analysis was performed as described earlier13. All primers were 
designed and used as described previously225. Target gene expression was normalized to the expression 
of the house keeping gene human acidic ribosomal phosphoprotein P0 (RPLP0). The ΔΔCt method was 
used to calculate relative mRNA expression levels132 (see Supplemental Table 5 for primer sequences).
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Accession numbers
The raw, and unprocessed 16S sequencing reads data is publicly available for download at the 
European Nucleotide Archive (ENA) database (http://www.ebi.ac.uk/ena) under study accession 
number PRJEB11661 (or secondary accession number ERP013063)252. The sequencing data is 
available in fastq-format, including corresponding metadata for each sample.
Statistics 
For the microbiota data in this manuscript, statistical significance between contrasts with regard 
to taxonomy abundances and thereof derived KEGG Orthologs abundances was tested by the 
non-parametric Mann-Whitney U, corrected with Bonferroni for multiple testing; unless stated 
otherwise. Statistical tests were performed by custom, in-house R-scripts (version 3.1.2; https://
www.r-project.org/) or as implemented in SciPy (https://www.scipy.org/), downstream of QIIME 
and PICRUSt analyses as described above. Multivariate Redundancy Analysis (RDA) was 
done using Canoco 5.04 253using default settings of the analysis type “Constrained”. Relative 
abundance values for either taxa were used as response data and the sample FLG status as 
explanatory variable. RDA calculates p-values by permutating the sample FLG status. For all 
other experiments, statistical significance was tested by a non-parametric Mann-Whitney U test 
or repeated measures ANOVA with Bonferroni’s post-hoc test.
Results
Differences in skin microbiota composition between filaggrin deficient individuals and 
healthy controls. 
We recruited 17 patients with the clinical diagnosis of IV (see Supplemental Table 1 for details). 
Patients were genotyped for the two most common FLG mutations in the Western population: 
R501X and 2282del4. In addition, we performed FLG protein staining on skin biopsies (Figure 1). 
Figure 1. Filaggrin staining of upper buttock skin. 
(a) Healthy controls (FLG+/+) show filaggrin staining in the stratum granulosum layer of the epidermis. 
Both keratohyalin granules and nuclei are positive. (b) Skin from IV patients homozygous or compound 
heterozygous for the FLG R501X and 2282del4 mutations (FLG-/-) were negative for FLG protein staining. (c) 
Genotyped patients wherein only one mutation was found (R501X, for N=2), were tested for FLG expression. 
When negative, the patient still has to have an unknown mutation somewhere else in the FLG gene (i.e. 
R501X/?) and consequently was classified in the FLG deficient group (FLG-/-). Scale bar = 100 µm.
(a) (b) (c)
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We identified FLG mutations in all 17 patients. All homozygous or compound heterozygous 
patients were negative for FLG protein staining. Notably, four patients with a clinical diagnosis of 
IV were heterozygous for FLG mutations and had residual FLG protein staining in skin biopsies 
(designated FLG+/-). This small group was analysed separately. We analysed the microbiota 
composition of the 13 FLG-/- patients, the four FLG+/- individuals and 10 healthy FLG+/+ 
controls (Supplemental Table 1). These groups did not significantly differ regarding age and 
sex. The lower leg was selected for biophysical measurements, as this is the area where the 
ichthyotic phenotype (dry and scaly skin) is most evident (15). A large proportion of IV patients 
has concomitant AD, a disease known to be characterized by microbiome alterations and 
colonization of the lesional skin by S. aureus. However, none of the IV patients in our study 
had eczematous lesions present at the lower leg, thereby excluding (lesional) AD-associated 
microbiome alterations as a confounding factor. Biophysical measurements showed increased 
transepidermal water loss (TEWL), decreased SC hydration, and an equal skin surface pH value 
in FLG-/- subjects compared to FLG+/+ subjects (Supplemental Figure 1). Microbiome samples 
were taken from the same location by swabbing, and subsequently analysed by barcoded 
16S marker gene sequencing. In total, 43,137 bacterial 16S rRNA sequences were analysed, 
resulting in an average of 1,598 ± 546 (range 811-3,471) reads per sample (Supplemental Table 
2 and 3). Taxonomic composition analysis revealed that 99.5% of the operational taxonomical 
units (OTUs) could be assigned to the phylum level, and 90.6% could be assigned to the genus 
level (Supplemental Table 2). In total, four-hundred and forty-seven different OTUs were detected 
(represented by at least five sequencing reads). Rarefaction curves show that the phylogenetic 
diversity does not differ between FLG+/+, FLG-/- and also FLG+/- samples (Supplemental Figure 2). 
Overall, no differences in bacterial diversity were found between the samples for all four diversity-
metrics tested (see Supplemental Figure 3 for whole tree phylogenetic diversity, observed 
OTUs, Shannon, and Chao1). Redundancy Analysis (RDA) revealed a significant effect of FLG 
deficiency on microbiota composition (Figure 2; permutation test p-value = 0.034). 
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Figure 2. Skin microbiota from FLG+/+ and FLG-/- individuals are significantly different. 
The figure shows a Redundancy Analysis (RDA) triplot. Green diamonds and black circles 
represent FLG+/+ and FLG
-/- samples, respectively. Red triangles are the centroids of the 
corresponding sample groups. The blue arrows are the 20 best-fitting genera (names in italic), i.e. 
best explaining microbiota compositional differences between the FLG contrast. The horizontal 
axis maximizes the variation in sample groups (in contrast to a principal component analysis 
plot, where the variation between individual samples is maximized). The difference in microbiota 
is significant (according to a permutation test; p = 0.034), i.e. randomly assigning samples to 
sample groups and repeating the RDA analysis produces a plot where the difference between 
sample groups is smaller than in the real data.
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Figure 3. Difference in microbial community composition between FLG+/+ and FLG-/- individuals. 
Nodes represent taxa, edges link the different taxonomic levels. Node colour indicates the difference in 
abundance (red is more abundant in FLG+/+, blue in FLG-/-), calculated as the 2log of the ratio of the relative 
abundance (0 = no difference between genotypes, 1 = twice as abundant in FLG+/+, and so on). The 
significance is represented by the thickness of the node borders and expressed as the p-value of a Mann-
Whitney U test of the samples. The size of a node represents the average relative abundance of a taxon (note 
that the relation between node-size and abundance is non-linear).
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In accordance, we used taxonomy-based OTU classification provided by the Ribosomal Database 
Project combined with statistical mining to identify significant differences in microbiota composition 
(Figure 3 and Excel file 1 of online repository http://www.sciencedirect.com/science/article/pii/
S0091674916311174)254. A lower relative abundance of proteolytic GPAC of the family Incertae-
Sedis-XI (average 1.7% of the total genera) was found in FLG-/- skin compared to FLG+/+ skin 
(average 9.3% of the total genera). This family included the genera Finegoldia, Anaerococcus, 
and Peptoniphilus and all belong to the class Clostridia (phylum Firmicutes), and no other genera 
were identified within this GPAC family above 0.1% of total reads. Most GPAC are asaccharolytic 
and use the products of protein degradation as substrates for metabolic energy generation255. 
The average relative quantities of these candidate discriminating genera (Figure 4) supported a 
significant difference between the FLG deficient and proficient state, or more specifically, a strong 
decrease by effect of FLG protein loss. Interestingly, in FLG+/- individuals these three genera tended 
to be present at intermediate relative abundance quantities, which suggests a FLG gene dosage 
effect. Other highly abundant genera present in the skin microbiome, such as Staphylococcus, 
Propionibacterium and Corynebacterium or the AD-associated species S. aureus did not show 
significant differences between the genotypes (see Excel file 1 of online repository http://www.
sciencedirect.com/science/article/pii/S0091674916311174), which is in accordance with the lack 
of eczematous lesions that would be expected to be accompanied by elevated relative abundance 
levels of S. aureus. We therefore focused on members of the GPAC group for further in silico 
analysis and experimental studies.
Figure 4. Differences in relative abundance between filaggrin genotypes for the genera 
Finegoldia, Anaerococcus and Peptoniphilus. 
Horizontal double-headed arrows indicate significant differences (Mann-Whitney U test).
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Figure 5. Lower total NMF levels in callus affect in vitro growth of Finegoldia magna bacteria. 
(a) NMF content analysis of callus derived from FLG-/- (N=4) and FLG+/+ (N=5) individuals. Data are 
represented as mean ± SEM. Mann-Whitney U test. *p < 0.02, **p < 0.01 (HIS, p = 0.06; UCA, p = 0.08). 
HIS, histidine; PCA, pyrrolidone carboxylic acid, UCA, urocanic acid. (b) F. magna growth on the in vitro 
stratum corneum model using callus derived from FLG-/- (N=4) and FLG+/+ (N=6) individuals. Data are 
represented as mean ± SEM. Mann-Whitney U test. *p < 0.03. (c) Correlation between the growth rate of F. 
magna and the NMF content of FLG-/- and FLG+/+ callus on which the bacteria are grown.
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Filaggrin deficiency influences stratum corneum NMF content and in vitro growth of 
Finegoldia magna. 
As the absence of FLG in the terminally differentiating keratinocytes can lead to lower levels 
of peptides and amino acids (NMFs) in the SC as reported for skin of the lower arm220, we 
hypothesized that the low abundance of proteolytic GPAC (as indicated in Figures 3 and 4) could 
be the result of FLG deficiency and decreased availability of its breakdown products. Plantar 
callus can serve in vitro as a sole carbon and nitrogen source for (commensal) microorganisms 
in order to survive and grow246. We investigated the growth of the GPAC type strain F. magna, 
a member of the genus that was most significantly different between FLG-/- skin compared to 
FLG+/+ skin, in our recently developed in vitro system that utilizes human SC for bacterial growth 
(Supplemental Figure 4), and which can be used to study individual microorganisms or (ex 
vivo) microbial ecology246. We found that FLG is present in normal plantar skin, which could 
therefore be conveniently used as a source of FLG-containing SC (Supplemental Figure 5). 
We used callus from healthy FLG+/+ controls and from IV patients homozygous for FLG LOF 
mutations (FLG-/-). As the composition of FLG breakdown products in human plantar callus 
was unknown, we analysed the NMF content of callus from patients and healthy subjects by 
high-performance liquid chromatography (HPLC). Indeed, we found that patient-derived callus 
contained significantly lower total NMF levels (Figure 5A). Approximately 2x103 F. magna bacteria 
were subsequently inoculated on the in vitro SC model and incubated at 32°C under anaerobic 
conditions. Bacterial growth of F. magna was determined after one week by enumerating colony 
forming units (CFUs). The data showed that callus derived from IV patients deficient for FLG is a 
less favourable substrate for these bacteria than callus from healthy individuals with normal FLG 
protein expression (Figure 5B), as concluded from the lower number of CFUs for F. magna when 
grown on FLG-/- callus. A positive correlation (Spearman rho = 0.82, p = 0.005, see Figure 5c) 
was found when we plotted the F. magna growth of all samples versus the total NMF content (i.e. 
PCA, UCA and histidine combined).
Hut genes are underrepresented in the microbiota of filaggrin deficient skin. 
We tested the potential involvement of microbial reactions utilizing NMF factors histidine, UCA 
and PCA. According to KEGG (Kyoto Encyclopedia of Genes and Genomes)256, two orthology 
groups utilize PCA (KEGG compound name C01879; Pidolic acid): KEGG Orthologs K00682 
and K01469. Only K01469 was predicted to be present in the microbiomes. Next to its very low 
relative abundance (0.0003%, on average) it did not differ significantly between FLG status. The 
microbial reactions utilizing histidine and UCA are the same, as UCA (urocanate; see Figure 6) 
is an intermediate product in the conversion of histidine to glutamate. The human profilaggrin 
polypeptide has a high histidine content (413/4061 residues; 10.2%)257. Histidine is a known carbon 
source for bacteria that possess the histidine utilization (Hut) pathway, which is highly conserved 
among bacteria and found with high frequency in most phylogenetic groups within the bacterial 
domain250. This notion, together with the observation of the low abundance of proteolytic GPAC in 
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FLG deficient patients, prompted us to examine the presence of Hut pathway genes in the skin 
microbiota of IV patients compared to healthy controls (Excel file 2 of online repository http://www.
sciencedirect.com/science/article/pii/S0091674916311174). The Hut operon contains several hut 
genes present as orthologs in a wide range of bacterial species, that allow loss-of-function for 
conversion of histidine to glutamate by different routes (Figure 6a)250. 
In the first phase, three core hut genes encoding a histidase (hutH), a urocanase (hutU) and an 
imidazolone-5-propionate hydrolase (IPase, hutI) are involved in catabolic conversion of histidine 
to formimino glutamate (FIG). In the second phase, FIG is converted to glutamate, either directly 
by the hutG encoded FIGase, or indirectly via the intermediate formyl glutamate by the hutF 
encoded FIGdeiminase. These five hut genes were chosen as candidates in a contrast analysis 
by PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of Unobserved 
States), based on functional predictions derived from the 16S marker gene sequencing data248. 
KEGG Orthologs (K numbers) of genes in the Hut pathway were extracted from KEGG. All five a 
priori selected hut gene candidates (Supplemental Table 4) were predicted to be present in the 
microbiota of IV (FLG-/- and FLG+/-) and healthy controls (FLG+/+). Interestingly, contrast analysis 
of IV versus healthy skin revealed that hutU, hutI and hutH orthologous genes were predicted 
to be significantly underrepresented in the microbiota of IV patients (Figure 6B). Furthermore, 
in an overrepresentation analysis of the FLG+/+ versus FLG-/- contrast, ranking all K numbers 
on their p-value (as determined by Mann-Whitney U test) from low to high resulted in a strong 
enrichment of the significant differentially abundant candidate hut genes K01712, K01468 and 
K01745 (Figure 6) in the top list, at ranks 41, 80 and 116 respectively (Supplemental Table 4), 
out of a total of 5838 identified K numbers. Correspondingly, the non-significantly different hut 
genes K01479 and K05603 rank considerably lower at positions 379 and 4200, respectively. 
This overrepresentation data corroborates that the observed effect on hut genes as a result of 
the FLG deficiency is not a random one, and is in agreement with the observation that patient 
derived callus contained lower levels of histidine and its metabolites.
6115
Figure 6. Function analysis of the skin microbiota reveals a decreased histidine utilization 
capacity in FLG deficient patients. 
(a) KEGG map of histidine metabolism (snapshot) and the candidate hut genes. Nodes represent 
compounds, the pink node represents our compound of interest: histidine; the green node represents the 
Hut pathway its end product: glutamate. Boxes represent enzyme functions/reactions, numbers shown 
(a)
(b)
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inside are K numbers (i.e. KEGG Orthologs). Coloured boxes correspond to hut gene candidates that were 
a priory selected for function analysis by PICRUSt: blue indicates a decrease in the relative abundance of 
a hut gene as effect of FLG deficiency, and orange indicates an increase in these genes compared to wild 
type; gray boxes were excluded from analysis. This colour representation of the fold-change difference is 
calculated as the 2log of the ratio of the relative abundance between FLG wild type and knockout (0 = no 
difference between genotypes, 1 = twice as abundant in wild type, etcetera). The significance (box border 
width) is expressed as the p-value of a Mann–Whitney U test with Bonferroni’s correction for multiple testing. 
Arrows link the conversion of one compound to another, facilitated by an enzyme function/reaction. (b) Box 
plots with relative abundances of the candidate hut genes for FLG+/+ and FLG-/- genotypes. The relative 
abundance is calculated over all K numbers identified in the total microbiota.
Distinct host defense responses depending on bacterial species. 
FLG LOF mutations predispose to AD both in haploinsufficient individuals but even more strongly 
in homozygous IV patients. A plausible mechanism, but still largely hypothetical, is an effect 
on skin barrier which would allow for increased exposure to environmental allergens. Other 
mechanisms have not yet been investigated to our knowledge. As microbial factors such as 
S. aureus colonization have been implicated in AD, we explored possible interactions of the 
pathogen S. aureus and the commensal F. magna with epidermal keratinocytes. We investigated 
the effect of S. aureus and F. magna on normal human epidermal keratinocytes. We used a 
submerged monolayer keratinocyte model from 10 FLG+/+ donors stimulated with viable or heat-
killed S. aureus and F. magna bacteria, and determined the keratinocyte host defense response 
following 10 hours of exposure to microorganisms. We selected 8 keratinocyte-expressed genes 
based on previous work or data from literature, which included the cytokines IL-1β, IL-6 and 
TNFα, the chemokines IL-8 and CCL20, and the antimicrobial peptides (AMP) hBD2, hBD3 and 
LL37 (Figure 7). Viable F. magna induced a significantly higher expression of AMPs and IL-1β 
compared to S. aureus. For viable S. aureus, keratinocyte stimulation caused a significantly 
higher expression of IL-6, IL-8 and CCL20 by these cells than seen for stimulation with viable 
F. magna. Heat-killed S. aureus cells were in general less potent stimuli, whereas heat-killed F. 
magna showed equal gene expression levels as viable F. magna.
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Figure 7. Keratinocyte host defense responses differ between bacterial stimulations.
Submerged keratinocytes (derived from healthy FLG+/+ controls, N=10) were stimulated for 10 hours with 
viable and heat-killed S. aureus and F. magna. Expression of 8 host defense genes was measured by qPCR. 
For each gene, the control cell culture (not stimulated) was set to 1. The following bacteria-induced expression 
levels of host defense molecules were significantly different compared to their non-stimulated controls: IL-6, 
IL-8, TNFα, IL-1β, and CCL20 levels in control versus viable S. aureus stimulation (p < 0.001), and hBD2 and 
CCL20 levels in control versus viable and heat-killed F. magna stimulation (p < 0.001). All other combinations 
of control compared to bacterial stimulation (viable and heat-killed) were not significantly different. Significant 
differences between bacterial species and viable versus heat-killed bacteria are indicated in the graphs. *p 
< 0.05, **p < 0.01, ***p < 0.001. Data are represented as mean ± SEM. Repeated measures ANOVA with 
Bonferroni’s post-hoc test on the ΔCt values of the qPCR data.
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Discussion
In this study, we report two novel findings with respect to genetic deficiency of the skin protein 
FLG and cutaneous microbiota. Firstly, we show that FLG deficiency is associated with a low 
relative abundance of proteolytic GPAC, and an underrepresentation of bacteria, not limited to 
GPAC taxa, capable of utilizing histidine. In vitro experiments support the hypothesis that there 
is a direct mechanistic link between the absence of FLG breakdown products and microbiome 
alterations. Secondly, we show that cultured keratinocytes express proinflammatory cytokines 
upon viable-microbiota stimulation by S. aureus, whereas F. magna stimulation revealed a rapid 
AMP response not seen upon S. aureus stimulation.
The composition of human microbiomes is strongly influenced by an array of environmental 
factors such as diet, lifestyle, antibiotics use, exposure to pathogens and social interactions. 
In addition to the contribution of environmental factors, evidence is accumulating to support 
a host genetic component as well. For example, this has been demonstrated for genetic 
polymorphisms that contribute to an increased predisposition to inflammatory bowel diseases258 
and Crohn’s disease in humans259. Recently, analysis of host genetic variation data mined from 
shotgun metagenomic data from the Human Microbiome Project (HMP) revealed a correlation 
between host genetic variation in immunity-related pathways and microbiome composition237. 
These studies have uncovered human genes and pathways associated with particular genetic 
backgrounds, although, an unequivocal demonstration of causality still remains challenging 
in human population-based studies. To date, no human studies are available regarding 
specific genetic defects of SC composition and structure in relation to cutaneous microbiome 
composition. Recently, the skin microbiota of wild type mice versus caspase-14 deficient mice 
was compared260. Caspase-14, a protease mainly active in terminally differentiated keratinocytes, 
is required for the generation of NMFs by processing of FLG protein261. It was hypothesized 
that a caspase-14 deficiency reduced the levels of NMFs and could create an altered nutrient 
environment for commensal bacteria, which was supported by an imbalance of skin-microbiota 
in caspase-14 deficient mice260. However, these mice also displayed increased AMP expression 
after Escherichia coli challenge, which may suggest an alternative explanation for the observed 
skin microbiota changes in these mice.
Genome-wide approaches that find an association between genetic polymorphisms and 
microbiome composition should be rigorously controlled for confounding effects of non-genetic 
factors such as population stratification, which may lead to spurious correlations. Monogenic, 
Mendelian disorders are easier to study and can be better controlled. Previous studies have 
documented the strongly abnormal microbiomes of skin lesions in patients with mucocutaneous 
candidiasis and Hyper-IgE Syndrome (HIES), based on mutations in host defense genes262,263. 
Deficient Th17 responses lead to uncontrolled growth of pathogens and overt infections. In these 
cases, there is a causal relationship between a genetic abnormality and infection. In our current 
study, a potential confounding factor could be the co-occurrence of AD, since heterozygosity for 
FLG null alleles is a known strong risk factor for AD in the general population, and homozygosity 
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for FLG LOF mutations, such as those in IV, is associated with a prevalence of AD of 60-70% in 
these patients73. The lesional skin of AD patients is often colonized by S. aureus, both in FLG 
null allele carriers and in FLG-proficient AD patients, suggesting that AD, and not FLG deficiency 
per se causes the colonization of this bacterium in lesional skin. In our study, although a large 
proportion of our patient cohort had a history of AD (65%, see Supplemental Table 1), none of 
them had active AD lesions in the skin areas that were sampled. This is also supported by the 
fact that dominance of Staphylococci was not observed in any of the samples, as would have 
been expected for lesional AD skin88. An additional RDA, based on genus-level compositional 
microbiota profiles of IV patients with and without comorbid AD, revealed that both patient 
groups (IV with/without AD) cannot be confidently separated based on microbiota composition 
(p = 0.63, p-value calculated by randomly permutating the samples’ AD status), indicating that 
our cohort data is not biased by AD status of the patient sample. This may be due to the fact that 
samples are derived from a location that is not commonly affected by eczema.
The microbiome function prediction strongly supports a metabolic basis for the microbiota 
compositional changes observed in IV patients, since the shift in bacterial composition in FLG 
deficient relative to wild-type skin could be connected to reduced levels of hut genes in the 
microbiota gene pool. The specific contribution of the Incertae-Sedis-XI family GPAC to the total 
microbial content of hut genes is very low (0.09% for FLG-/- and 0.36% for FLG+/+, data not shown); 
which may not be surprising, as the relative abundance of the three candidate GPAC bacteria 
is relatively low (1.22% and 8.67% for FLG-/- and FLG+/+, respectively, see Figure 4). Notably, the 
reduced levels of any of the candidate hut genes (i.e. hutH, hutI and hutU, see Figure 6) did not 
correlate to the abundance of any single bacterial genus or family (data not shown), illustrating 
the broad phylogenetic distribution of the hut genes within the total microbiota, and exemplifying 
the importance of the decreased hut prevalence associated with FLG deficiency. In conclusion, 
our study reveals that FLG deficient skin harbours significantly fewer bacterial taxa capable of 
utilizing histidine as nutrient (carbon) source, which we postulate to be a consequence of nutrient 
competition driven by the loss of the histidine-rich protein FLG.
Although the primary scope of this study was to investigate a relationship between FLG 
deficiency and cutaneous microbiome alterations, an obvious and highly relevant question 
would be whether the shift of cutaneous microbiota could play a role in the development of AD 
in patients that carry FLG null alleles. It has to be noted, however, that FLG LOF mutations are 
neither a necessary nor a sufficient condition for the development of AD. This is illustrated by 
the observation that in Western Europe only 20-40% of AD patients carry FLG null alleles and 
up to 9% of healthy controls are carriers of FLG null alleles264. Clearly, other genetic causes and 
exposure to environmental factors (allergens, microbes) could be important in the development 
of AD265. It is, nevertheless, very well possible that microbiota changes due to FLG deficiency 
will affect the cutaneous immune system in such a way that a Th2 response against common 
environmental allergens is facilitated. Host-microbe and microbe-microbe interactions could alter 
the local skin microbiota composition, as resident skin bacteria are able to control colonization 
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by potentially pathogenic microorganisms266,267 and can modulate the cutaneous immune 
system268-270. Very recently, an individual’s skin microbiota community structure was linked to the 
ability to clear a bacterial pathogenic infection271. Furthermore, commensal microorganisms may 
produce numerous small molecules with a diverse range of targets that can modulate immune 
responses, for example, to compete with other bacteria272.
Our observation that keratinocytes appear to exhibit different cytokine/AMP responses towards 
S. aureus or F. magna stimulation is intriguing. Given the known functions and activities of 
IL-8 (neutrophil chemoattractant), TNF-α (proinflammatory, induction of AMPs) and CCL20 
(chemoattractant for various white blood cell types, antimicrobial activity), their strong induction 
by S. aureus (25 to 85-fold) contributes to control of infection. The observed rapid induction 
of AMPs by F. magna, however, suggests that this bacterium may be an important signalling 
factor to the keratinocytes when the skin barrier is breached. It should be noted that there is not 
a well-developed stratum corneum in a submerged culture, the bacteria are in direct contact 
with the keratinocytes. Although F. magna is not known as a major taxon of the commensal skin 
microbiota, we found it to represent on average 8% of all the mapped OTU’s of normal lower 
leg skin, which is not insignificant. Complete or partial absence of F. magna could cause an 
impaired or delayed danger signalling to the keratinocytes in FLG-/- or FLG+/- individuals. This 
could, speculatively, be a mechanism that favours S. aureus colonization or infection, but clearly 
requires further investigation.
In conclusion, we have uncovered new and potentially important biological aspects of a very 
common genetic polymorphism that is associated with a major inflammatory disease. The 
notion that FLG deficiency or haploinsufficiency may cause skin barrier dysfunction, microbiome 
alterations and attenuated danger signalling generates new testable hypotheses regarding the 
disease mechanisms of AD.
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Supplemental Methods
Exclusion / Inclusion Criteria
Any subject who meets any of the following criteria will be excluded from participation in this 
study. Keep in mind that these criteria are written for healthy controls! IV patients can have 
eczematous lesions (obviously) and therefore this not an exclusion criterion for this group.
Criteria:
•  Body Mass Index greater than or equal to 35 or less than or equal to 18.
•   Use of any of the following drugs within the last 6 months:
  - systemic antibiotics (intravenous, intramuscular, or oral);
  -  oral, intravenous, intramuscular, nasal or inhaled corticosteroids;
  - cytokines;
  -  methotrexate or immunosuppressive cytotoxic agents;
  -  large doses of commercial probiotics consumed (greater than or equal to 108 CFU or 
organisms per day) - includes tablets, capsules, lozenges, chewing gum or powders 
in which probiotic is a primary component. Ordinary dietary components such as 
fermented beverages/milks, yogurts, foods do not apply.
• Use of topical antibiotics, antifungal or topical steroids within the previous 7 days.
•  Acute disease at the time of enrolment (defer sampling until subject recovers). Acute disease 
is defined as the presence of a moderate or severe illness with or without fever.
•   Chronic, clinically significant (unresolved, requiring on-going medical management 
or medication) pulmonary, cardiovascular, gastrointestinal, hepatic or renal functional 
abnormality, as determined by medical history or physical examination.
•   History of cancer except for squamous or basal cell carcinomas of the skin that have been 
medically managed by local excision.
•   Unstable dietary history as defined by major changes in diet during the previous month, 
where the subject has eliminated or significantly increased a major food group in the diet.
•   Recent history of chronic alcohol consumption defined as more than five 1.5-ounce servings 
of 80 proof distilled spirits, five 12-ounce servings of beer or five 5-ounce servings of wine per 
day.
•  Confirmed positive test for HIV, HBV or HCV. 
•   Any confirmed or suspected condition/state of immunosuppression or immunodeficiency 
(primary or acquired) including HIV infection.
•   Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in 
the past five years. Any major bowel resection at any time.
•   History of active uncontrolled gastrointestinal disorders or diseases including:
  -  inflammatory bowel disease (IBD) including ulcerative colitis (mild-moderate-severe), 
Crohn's disease (mild-moderate-severe), or indeterminate colitis;
  - irritable bowel syndrome (IBS) (moderate-severe);
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  -  persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown 
etiology, Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated);
  - chronic constipation.
•  Female who is pregnant or lactating.
•  Treatment for or suspicion of ever having had toxic shock syndrome.
•  History of psoriasis or recurrent eczema.
•  History of recurrent rashes within the past 6 months.
•   At the time of the screening visit or on the specimen collection day:
  -  acne at sites other than on the face, chest, back or shoulders;
  -  multiple blisters, pustules, boils, abscesses, erosions or ulcers on the scalp, face, neck, 
arms, forearms or hands;
  -  a single blister, pustule, boil, abscess, erosion, ulcer, scab, cut, crack or pink/
hyperpigmented patch or plaque at or within 4 cm of the sampling sites; sampling may 
be deferred until the lesion resolves either without treatment or with local treatment only;
  -  more than one pink/red scaly patch/plaque anywhere on the body (suggestive of 
psoriasis or eczema);
  -  uniformly thickened, cracking, “dry” skin on bilateral palms and/or soles;
  -  scalp dandruff that does not clear up with over-the-counter dandruff shampoos used 
daily for 2 weeks;
  -  disseminated rash (at multiple body sites or extending throughout a broad body area).
•  Chronic dry mouth.
•  Periodontitis / gingivitis. 
•  Evidence of untreated cavitated carious lesions or oral abscesses.
•  Evidence of precancerous or cancerous oral lesions.
•  Evidence of oral candidiasis.
•   More than 8 missing teeth. The missing teeth must be due to 3rd molar extractions and/or 
teeth extracted for orthodontic purposes, teeth extracted as a result of trauma, or teeth that 
are congenitally missing.
Study procedures
• Subjects have to refrain from swimming in a chlorinated pool or using a hot tub for 48 hours 
prior to sampling visit.
• Subjects have to avoid the use of sauna/steam baths for 48 hours prior to sampling visit.
• Subjects have to avoid the use of tanning bed for 48 hours prior to sampling visit.
• Bathe/shower procedure:
  -  iDo NOT shower on the sampling day (you can wash your hair but avoid leaking soap to the 
rest of your body, and do NOT rub up your lower leg skin (avoid soap as much as possible).
  -  iDo NOT scrub your lower leg skin with a towel, please dab a little to dry if necessary.
  -  iAvoid the use of body lotion on the lower leg on the sampling day.
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Supplemental Figures
Supplemental Figure 1. Biophysical measurements on the lower leg skin. 
Transepidermal water loss (TEWL), stratum corneum hydration (SC) and pH of the skin surface was measured 
on the lower leg of IV patients (N=5) and healthy controls (N=6). a.u. = arbitrary units. Data are represented 
as mean ± SEM. Mann Whitney U test. *p < 0.05, **p < 0.01.
Supplemental Figure 2. Microbial diversity of samples between different FLG genotypes. 
Phylogenetic diversity rarefaction curves for communities sampled from the lower leg skin do not show 
differences between FLG+/+, FLG-/- and FLG+/- individuals. Note that, as sequencing depth is inherently 
biased by read count (i.e. a higher number of reads in a sample increases the chance of finding additional 
new biodiversity, that was not before observed in that sample), the rarefaction curve calculations shown in 
this graph are for each experimental group limited by the one sample within that group that has the lowest 
number of reads (sequences per sample). For this reason, FLG+/- has three more measurement points than 
the FLG+/+ and FLG-/- genotypic groups.
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Supplemental Figure 3. Alpha diversity metrics in FLG genotypes. 
No differences in microbial diversity of superficial skin microbiota of hetero- and homozygous FLG genotype 
and unaffected control subjects were observed as tested for whole tree phylogenetic diversity, observed 
OTUs, Shannon, and Chao1.
Supplemental Figure 4. In vitro stratum corneum model. 
The model is prepared in a 24-wells plate. 2% agar (in PBS) serves as a basis to position the 2% callus 
suspension originating from the heel of healthy volunteers (FLG+/+ and FLG-/-). After drying, a thin layer of 
dead corneocytes will be present on top of the agar, upon which the bacteria are cultured.
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Supplemental Figure 5. Filaggrin protein expression in the sole of the foot. 
Biopsies from two healthy individuals show positive staining for filaggrin in the upper layers of the epidermis. 
Note the massive amount of callus on top of the epidermis in the right figure. Scale bar = 100 µm.
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Supplemental Tables
Supplemental Table 1. Cohort of IV patients and healthy controls
Sample
ID
Diagnosis Genotype
FLG
Mutation Sex
(M/F)
Age
(years)
IV1 IV -/- R501X, 2282del4 M 66
IV2 IV+AD +/- R501X, wild-type M 20
IV3 IV+AD -/- R501X, unknown mutation M 82
IV4 IV+AD +/- 2282del4, wild-type F 48
IV5 IV -/- 2284del4, 2282del4 M 52
IV6 IV+AD +/- 2282del4, wild-type M 22
IV8 IV+AD -/- R501X, 2282del4 M 31
IV9 IV+AD +/- 2282del4, wild-type F 46
IV11 IV -/- R501X, unknown mutation M 70
IV12 IV+AD -/- R501X, 2282del4 M 36
IV13 IV -/- 2284del4, 2282del4 M 21
IV14 IV+AD -/- R501X, 2282del4 F 51
IV15 IV+AD -/- R501X, 2282del4 F 55
IV16 IV -/- R501X, R501X F 51
IV17 IV+AD -/- R501X, 11033del4* F 27
IV19 IV -/- R501X, 2282del4 M 60
IV20 IV+AD -/- R501X, 2282del4 M 26
C1 healthy +/+ wild-type F 36
C2 healthy +/+ wild-type M 28
C3 healthy +/+ wild-type M 31
C4 healthy +/+ wild-type M 42
C5 healthy +/+ wild-type M 33
C6 healthy +/+ wild-type F 47
C7 healthy +/+ wild-type F 26
C8 healthy +/+ wild-type M 59
C9 healthy +/+ wild-type F 60
C10 healthy +/+ wild-type M 53
AD, atopic dermatitis; C, control; IV, ichthyosis vulgaris; M, male; F, female. *11033del4 mutation genotyped 
by MUMC273. FLG-/- individuals in red, FLG+/- individuals in black, and controls (FLG+/+) in green. Mean age 
± SD for patients vs. controls is 45 ± 19 and 42 ± 13 years. Male to female ratio is not significantly different 
between patients and controls (11/6 vs. 6/4, Chi square p-value = 0.81). 65% (11/17) of IV patients also 
suffers from AD.
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Supplemental Table 2. Microbiota analysis of the lower leg
Microbiome  
lower leg
Reads Percentage
Total readsa 43137 100
Assigned at phylum level 42914 99.5
Assigned at genus level 39085 90.6
aN=27 individuals (10 healthy controls and 17 IV patients).
Supplemental Table 3. Read and OTU counts
Subject Readsa OTUsb Barcodec
C1 913 135 acctgt
C2 2102 268 acgact
C3 1373 199 acgcat
C4 1755 227 acgcgc
C5 811 76 acggca
C6 1772 108 acgtgg
C7 2110 210 actaac
C8 1635 169 actagt
C9 1828 290 actcgg
C10 2120 183 actgat
IV1 1556 276 aacatg
IV2 1624 250 aaccgg
IV3 1868 309 aacgct
IV4 1292 219 aactaa
IV5 1381 200 aagatc
IV6 3471 202 aaggag
IV8 2077 272 aagtcg
IV9 1958 276 aataag
IV11 1361 100 aatcca
IV12 1536 188 aatgac
IV13 1508 218 aatgta
IV14 952 181 acaatg
IV15 906 52 acactt
IV16 1975 149 acagct
IV17 969 153 acatac
IV19 1182 233 accata
IV20 1102 196 accgga
a Number of reads after quality control and removal of chimeric sequences
b Number of OTUs at an identity threshold of 97%
c The six-nucleotide tag used to identify individual samples in the pooled sequencing reads
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Supplemental Table 4. Selection of Hut pathway genes
Protein Gene Enzyme Code K numbera p-valueb Rankc
Urocanase hutU EC:4.2.1.49 K01712 0.0175 41
IPase hutI EC:3.5.2.7 K01468 0.0301 80
Histidase hutH EC:4.3.1.3 K01745 0.0500 116
FIGase hutG EC:3.5.3.8 K01479 0.1685 379
FIGdeiminase hutF EC:3.5.3.13 K05603 1.7750 4200
a According to the KEGG orthology group numbering
b p-value by Mann–Whitney U, Bonferroni corrected, for FLG+/+ versus FLG-/-
c Rank according to overrepresentation analysis based on p-value (for 5838 total K numbers)
Supplemental Table 5. qPCR primers
HUGO  
Gene  
Symbol
ENSemble 
Transcript no.
Description  
Gene/Protein
Forward primer 
(5’ ® 3’)
Reverse primer 
(5’ ® 3’)
CAMP ENST00000296435 cathelicidin, LL-37 ccaggcccacgatggat accagcccgtccttcttga
CCL20 ENST00000358813 chemokine ligand 20, MIP3-a tggccaatgaaggctgtga gatttgcgacacagacaactt
DEFB103 ENST00000318124 human b-defensin-3, hBD-3 gtgaagcctagcagctatgaggat tgattcctccatgacctggaa
DEFB4 ENST00000318157 human b-defensin-2, hBD-2 gatgcctcttccaggtgttttt ggatgacatatggctccactctt
IL1B ENST00000263341 interleukin 1b, IL-1b aatctgtacctgtcctgcgtgtt tgggtaatttttgggatctacactct
IL6 ENST00000258743 interleukin 6, IL-6 agccctgagaaaggagacatgta ggcaagtctcctcattgaatcc
IL8 ENST00000307407 interleukin 8, IL-8, CXCL8 agaagtttttgaagagggctgaga agtttcactggcatcttcactgatt
RPLP0 ENST00000228306 ribosomal phospoprotein P0 caccattgaaatcctgagtgatgt tgaccagcccaaaggagaag
TNF ENST00000229681 tumor necrosis factor, TNFa tcttctcgaaccccgagtga cctctgatggcaccaccag
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Abstract
Deletion of the late cornified env3lope (LCE) proteins LCE3B and LCE3C is a strong and widely 
replicated psoriasis risk factor. It is amenable to biological analysis because it precludes the 
expression of two epidermis-specific proteins, rather than being a single-nucleotide polymorphism 
of uncertain significance. The biology of the 18-member LCE family of highly homologous 
proteins has remained largely unexplored so far. To analyse LCE3 expression at the protein level 
in human epithelia, as a starting point for functional analyses of these proteins in health and 
disease. We generated the first pan-LCE3 monoclonal antibody and provide a detailed analysis 
of its specificity towards individual LCE members. LCE2 and LCE3 expression in human tissues 
and in reconstructed human skin models was studied using immunohistochemical analyses and 
quantitative polymerase chain reaction.
Our study reveals that LCE2 and LCE3 proteins are differentially expressed in human epidermis, 
and colocalize only in the upper stratum granulosum layer. Using an in vitro reconstructed 
human skin model that mimics epidermal morphogenesis, we found that LCE3 proteins are 
expressed at an early time point during epidermal differentiation in the suprabasal layers, while 
LCE2 proteins are found only in the uppermost granular layer and stratum corneum. Based 
on the localization of LCE2 and LCE3 in human epidermis we conclude that members of the 
LCE protein family are likely to have distinct functions in epidermal biology. This finding may 
contribute to understanding why LCE3B/C deletion increases psoriasis risk.
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Introduction
Genetic studies of major skin diseases such as psoriasis (PS) and atopic dermatitis (AD) have 
identified large numbers of risk factors and suggest that multiple biological pathways are involved 
in these conditions274,275. These studies have revealed that polymorphisms of skin barrier function 
are likely to be important, as witnessed by the association of filaggrin null alleles with AD73 and 
the association of deletion of the late cornified envelope (LCE) genes LCE3B and LCE3C with 
psoriasis103. This deletion of a 32-kbp DNA fragment of the epidermal differentiation complex on 
chromosome 1 is very common in the general population, and the association with psoriasis has 
been replicated in many different ethnic groups105,106,276. Whereas in AD there is some evidence that 
filaggrin deficiency affects stratum corneum (SC) properties and skin barrier function220,221,229, the 
functional consequences of the LCE3B/C deletion are unknown. The SC, which is the result of a 
process known as terminal differentiation, is composed of lipids and structural proteins such as 
involucrin, loricrin, filaggrin and members of the LCE protein family277. The LCE gene family consists 
of 18 members subdivided into six subgroups, LCE1 to LCE6, based on the amino acid sequence 
and their gene expression pattern13. These genes are located within the epidermal differentiation 
complex, neighbouring various skin differentiation genes such as small proline-rich proteins, S100 
family proteins and S100 fused-type proteins15. Previous tissue distribution studies at the mRNA level 
have revealed that LCE genes show a tissue-specific expression in skin and a limited number of 
other stratifying epithelia172,278. There is not much known about the function of individual LCE proteins 
or LCE subgroups in the epidermis. The strong sequence identity and homology between the 18 
members points to potential functional redundancy. mRNA expression analysis studies have shown 
that LCE3 genes are specifically upregulated in lesional psoriatic skin and in skin after wounding13,103, 
whereas the expression of other LCE genes is rather decreased. These findings suggest functional 
heterogeneity between LCE proteins. The lack of specific antibodies for LCE subgroups or members 
has precluded functional analysis of the psoriasis-associated LCE3 genes so far. Due to the large 
sequence identity and homology it is a challenge to generate monospecific antibodies against 
individual LCE members or LCE subgroups. Here we describe the generation and characterization 
of a monoclonal antibody that specifically targets all paralogues of the psoriasis-associated LCE3 
group, with the strongest reactivity towards LCE3B/D/E. Using this antibody, we demonstrate the 
spatial and temporal differences between LCE2 and LCE3 proteins in vivo and in vitro.
Materials and methods
Production of recombinant glutathione S-transferase–late cornified envelope fusion proteins
cDNA of all 18 LCE genes was obtained by reverse-transcriptase polymerase chain reaction (PCR) on 
mRNA from differentiated keratinocytes, and ligated into a TOPO vector, which was used to transform 
TOP10 cells (Invitrogen, Carlsbad, CA, U.S.A.). All constructs were verified using Sanger sequencing. 
LCE protein-coding cDNA parts were PCR amplified and ligated into a pET-32a vector (Millipore, 
Bedford, MA, U.S.A.) or a pGEX-2T vector (GE Healthcare, Little Chalfont, U.K.), and glutathione 
S-transferase (GST)-LCE proteins were expressed in BL21 Escherichia coli cells (Invitrogen). Protein 
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purification was performed according to standard procedures using Glutathione Sepharose 4B beads 
(GE Healthcare). The molecular weights and purities of the obtained fusion proteins were checked by 
sodium dodecyl sulphate polyacrylamide gel electrophoresis.
Production of monoclonal antibodies
To generate antibodies specific for one of the psoriasis-associated LCE proteins, 12 peptides 
were selected based on LCE3B (Supplemental Figure 1b; see Supplemental materials and 
methods). These peptides were commercially synthesized and used for immunization during 
monoclonal antibody production (Abmart, Berkeley Heights, NJ, U.S.A.). For specific details see 
Supplemental materials and methods.
Characterization of the monoclonal antibodies
A direct enzyme-linked immunosorbent assay (ELISA) format was used to determine the affinity 
and specificity of the anti- LCE antibody clones (ascites) against individual GST-LCE fusion 
proteins. Briefly, 96-well plates were coated overnight at 4°C with 500 ng recombinant protein per 
well in phosphate- buffered saline (PBS) and blocked with 1% bovine serum albumin (BSA)/PBS 
(Sigma-Aldrich, St Louis, MO, U.S.A.) and 1% normal rabbit serum (Vector Laboratories Inc., 
Burlingame, CA, U.S.A.) for 1 h and were then washed with 0.05% Tween-20 washing solution. 
Dilutions of ascites fluids were then added to the wells and incubation was carried out for 60 min 
at 37°C in 0.05% Tween-20 and 0.1% BSA solution. After washing with PBS, wells were incubated 
for 30 min with 1 : 500 rabbit anti mouse peroxidase secondary antibody in 0.05% Tween-20 and 
0.1% BSA solution. Finally, protein–antibody binding was visualized by TMB ELISA Substrate 
(Pierce Biotechnology, Rockford, IL, U.S.A.) and the reaction was stopped by addition of sulfuric 
acid. Absorbance was measured at 450 nm.
Primary keratinocyte isolation
Primary human keratinocytes were obtained from skin derived from abdominal-wall corrections. 
Isolation and cell culture were performed as previously described146. Submerged keratinocyte 
culture Keratinocytes were cultured in 24-well plates using keratinocyte growth medium (KGM 
BulletKit; Lonza, Basel, Switzerland) and differentiated by depletion of growth factors, as 
previously described131. Specific details are provided in the Supplemental materials and methods.
Human skin equivalent development
Human skin equivalents were generated using de-epidermized dermis (DED) as described 
previously (also see Supplemental materials and methods).15 Briefly, 100 000 cells were seeded 
onto the DED in a Costar 24-transwell culture plate (Corning Inc., Corning, NY, U.S.A.). After 3 
days of submerged culture, the equivalents were lifted to the air–liquid interface and cultured for 
up to 10 days. 
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Immunohistochemistry and immunofluorescence
All tissues and skin equivalents were fixed in 4% buffered formalin, processed and embedded in 
paraffin. Sections (6 µm) were processed for immunohistochemistry and immunofluorescence 
analyses (Supplemental materials and methods). The final working concentration of the clone 7 
anti-LCE3 antibody was determined as 100 ng/ml. For competition experiments synthetic LCE 
peptides (GenScript, Piscataway, NJ, U.S.A.) were preincubated at a concentration of 100 µg/ml 
together with clone 7 antibody.
Quantitative real-time polymerase chain reaction
The epithelial sheet of human skin equivalents or skin biopsies was taken to isolate RNA, generate 
cDNA and perform quantitative PCR analyses as described previously13. Target gene expression was 
normalized to that of the housekeeping gene human acidic ribosomal phosphoprotein P0 (RPLP0).
Human tissue
Skin biopsies of healthy or diseased human skin, as well as autopsy material, were used in 
previous studies by our group122,279, on which we provide more details in the Supplemental 
materials and methods.  
Results
Generation and validation of anti-LCE3 monoclonal antibodies
LCE proteins are small (80-118 residues long) cysteine-rich proteins with extensive homology 
(Supplemental Figure 1a), which strongly limits the opportunity to generate specific antibodies. 
Twelve peptides derived from LCE3B were used for immunization (Supplemental Figure 1b), 
resulting in 27 clones recognizing the peptides used for immunization. These antibodies were 
thoroughly tested and validated for their specificity to LCE proteins. We generated 18 recombinant 
LCE-GST fusion proteins to test all these clones by ELISA. Clones that were positive in the ELISA 
were subsequently tested on human skin sections by immunohistochemistry. Only two clones 
(7 and 8) both raised against the epitope GGPSSEGG showed specific staining in both assays. 
Clone 7 was selected for further characterization as its affinity was the highest. Clone 7 showed 
a strong ELISA signal with LCE3B from which the immunizing peptide was derived (Figure 1a). 
LCE3D and LCE3E fusion proteins, however, also yielded a positive ELISA signal, which was 
expected in view of the seven amino acid sequence identity (Figure 1a). A borderline ELISA 
signal was obtained for four other LCE proteins (Figure 1a), two of them from the LCE3 group 
sharing five or six amino acids with the immunizing peptide. Clone 7 showed a strong staining of 
the upper spinous layers and granular layer of normal human epidermis (Figure 1b).
Using skin from donors homozygous for the LCE3B/C-del, we observed that the epidermis 
stained positive with clone 7, confirming its affinity for other LCE3 proteins (Supplemental Figure 
2). To corroborate this cross-reactivity with LCE3D or LCE3E further, we performed competition 
experiments with the synthetic peptides listed in Figure 1a. Immunostainings could be completely 
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blocked by an excess of peptides from LCE3B, 3D and 3E. LCE3C and especially LCE3A 
peptides only showed partial blocking and no blocking was observed using peptides from 
LCE2C (Figure 1c) or a scrambled LCE3B peptide. These findings indicate that the specificity of 
clone 7 is towards all LCE3 proteins with the highest affinity for LCE3B, LCE3D and LCE3E and 
is therefore considered a pan-anti-LCE3 antibody.
Figure 1. LCE3 protein peptide recognition pattern. 
(a) Affinity data of anti-LCE3 monoclonal antibody against different LCE3 proteins based on ELISA analysis, 
and the comparison of the epitope sequences in the LCE3 members. The LCE3B peptide was used for 
mouse immunization. (b) Immunohistochemical staining of LCE3 proteins in normal human epidermis with 
the developed anti-LCE3 monoclonal antibody. The picture is representative for the expression in N=3 
different skin biopsies. (c) Staining of LCE3 proteins in normal human skin after competition with our anti-
LCE3 antibody and LCE peptides. Scale bar = 100 µm.
(a)
(b)
(c)
LCE protein ELISA signal ranking peptide similarity
LCE3B +++ GGPSSEGG
LCE3D + CGPSSEGG
LCE3E + CGPSSEGG
LCE3A ± CGPSSERS
LCE6A ± no similar sequence
LCE3C ± CGPSSESG
LCE2C ± CGPSSGGC
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Distinct epidermal LCE2 and LCE3 protein expression patterns in vivo and in vitro
The pan-anti-LCE3 antibody was used to investigate the expression of the psoriasis-associated 
and cytokine-inducible LCE3 group. As stated above, immunopositivity with clone 7 antibody 
primarily indicates expression of LCE3B, 3D or 3E, or a combination of these proteins. To be 
able to detect LCE2 proteins we exploited a previously described polyclonal antiserum raised 
against a peptide that is identical in LCE2B, LCE2C and LCE2D. We previously demonstrated 
that members of the LCE2 group showed a decreased mRNA expression in psoriatic epidermis 
and in vitro following cytokine stimulation13. Using our screen with recombinant LCE fusion 
proteins we confirmed that the LCE2 antiserum recognizes LCE2B, LCE2C, LCE2D and 
additionally LCE1F (data not shown). We refer to positive staining for this LCE2B peptide-raised 
antiserum as ‘LCE2 reactivity’. Immunofluorescence double labelling using the LCE2 and pan-
LCE3 antibodies confirmed that LCE2 expression is localized in the uppermost granular layer 
and the SC of normal and psoriatic skin. In contrast, LCE3 proteins are expressed in the stratum 
spinosum (SS) and stratum granulosum (SG) and are not detected in the SC (Figure 2a). Co-
localization of both protein groups is only sparse and limited to the last living cell layer of the 
SG (indicated with the arrow). It appears that LCE3 protein is replaced by LCE2 protein during 
keratinocyte transition throughout the epidermis towards the SC. LCE3 protein is mainly located 
at the ‘sunny side’ of the upper SS cells. This is even more prominent in psoriatic skin, where a 
large part of the acantholytic SS shows elevated LCE3 expression (Figure 2, right panel). This 
expression pattern has earlier been shown for other epidermal proteins like the host defense 
protein SKALP/Elafin280,281, SLPI150  and human beta-defensin proteins282. Using a human skin 
equivalent model, we investigated the expression of LCE2 and LCE3 from day 0 to day 10 of 
the air-liquid interface culture, as model system for epidermal morphogenesis and/or healing of 
epidermal injury (Figure 2b). Protein staining’s reveal that this model represents differentiation 
stages comparable to in vivo skin starting with early differentiation markers like keratin 10 in all 
suprabasal layers, followed by expression of later differentiation proteins such as filaggrin and 
loricrin in the granular layer (Supplemental Figure 3). Here, we found that LCE2 proteins are 
present after three days of differentiation, whereas LCE3 proteins are already present at day 0, 
immediately after the equivalent has been lifted to the air-liquid interface to induce stratification, 
suggesting that LCE3 proteins are necessary in the very early steps of de novo formation of the 
epidermis.
Distribution of LCE2 and LCE3 proteins in diseased epidermis and oral epithelia
As the LCE proteins are putatively involved in skin differentiation and barrier function, we studied 
LCE2 and LCE3 immunolocalization in skin conditions known to exhibit abnormal differentiation 
or barrier deficiency. We therefore stained tissue sections of normal skin (NS), psoriatic skin 
(PS), atopic dermatitis (AD), ichthyosis vulgaris (IV), skin warts and skin after tape-stripping 
(TS). Figure 3 shows that LCE2 protein expression is reduced in PS skin and after TS. AD and 
IV skin does not show altered LCE2 expression. In contrast, LCE3 proteins are expressed in 
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more epidermal layers in PS, AD, IV and after tape-stripping, all in which acanthosis is observed. 
In trunk skin warts, LCE2 protein expression is increased to two layers of the SG, while LCE3 
protein is undetectable. In addition, we also studied LCE2 and LCE3 protein expression in plantar 
epidermis and epithelia of several other tissues (Figure 4). The highest expression levels of LCE 
proteins in non-cutaneous epithelia are found in oral epithelia such as gingiva, tonsil and tongue 
where the localization is similar to that of skin.
Figure 2. Epidermal localization of LCE2 and LCE3 proteins. 
(a) Immunofluorescence double labelling of anti-LCE2 (red signal) and anti-LCE3 (green signal) in normal 
and psoriatic skin. Nuclei are stained with DAPI (blue signal). The right panel of both skin conditions shows 
a magnification inlay corresponding to the white box in the left panel. (b) Immunohistochemical staining of 
LCE2 (upper panel) and LCE3 (lower panel) proteins in 3D skin equivalents during skin morphogenesis. 
Scale bar = 100 µm.
Submerged and air-exposed keratinocyte cultures as a model to study LCE biology
In order to study LCE biology in vitro and to decipher the mechanistic role of the LCE3B/C deletion in 
psoriasis, it would be desirable to have a flexible keratinocyte culture system that allows investigation 
and manipulation of LCE protein expression. We therefore investigated the expression of a number 
of LCE genes (LCE1A, 2A, 3A, 5A, 6A) in submerged keratinocyte cultures and a human skin 
equivalent model and compared this with expression of the same genes in vivo in normal skin 
(Supplemental Figure 4a). Day 0 represents 100% confluency after which differentiation is initiated 
by growth factor depletion and contact inhibition and is continued until day 7. Expression of LCE1A 
mRNA at day 0 of one keratinocyte donor (Ct value 25.8) was used as reference sample to enable 
comparison between different LCE genes. We found highest expression levels of LCE1, LCE2 and 
LCE6 within the LCE gene family. LCE3 and LCE5 are expressed at much lower levels. Expression 
levels changed over time during the submerged culture and for all LCE genes, a maximum 
expression level was reached after 6 days of differentiation.
(a)
(b)
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For comparison, we studied mRNA expression changes during the development of our 3D 
skin equivalent (Supplemental Figure 4b). Again, expression of LCE1A mRNA at day 0 of one 
keratinocyte donor (Ct value 16.77) was used as reference sample to enable comparison 
between different LCE genes. In contrast to submerged cultures there are fewer changes in the 
LCE mRNA expression levels upon differentiation. Again, we found LCE3 and LCE5 expression to 
be moderate as compared to the LCE1,2,6 subfamilies, Furthermore, when comparing the very 
early and terminally differentiated skin equivalents, significant differences in gene expression 
levels were observed for the LCE5 group.
Figure 3. LCE2 and LCE3 protein expression in healthy and diseased skin. 
H&E and immunohistochemical staining using anti-LCE2 and anti-LCE3 on normal skin (NS), psoriatic skin 
(PS), atopic dermatitis skin (AD), both of stable plaques, ichthyosis vulgaris skin (IV), skin warts (W) and 
normal skin after tape-stripping (TS). The pictures are respectively representative for the expression in at 
least two different skin biopsies. Scale bar = 100 µm.
To address the question to what extent our keratinocyte culture models reflect LCE gene 
expression levels in vivo, we compared the in vitro LCE gene expression data to that obtained from 
epidermal sheets of normal skin biopsies (Supplemental Figure 4c). For submerged cultures, 
we plotted the maximum LCE gene expression at day 6. For the 3D skin equivalents, day 10 
of the air-liquid interface culture was chosen because the morphology and protein expression 
resembles healthy skin at this stage. As shown in Supplemental Figure 4c, advanced epidermal 
differentiation is achieved in both our in vitro models.
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Figure 4. Tissue screen of LCE2 and LCE3 protein expression in human epithelia. 
(a) H&E and immunohistochemical staining of LCE2 and LCE3 proteins in foot sole, pharynx (red staining 
shows endogenous peroxidase activity of red blood cells and is therefore to be distinguished from LCE 
protein staining) and gingiva. Expression in other epithelial tissues is scored from strong expression to no 
expression and is summarised in (b). Scale bar = 100 µm.
Table: Scoring for LCE2 and LCE3 protein  
expression in overall tissue screen:
Epithelial tissue LCE2 LCE3
Normal skin ++ ++
Psoriatic skin +/- +++
Atopic dermatitis
Ichtiosis vulgaris ++ +
Actinic keratosis + +++
Allergic contact dermatitis ++ ++
Tape-stripped skin +/- +++
Foot sole ++ ++
Wart +++ -
Gingiva +/- +++
Tonsil +/- +/-
Pharynx - -
Trachea - -
Stomach - -
Bladder - -
Prostate - -
Testis - -
Lymph node - -
Oesophagus - -
Tongue +/- +
Colon - +/-
Lung - -
Epiglottis - +
Small intestine - +/-
Larynx - -
Bronchus - -
Urethra - -
Scoring system:
+++  strong expression
++  medium  expression
+  moderate expression
+/-  low expression
-  no expression
(a) (b)
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Discussion
Genome-wide association studies (GWASs) have generated more than 40 replicated genetic 
risk factors for psoriasis. Many of these risk factors have very small odds ratios and the majority 
of them are single-nucleotide polymorphisms located in or near putative candidate genes. 
Only very few established risk factors have clear biological implications or even experimentally 
proven biological effects that would explain their contribution to the disease. By far the strongest 
psoriasis risk factor is human leucocyte antigen (HLA)-C*06:02, which has an established 
function in antigen presentation, and may therefore be involved in presentation of autoantigens 
or exogenous antigens283. The fact that both HLA-C*06:02 positivity and the LCE3B/C deletion 
have obvious biological implications provides a unique opportunity to translate genetic data 
into plausible biological mechanisms, which is one of the major challenges of the post-GWAS 
era. For this reason, the development of research tools (antibodies, skin models) to study LCE 
biology is essential. 
The development of specific antibodies is far from trivial in the case of an 18-member family of 
very similar proteins. We have made a considerable effort to characterize the antibodies used 
here. We think that in the light of the recent discussions on the lack of reproducibility of cell 
biological studies284,285 and the widely known concerns on antibody specificity286 that this is an 
absolute requirement. We have developed and characterized the first monoclonal antibody 
directed against the psoriasis-associated and cytokine-inducible members of the LCE3 group of 
proteins. We demonstrate the distinct localization patterns of LCE2 and LCE3 proteins in human 
epidermis and in relevant skin culture models. 
A previous immunohistochemical study revealed that LCE2 is expressed in the granular layer 
and is present in the corneocytes of the SC13. Based on this observation and their restricted 
expression in epidermis it was assumed that LCE proteins are constituents of the SC and 
contribute to barrier function, but actual proof for this was lacking and initially a number of 
limited proteomics studies did not identify LCE sequences in SC extracts24,287. However, a recent 
paper on comprehensive profiling of ichthyotic and normal skin reported the presence of LCE 
members 1A, 1B, 1C, 1D, 1F, 2A and 2B in SC288. As these are the most abundant LCE members 
at the mRNA level in normal human epidermis13, the absence of other LCE proteins in that study 
could be a matter of sensitivity. Our study demonstrates a difference between the presence of 
LCE2 (SC and last granular layer) and LCE3 (absent in SC, present in the lower granular layer). 
The absence of LCE3 in the SC could be explained by targeted breakdown of these proteins by 
the abundant epidermal proteases289-292. The presence of LCE2 proteins in the last living granular 
layer and the nonviable cornified layer might imply that LCE2 proteins have a function in the skin 
barrier, but other functions are also possible such as antibacterial activity or antioxidant activity, 
based on the high cysteine content of LCE proteins.
From an earlier study, we know that LCE3 gene expression in vivo is increased in psoriasis 
and AD and following epidermal injury by tape stripping, whereas expression of LCE2 genes 
is unaffected or decreased compared with normal skin.12 In this study we now confirm these 
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findings at the protein level. We show that under these disease circumstances, most evidently in 
psoriasis, LCE3 staining now extends to the upper SS layers of the acanthotic epidermis. 
It was previously reported that LCE1 and LCE2 genes are hardly expressed in internal stratified 
oral epithelia such as the tongue and the oesophagus, whereas LCE3 genes are sometimes 
expressed at even higher levels than in the skin15. We show here that some oral epithelia, such as 
gingiva, tonsil, tongue and epiglottis, express both LCE3 and LCE2 proteins, although in lower 
levels than in the skin, with the exception of stratified gingival epithelium, where LCE3 protein 
levels are even higher than in the epidermis.
We found that in both submerged and three-dimensional air-exposed models, LCE mRNA 
and protein expression could be studied, as the proportions of expression between the LCE 
members properly resemble in vivo skin. This opens the possibility to use keratinocytes of defined 
genotypes (carriers of the deletion vs. wild-type) in future functional studies. Although overall 
LCE mRNA levels are increased in vitro, LCE protein expression and epidermal morphology are 
equal to those in in vivo skin. This discrepancy might be due to lack of interaction with other skin-
homing cells, our microbiome or circumstances of the cell culture environment in which three-
dimensional equivalents are being formed that could influence gene regulation.
The observed association with psoriasis and the selective responsiveness to proinflammatory 
cytokines indicate that LCE proteins may have a function that extends beyond the putative 
role in the skin barrier. As shown by de Guzman Strong et al.293, the deleted fragment contains 
a functional enhancer sequence that may affect transcription of multiple genes of the LCE 
region. We believe that further study of the biology of LCE proteins will provide an excellent 
opportunity to translate genetic findings into plausible biological mechanisms that contribute to 
our understanding of the disease mechanisms in psoriasis.
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Supplemental Figure 2. LCE3 expression in LCE3B/C del/del genotyped skin biopsies. 
Immunohistochemical staining of LCE3 protein in human skin biopsies from normal skin (NS) and psoriatic 
skin (PS). Skin biopsies being either wildtype (wt/wt), heterozygous (wt/del) or homozygously deleted (del/
del) for the LCE3B/C locus, all show equal expression of LCE3 protein in the epidermis. Scale bar = 100 µm. 
Supplemental Figure 3. Expression of early and late differentiation proteins in a 3D skin 
morphogenesis model. 
In this 3D skin morphogenesis model, we show that late differentiation markers like filaggrin (FLG) and 
loricrin (LOR) are only expressed around day 7 of air-liquid interface culture whereas the earlier differentiation 
protein keratin 10 (K10) is already present at day 0, the starting point of the differentiation phase, Scale bar 
= 100 µm. 
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Supplemental Figure 4. LCE gene expression patterns during keratinocyte differentiation. 
Relative expression levels of LCE genes of different subgroups in submerged (a, N=2) and 3D (b, N=3) 
primary human keratinocytes cultures at different time points of differentiation (day 0 – day 7/10). (c) 
Comparison of maximal LCE mRNA expression in different keratinocyte in vitro models (submerged data 
day 6, 3D data day 10) compared to normal in vivo skin. For all graphs (a, b, c) the values were expressed 
relative to the expression of LCE1A gene of one included sample to allow comparison of expression between 
genes. In a,b the reference timepoint was day 0, whereas in c the in vivo expression was used as reference 
for the other variables (* = P < 0.05). qPCR analysis was performed according to the method of Livak et al 35. 
(a)
(b)
(c)
(d)
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Supplemental materials and methods
Production of monoclonal antibodies
To generate antibodies specific for one of the psoriasis-associated LCE proteins, twelve peptides 
were selected based on LCE3B (Supplemental Figure 1b). These peptides were commercially 
synthesized and used for immunization during monoclonal antibody production (Abmart). 
Mouse spleen cells were fused with SP2/0 myeloma cells to generate the hybridomas. Clones 
were grown from single parent cells on microtiter wells in hypoxanthine-aminopterin-thymidine 
selection medium. The antibodies secreted by the different clones were assayed with ELISA for 
their ability to bind to the antigen. The most productive and stable clones were selected and 
injected into the peritoneal cavity of mice, and 10-14 days later ascites fluid was collected.
Submerged keratinocyte culture
Primary keratinocytes were primarily cultured in proliferation medium (KGM BulletKit, Lonza) 
consisting of Keratinocyte Basal Medium, 0.15 mMCa2+ (Lonza), supplemented with 0.1mM 
ethanolamine (Sigma), 0.1 mM phosphoethanolamine (Sigma), bovine pituitary extract 
(0.4%) (vol/vol) (Bio Whittaker), 10 ng/mL EGF (Sigma), 5 µg/mL insulin (Sigma), 0.5 µg/mL 
hydrocortisone (Calbiochem), 100 U/mL penicillin (Gibco), and 100 µg/mL streptomycin (Gibco). 
Upon confluency differentiation was induced by depletion of growth factors from the medium 
consisting of KGM, 0.15 mM Ca2+ (Lonza), supplemented with 0.1 mM ethanolamine (Sigma), 
0.1 mM phosphoethanolamine (Sigma), 100 U/mL penicillin (Gibco), and 100 µg/mL streptomycin 
(Gibco). Cells were maintained for maximally 7 days depending on the experimental set-up and 
the medium was refreshed every other day.
Human skin equivalent development
For the generation of human skin equivalents 100.000 primary keratinocytes were seed onto de-
epidermised dermis (DED in medium containing 5% serum, consisting of two parts Dulbecco’s 
modified Eagle’s medium (Life Technologies, Inc.) and one part Ham’s F12 medium (Life 
Technologies, Inc.) supplemented with 5% calf serum (Hyclone), L-glutamine (4 mmol/L, Life 
Technologies, Inc.), penicillin/streptomycin (50 IU/ml, Life Technologies, Inc.), adenine (24.3 µg/
ml, Calbiochem), ascorbic acid (50 µg/ml, Sigma), insulin (0.2 µmol/L, Sigma), hydrocortisone 
(1 µmol/L, Merck), triiodothyronine (1.36 ng/ml, Sigma), and cholera toxin (10-10 mol/L, Sigma). 
After 1 day, the ring was removed, and the construct was cultured submerged for 3 days. Then, 
the skin equivalents were placed on a grid, and cultured for 10 days at the air-liquid interface 
in medium without serum, consisting of two parts Dulbecco’s modified Eagle’s medium (Life 
Technologies, Inc.) and one part Ham’s F12 medium (Life Technologies, Inc.) supplemented 
with L-glutamine (4 mmol/L, Life Technologies, Inc.), penicillin/ streptomycin (50 IU/ml, Life 
Technologies, Inc.), adenine (24.3 g/ml, Calbiochem), L-serine (1 mg/ml, Sigma), L-carnitine (2 
µg/ml, Sigma), BSA lipid mix (palmitic acid (25 µmol/L, Sigma), arachidonic acid (7 µmol/L, 
Sigma), linoleic acid (15 µmol/L, Sigma), vitamin E (0.4 µg/ml, Sigma), ascorbic acid (50 µg/ml, 
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Sigma), insulin (0.1 µmol/L, Sigma), hydrocortisone (1 µmol/L, Merck), triiodothyronine (1.36 ng/
ml, Sigma), cholera toxin (10-10 mol/L, Sigma), keratinocyte growth factor (KGF) (5 ng/ml, Sigma) 
and epidermal growth factor (2 ng/ml, Sigma). 
Immunohistochemistry and immunofluorescence
All tissues and skin equivalents were fixed in 4% buffered formalin, processed and embedded 
in paraffin. 6 µm sections were processed for immunohistochemistry and immunofluorescence 
analyses. For immunohistochemistry, primary antibodies were diluted in 1%BSA/PBS (as 
described in Supplemental Table 1) and incubated for 60 minutes at RT. Secondary antibodies 
(1:200) were diluted in 1% BSA/PBS and incubated at RT for 30 minutes. An indirect 
immunoperoxidase technique with avidin-biotin complex (Vectastain) enhancement was used 
according to manufacturer’s recommendations. Haematoxylin (Sigma) was used to counterstain 
cell nuclei and slides were mounted with glycerol gelatine (Sigma).
For immunofluorescence, the primary antibodies were used in the same dilutions in 1% BSA/
PBS as used for immunohistochemistry. For the anti-LCE2 a goat-anti-rabbit Alexa-Fluor 594 
antibody was used and for the anti-LCE3 staining we used a goat-anti-mouse Alexa Fluor 488 
secondary antibody. Both secondary antibodies (Molecular Probes, Eugene) were diluted 1:200 
in 1%BSA/PBS. Nuclei were counterstained with 4’6-diamide-2’-phenylindole dihydrochloride 
(Dako) and slides were mounted with Fluoromount-G (Southern Biotech).
Human tissue
Patients and healthy controls were recruited by the Dermatology clinic of the Radboud University 
Medical Center. All patients were diagnosed by a dermatologist. The studies were approved by 
the institutional medical ethics committee, and biopsies from human volunteers were obtained 
following written informed consent. All biopsy taking and tape stripping was performed by a 
dermatologist. For the skin tissue of healthy and diseased skin 4 mm punch biopsies were 
taken from the trunk or lower back of non-sun-exposed areas of healthy volunteers (N=5) and 
patients (N=2-3 for each type of skin disease). All individuals were between 18 and 65 years of 
age. Skin biopsies from psoriatic patients were taken from stable plaques from the trunk148,279. 
Biopsies of atopic dermatitis patients were taken from chronic lesions from the trunk148,279,294. 
Skin of healthy volunteers was tape-stripped by application and removal of adhesive tape of the 
lower back until total removal of the stratum corneum294-296. Skin wart biopsies were used from 
the study of de Koning et. al297. Tissue from different organs was available from archival autopsy 
material of one individual (Department of Pathology, Radboud University Medical Centre, The 
Netherlands)279,298,299.
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Supplemental Tables
Supplemental Table 1. Antibodies for immunohistochemistry and immunofluorescence. 
Antibodies for immunohistochemistry either commercially or received from previous research of our group 
and others were used in the following dilutions.
Target protein Antibody clone Dilution
late cornified envelope 2 kind gift of M. Narita 
(University of Cambridge, UK)
1:1000
late cornified envelope 3 generated by our group 
(this manuscript)
1:5000
cytokeratin-10 DE-K10, Euro Diagnostics 1:100
loricrin PRB145P, Covance 1:2000
filaggrin NCL-Filaggrin, Novocastra 1:200
Niehues H*1, Tsoi LC*2,3,4, van der Krieken DA*1, Jansen PAM1, Oortveld MAW1, Rodijk-Olthuis 
D1, van Vlijmen IMJJ1, Hendriks WJAJ5, Mesman R6, van Niftrik L6, Helder RW7, Bouwstra JA7, van 
den Bogaard EH1, Stuart PE2, Nair RP2, Elder JT2,8, Zeeuwen PLJM1 and Schalkwijk J1
*equal author contribution
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Abstract
Disease associated genetic risk factors often involve non-coding variants, which has precluded 
understanding of their functional consequences in complex diseases. Here we used analysis of 
expression quantitative trait loci (eQTL) and functional genomics to investigate the psoriasis risk 
factor LCE3B/C-del, which involves the deletion of two Late Cornified Envelope (LCE) genes, a 
gene family that encodes 18 epidermis-expressed proteins of unknown function. RNA-seq data 
from human skin revealed that LCE3B/C-del was associated with a markedly increased expression 
of LCE3A, a gene directly adjacent to LCE3B/C-del. We confirmed these findings in a 3D skin 
model using primary keratinocytes from LCE3B/C-del genotyped donors. Functional analysis 
revealed that psoriasis-associated LCE3 proteins, and LCE3A in particular, have defensin-like 
antimicrobial activity against a variety of bacterial taxa at low micromolar concentrations.  Our 
findings identify an unknown biological function for LCE3 proteins and suggest a role for LCE3A 
in epidermal host defense and LCE3B/C-del mediated psoriasis risk.
8155
Introduction
Psoriasis vulgaris is a common inflammatory skin disease determined by both genetic and 
environmental factors300. Based on a number of genome wide association studies (GWAS) and 
meta-analyses thereof, more than 60 susceptibility loci have been identified that account for 20-
25% of psoriasis heritability301-303. Psoriasis is characterized by dysregulated cutaneous immune 
responses involving innate immunity (TNF-alpha and NFkB pathways) and exaggerated Th1 
and Th17 lymphocyte activation304-306. In addition, psoriasis-associated genes expressed by 
keratinocytes and with a presumed role in epidermal homeostasis have also been genetically 
implicated in psoriasis, including the late cornified envelope (LCE) genes103,106 and the beta-
defensins101. Despite the identification of many candidate genes, functional studies that explain 
the contribution of genetic polymorphism to psoriasis risk are largely lacking. A number of studies, 
however, have shown a plausible link between genes from susceptibility loci and immunobiological 
features of psoriasis such as an association between variation at TNFAIP3 and response to TNF-
alpha blockade307, and the association between the IL12B risk allele and increased Th1-cytokine 
levels306. In addition, only very few risk loci involve coding variants that are amenable to experimental 
verification in animal models or in vitro cellular models of skin biology or inflammation301,305. 
Among the psoriasis susceptibility regions, the MHC class 1 gene HLA-C*06:02 (PSORS1) and 
the LCE region harbouring a deletion of the LCE3B and LCE3C genes (originally designated 
PSORS4)308, provide plausible candidates to investigate at the functional level. HLA-C*06:02 is 
by far the strongest psoriasis risk factor, with an odds ratio estimated to be between 2.6 to 5 in 
Caucasians309,310, and the odds ratio for the LCE3B/C deletion (OR ~ 1.3)106 is one of the highest 
among the remaining psoriasis-associated loci301. Besides psoriasis, LCE3B/C-del has also been 
associated with rheumatoid arthritis311 and systemic lupus erythematosus312. LCE genes are 
expressed only in epidermis and oral epithelia13,15 and are assumed to encode structural proteins 
with a role in epithelial barrier formation; however, no functional studies supporting this contention 
have been published so far. Remarkably, the LCE3 group, which encompasses the LCE3B and 
LCE3C genes, is under regulation of psoriasis-associated Th1 and Th17 cytokines13,231. LCE3B/C-
del affects a 32-kb fragment in the epidermal differentiation complex (EDC) on chromosome 1, 
which is commonly deleted in the non-African population (allele frequency of LCE3B/C-del: 60-
70%)103. In addition to the loss of the protein coding genes LCE3B and LCE3C, it also removes 
three intergenic fragments that harbour potential regulatory sequences293. In this study, we show 
that LCE3B/C-del causes an upregulation of the flanking LCE3A gene. Our hypothesis-driven 
functional studies have revealed that these three proteins are unlikely to be involved in skin barrier 
function and rather represent antimicrobial proteins. 
Materials and methods 
QTL analysis of skin biopsies
All subjects involved in this study provided written informed consent under a protocol adherent 
to the Helsinki Guidelines and approved by the Institutional Review Board of the University 
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of Michigan Medical School. To evaluate the associations between the LCE3B/C-del and 
expression traits in the EDC region (between 151.5-154 Mb of chromosome 1), we utilized 
our RNA-seq cohort for psoriasis313,314 to measure the gene expression levels in normal (NN), 
uninvolved (PN), and psoriatic (PP) skin samples, respectively. Most of the samples in the RNA-
seq cohort were genotyped in our Exomechip cohort315. Altogether 80 non-psoriatic controls and 
92 psoriatic patients with both genetic and expression data were included, with 27 of the patients 
also providing expression data for PN skin. The samples and data processing procedures for 
the RNA-seq data were described previously313,316. Briefly, we employed Tophat and Cufflink to 
align reads and estimate expression levels, respectively. We included in the eQTL analysis only 
genes in the EDC region (chromosome 1: 151.5-154Mb) that were expressed in at least 20% of 
the samples in the condition being studied (i.e. NN, PN, or PP skin). For each expression trait, 
we removed expression outliers (i.e. three times the interquartile range smaller than the lower 
quartile or three times the interquartile range larger than the upper quartile), and we further 
performed inverse normal transformation on each gene’s expression values. Genetic marker 
rs4112788 has been reported to be a close proxy of LCE3B/C-del103, and it was genotyped in the 
Exomechip cohort, therefore we used this SNP as a surrogate for the deletion and correlated its 
genotypes with expression traits using a linear model. The eQTL analysis was performed for NN, 
PN, and PP skin separately.
LCE3B/C-del genotyping of keratinocytes
All subjects involved in this study provided written informed consent under a protocol adherent to 
the Helsinki Guidelines and approved by the local Medical Ethics Committee in The Netherlands 
(CMO Regio Arnhem-Nijmegen, The Netherlands). Individuals that donated skin biopsies for 
keratinocyte culture were genotyped for their LCE3B/C-del status as previously described103. 
The non-deletion allele (i.e. those alleles containing LCE3B and 3C) is designated as wild type 
(wt). The deletion allele is designated del. Genotypes are referred to as wt/wt, del/wt and del/del.
3D reconstructed epidermis
3D reconstructed epidermis was generated as described previously147. For cytokine stimulation, 
combinations of cytokines, selected to model the response of Th1- or Th 17 T-cells, were added 
into the medium during days 5 - 8 of the air-liquid interface culture (Th1 mix: 10 ng/ml IL-1α, 0.5 ng/
ml TNF-1α, 250 U/ml IFN-γ; Th17 mix: 50 ng/ml IL-17, 50 ng/ml IL-22; Preprotech, Rocky Hill, NJ).
Quantitative real-time PCR
RNA isolation, cDNA synthesis, qPCR analysis and primer design was performed as described 
previously13,225 (Supplemental Table 2). Target gene expression was normalized to the expression 
of the housekeeping gene human acidic ribosomal phosphoprotein P0 (RPLP0). The ΔΔCt 
method was used to calculate relative mRNA expression levels132. Statistical analysis of qPCR 
data was performed on ΔCt values using commercially available software (IBM, SPSS Statistics 
8157
22). Repeated measures ANOVA, followed by Bonferroni post hoc testing was performed P < 
0.05 was considered statistically significant. 
Immunohistochemistry
3D reconstructed epidermis was fixed in formalin and processed for routine histology. 6 µm 
paraffin sections were stained with antibodies using an indirect immunoperoxidase (Vectastain, 
Vector Laboratories) or immunofluorescence technique. Details on antibodies are presented in 
Supplemental Table 3.
Transepidermal water loss measurement
Transepidermal water loss (TEWL) was determined according to condenser-chamber method 
(Aquaflux AF200, Biox Systems, London, UK), as described before147.
In vitro outside-in dye penetration
1 mM Lucifer Yellow (LY, Sigma Aldrich) was added to the upper chambers of 3D reconstructed 
epidermis in 12-well dishes for one hour. Immunohistological sections were counterstained with 
4',6-diamidino-2-phenylindole (DAPI, Boehringer Mannheim) and assessed with fluorescence 
microscopy for LY penetration. Validation of this model is described in Niehues et al.147.
Hydrocortisone diffusion analysis
Stratum corneum (SC) isolation was performed according to the procedure as earlier 
described317,318. In short, the fat was removed from the ex vivo skin and dermatomized to a 
thickness of 400 µm (Deca dermatome, DePuy Healthcare, Leeds, UK). The skin or 3D 
reconstructed epidermis was placed on Whatman filters soaked in a 0.1% trypsin PBS solution 
(v/v) and stored overnight at 4°C, followed by 37°C incubation for 1 hour. This allowed the 
separation of the SC from the skin. The isolated SC was washed with trypsin inhibitor 0.1% in 
PBS (v/v) (1x) and demi water (2x) and dried overnight. The SC sheets were stored in the dark 
and oxygen-free until usage. 
The diffusion studies were performed with flow-through permegear cells as described 
previously319. The donor compartment contained 1 ml of 0.34 mg/ml hydrocortisone in acetate 
buffer (pH 5.0). The flow speed for the acceptor compartment was set between 2-2.5 mL PBS 
(pH 7.4)/hour and collected into vials during 60 min for a period of 15 hours. 
After diffusion, the volume in each of the vials was determined by weighting. 5 µl of each fraction 
was used for analysis using an Acquity UPLC-UV system (Milford, USA) with an ethylene bridged 
hybrid C18 1.7 µm 2.1x50 mm column (Milford, USA). The solvents used were 50% acetonitrile 
and 50% milliQ containing 0.1% of trifluoracetic acid. The UV detection of hydrocortisone was 
performed at 243 nm. After detection, Masslynx v4.1 was used for peak integration, calculation 
of the concentration and flux determination, which is represented as flux in µg/cm2/hour. 
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Expression and synthesis of LCE proteins
The cloning of LCE genes has been described previously231. LCE fusion proteins of glutathione 
S-transferase (GST) were produced according to standard procedures320. GST-LCE fusion 
proteins were cleaved with thrombin to liberate the LCE protein from the GST tag. In our 
initial experiments, we noted that recombinant LCE3B-GST fusion protein did not show any 
antibacterial activity, but after protease-mediated removal of the GST moiety, the LCE protein 
clearly displayed antimicrobial activity. As pure LCE proteins were difficult to obtain at high yield, 
most likely due to their extremely high cysteine content, LCE3A, LCE3B and LCE3C proteins were 
synthesized by solid phase peptide synthesis, purified to 85-90% purity by reverse-phase HPLC 
and characterized by electrospray mass spectroscopy (Pepmic, Suzhou, China). LCE proteins 
were delivered in reduced form. Reducing agents and other low molecular weight components 
were removed by spin column dialysis (Amicon Ultra Centrifugal Filters 3K, Merck Millipore) and 
LCE proteins were extensively dialyzed against 10mM sodium phosphate buffer (PB, pH 7.4) 
before being stored at -20oC.
Reduction, alkylation or oxidation of LCE3a protein
To 50 µl of 100 µM synthetically produced LCE3A protein in PB, 5 µl of 100 mM tris(2-carboxyethyl) 
phosphine (TCEP) or 100 mM hydrogen peroxide was added for protein reduction or oxidation, 
respectively. Samples were incubated for 1 hour at 37°C, and hereafter dialyzed against PB to 
remove the TCEP or hydrogen peroxide. After dialyzing, 5 µl of 100 mM iodoacetamide was added 
to 50 µl of the reduced proteins for the alkylation reaction. Samples were again incubated for 1 hour 
at 37°C, and extensively dialyzed against PB. The concentration and electrophoretic mobility of the 
proteins was determined using the micro BCA kit (Thermo Scientific) and SDS-PAGE.
Bacteria culture
Diverse bacterial strains were grown on Columbia agar with 5% sheep blood (Becton, Dickinson 
and Co.) and single colonies were used to inoculate cultures in brain heart infusion medium 
(Mediaproducts BV, Groningen, The Netherlands) overnight at 37°C. Bacterial cultures were 
diluted 102 times in BHI medium and allowed to grow for another 2.5 hours to reach exponential 
growth (except for P. acnes). For strains and specifications of all bacterial strains see Supplemental 
Table 4.
Antimicrobial assay
Bacteria were harvested from exponential growth cultures by centrifugation (2100 g, 5 min), 
washed with PB, and resuspended in PB at a concentration of 104 ~ 105 CFU/ml. Bacterial 
suspensions were exposed to LCE peptides in an assay volume of 100 µl, for 2 hours at 37°C in 
a 96 wells microplate (Greiner Bio-one). After two hours, the suspensions were serially diluted in 
steps of ten and 10 µl of each dilution was plated on 5% sheep blood containing Columbia agar 
plates overnight at 37°C. Antimicrobial effects were determined by counting CFU.
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Transmission electron microscopy
About 105 CFU/ml bacteria were incubated in PB with 10µM LCE protein for one hour. Thereafter, 
2.5 µl of this reaction was loaded on a 100 mesh# copper TEM grid containing a carbon coated 
Formvar support film. Grids were incubated 5 minutes at room temperature before blotting away 
the excess liquid and then air-dried for about 24 hours. Samples were imaged in a Jeol 1010 
transmission electron microscope, operating at 60kV. 
Electronic data base-information
UCSC Genome browser (URL: https://genome.ucsc.edu).
Results
eQTL analysis of genes in the epidermal differentiation complex (EDC)
The association results between the deletion surrogate rs4112788 and expression traits are 
shown in Figure 1a. Within the EDC region, only the expression levels of LCE3A, LCE3B, and 
LCE3C are significantly (False Discovery Rate < 0.1) associated with the marker in both normal 
(NN) and psoriatic (PP) skin (Table 1). As expected, expression of both LCE3B and LCE3C 
are decreased in PP skin in the presence of the G allele of rs4112788, which is in linkage 
disequilibrium with LCE3B/C-del. We observed the same result for LCE3C expression in NN, 
while LCE3B could not be assessed as it was not expressed in more than 20% NN skin samples. 
In fact, out of the 80 NN samples, we detected expression of LCE3A and LCE3C in 43 and 40 
samples, respectively, but LCE3B was expressed only in one sample. In contrast, out of the 92 
PP samples, we detected expression of LCE3A, LCE3B, and LCE3C in 92, 48, and 55 samples, 
respectively. Figure 1b shows that LCE3A expression levels were elevated in individuals with 
the GG genotype (surrogate for del/del) compared to individuals with the AA genotype, in 
both NN and PP samples. LCE3A is strongly and significantly (p=7.7x10-30) up-regulated in PP 
(mean expression level = 5.8 x 103) compared to NN skin (mean expression level = 20). The 
fold change difference in expression between GG/AA genotypes is 2.1 in PP samples, and the 
contrast is even higher in NN samples (mean expression level is 35 for GG and 0 for AA). We 
did not observe a significant genotype difference for LCE3A expression in PN skin samples, 
likely due to the smaller sample size. RNA-seq data showed that expression of LCE3A behaves 
similarly between NN and PN skin (NN =4.6 vs. 4.5 in PN skin). See Supplemental Table 1 for the 
normalized RNA-seq expression data of all individuals.
LCE3 proteins are antibacterial
160
Table 1. Top significant e-QTL results in NN and PP skin between rs4112788 versus EDC genes. 
Note LCE3B is not expressed in more than 20% of the NN skin samples, therefore the eQTL analysis was 
not conducted.
Skin type Gene Relative location  
to deletion
Effect P-value FDR
Normal LCE3C* within - 1.60 x 10-11 1.96 x 10-9
LCE3A* downstream + 5.36 x 10-5 3.30 x 10-3
RP11-216N14.9 downstream + 2.75 x 10-3 1.13 x 10-1
LCE1D downstream - 7.1 x 10-3 0.18
LINGO4 upstream - 7.29 x 10-3 0.18
Psoriasis LCE3C* within - 4.09 x 10-15 5.11 x10-13
LCE3B* within - 5.34 x 10-13 3.34 x 10-11
LCE3A* downstream + 8.73 x 10-4 3.64 x 10-2
LCE1D downstream - 1.92 x 10-2 0.6
ILF2 downstream - 3.49 x 10-2 0.67
*indicates significant at the false discovery rate (FDR<= 0.1) level. “Effect” refers to whether the gene is up 
(+) or down (-) regulated in the presence of the G allele for rs4112788 (surrogate for del/del).
Genotype dependent expression of LCE genes in 3D reconstructed epidermis
To substantiate these findings in vitro, and to determine LCE3B/C-del dependent epidermal 
morphology and differentiation, we generated 3D reconstructed epidermis from wt/wt (N=6) 
and del/del (N=6) keratinocytes. We have previously shown that in such a 3D reconstructed 
epidermis model, the spatio-temporal expression of LCE proteins is similar to in vivo epidermis231. 
Histopathological examination of the 3D reconstructed epidermis did not reveal obvious 
morphological differences between the two genotypes (H&E staining), nor did immunohistochemical 
staining reveal abnormalities in expression of differentiation proteins (Supplemental Figure 1). 
Confirming what was observed in vivo (Figure 1a-b), qPCR analysis showed a significant effect 
of the LCE3B/C-del on LCE3A expression (Figure 1c): LCE3A mRNA expression was 6.6-fold 
higher in del/del keratinocytes compared to wt/wt keratinocytes (p<0.003). To mimic psoriasis in 
vitro and confirm the in vivo findings, we stimulated 3D reconstructed epidermis with psoriasis-
associated cytokines. To verify the effect of cytokine stimulation, expression levels of known Th1 
and Th1/Th17 responsive genes CXCL10 and DEFB4 were analysed and found to be strongly 
induced irrespective of the LCE3B/C-del genotype. (Supplemental Figure 2a-b). Following Th1-
, but not Th17- cytokine stimulation, we found a significant genotype effect (4.7-fold, p<0.05, 
Figure 1d-e). Generally, Th1-cytokines induced expression of all tested LCE family genes (Figure 
1f) whereas Th17-cytokines specifically increased LCE2 and LCE3 genes (Figure 1g). These in 
vitro findings corroborate the in vivo findings of the effect of LCE3B/C-del on LCE3A expression. 
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The fold increase in 3D reconstructed epidermis of del/del keratinocytes is modest compared 
to the huge relative increase in vivo, which is caused by the relatively high basal expression of 
LCE3A in wt/wt cells in the skin equivalents, whereas LCE3A expression in vivo for the AA (wt/
wt) genotype is zero.
Figure 1. Expression of LCE genes in LCE3B/C wt/wt and del/del skin in vivo and in vitro. 
(a) A quantile-quantile plot of rs4112788 versus expression traits in the EDC region under different skin 
conditions. Shaded area indicates 95% confidence interval of statistical significance. In addition to the 
expected effect on deleted genes LCE3B and 3C, a significant effect was noted for LCE3A. (b) Estimated 
effect size of LCE3B/C-del on in vivo LCE3A expression in the e-QTL data set. Figures a-b represent eQTL 
data. NN, normal skin; PN; non-lesional psoriatic skin; PP, lesional psoriatic skin. Error bars represent SEM. 
n.e.=no expression. (c-e) Fold change in expression levels of six LCE members (one of each LCE group) 
in 3D reconstructed epidermis of LCE3B/C del/del keratinocytes compared to LCE3B/C wt/wt keratinocytes. 
(c) control (unstimulated) cells, (d) Th1 cytokine stimulated cells, and (e) Th17 cytokine stimulated cells. 
(f-g) Fold difference in expression of LCE family genes in keratinocytes from 10 donors, irrespective of 
the LCE3B/C-del genotype, upon Th1 cytokine and Th17 cytokine stimulation respectively. Figures c-g 
are qPCR data. Error bars represent SEM. Fold increases were calculated compared to expression in wt/
wt keratinocytes or unstimulated keratinocytes (set to 1), indicated by the red lines. * indicate statistical 
significant difference to control (LCE3B/C wt/wt genotype or unstimulated keratinocyte culture). * P<0.05, 
** P<0.005, ***P<0.0005.
(b)
(c)
(e)
(g)
(a)
(d)
(f)
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Figure 2. Barrier function of LCE3B/C wt/wt and del/del 3D reconstructed epidermis. 
Inside-out Trans-Epidermal Water Loss (TEWL) was determined for LCE3B/C wt/wt and del/del reconstructed 
epidermis under unstimulated (a), Th1 cytokine stimulated (b) and Th17 cytokine stimulated (c) conditions. 
(d) TEWL levels were equal in both LCE3B/C genotype groups but were generally decreased by Th1 and 
Th17 cytokine stimulation. (e) Outside-in diffusion of hydrocortisone through the isolated stratum corneum 
of LCE3B/C wt/wt and del/del reconstructed epidermis was measured for 15 hours. (f) Outside-in lucifer 
yellow (LY; green) penetration into the epidermis of unstimulated, Th1 cytokine and Th17 cytokine stimulated 
3D reconstructed epidermis shows equal barrier function of LCE3B/C wt/wt and del/del in vitro epidermis. 
Keratinocyte nuclei are stained with DAPI (blue). Scale bar = 100 µm. All assays were performed with at least 
N=5 keratinocyte donors per LCE3B/C genotype group. Error bars represent SEM.
LCE3B/C-del is not associated with skin barrier alterations
We asked whether genotype dependent alterations of LCE3A expression, i.e. the absence of 
LCE3B and LCE3C and the upregulation of LCE3A, had functional consequences that would 
provide a clue to its genetic association with psoriasis. Many epidermis-specific genes encode 
either structural proteins involved in physical barrier function159 or small proteins that provide 
an antimicrobial barrier321,322. Limited proteomic data suggest that LCE proteins are part of the 
stratum corneum (SC), hence participate in physical skin barrier function, although direct proof 
is lacking. We therefore assessed trans-epidermal water loss (TEWL) from 3D reconstructed 
epidermis of wt/wt and del/del genotypes to unveil a possible effect on inside-out barrier 
function. No difference in TEWL was observed between the genotypes (Figure 2a). We noticed 
that cytokine-stimulated 3D reconstructed epidermis had a lower TEWL compared to control 3D 
constructs (control vs. Th17, p<0.001), but again no differences between the two genotypes 
were observed. The outside-in barrier function was investigated by analysis of the penetration 
of hydrophilic and hydrophobic low molecular weight tracers. Quantitative determination of 
hydrocortisone diffusion by UPLC analysis through the SC did not reveal a difference between 
the two genotypes (Figure 2e). Penetration of the more hydrophilic Lucifer Yellow (LY) dye again 
(a) (b) (c) (d)
(e) (f)
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showed no difference between the genotypes in both unstimulated and Th1- or Th17-cytokine 
stimulated 3D reconstructed epidermis (Figure 2f). In contrast, SDS treatment of 3D reconstructed 
epidermis allows LY to penetrate deeper into the epidermis, revealing a higher permeability due 
to a weakened epidermal barrier147. Collectively, these data indicate that LCE3B/C-del is not 
associated with altered skin barrier function.
LCE3 proteins have antibacterial activity 
Keratinocytes are a known source of antimicrobial peptides (AMPs) such as defensins, SLPI, 
SKALP/Elafin, psoriasin and LL37, many of which are small, cationic and/or cysteine-rich 
proteins323. As LCE3 proteins are also small (9-11 kD), cationic (isoelectric points > 8.6) having 
an extremely high cysteine content (18-23%) we tested the hypothesis that LCE proteins are 
antimicrobial. Based on the finding that LCE3A expression is firmly increased in LCE3B/C-del 
carriers, we decided to study the antimicrobial activity for all three LCE3 proteins (LCE3A/
B/C). We used chemically synthesized LCE3A, LCE3B and LCE3C which demonstrated clear 
antimicrobial activity against 10 commensal and pathogenic bacteria (Figure 3 and Supplemental 
Table 3). Remarkably, even at sub micromolar concentrations, activity was observed against 
a variety of taxa, including Gram-negative (Figure 3a-d) and Gram-positive (Figure 3e-j) 
microorganisms, including both aerobic and aerotolerant species. Notably, antimicrobial activity 
was present under the same experimental (low salt) conditions that reveal antibacterial activity of 
human beta-defensin 2(hBD2), a prototypic cationic, epidermal cysteine-rich AMP324. High salt 
concentrations inhibited antimicrobial activity of LCE3 proteins (Supplemental Figure 3a). LCE3A 
appeared to be the strongest antimicrobial protein of the tested LCE’s, and its potency towards 
gram-negative bacteria is similar to the reported potency of hBD2 for E.coli and P.aeruginosa324. 
Overall, LCE3A antimicrobial activity was found to be a very rapid process and, at least for P. 
aeruginosa (Supplemental Figure 3b).
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Figure 3. Broad-spectrum antimicrobial activity of LCE3A, B and C proteins. 
Synthetic LCE3 proteins were incubated with various bacterial strains in a dose range of 0.1 to 10 µM. 
Antimicrobial activity was tested against diverse gram negative (a-d) as well as gram positive (e-j) commensal 
and pathogenic bacteria. More specifications can be found in Supplemental Table 4. Note that the assay 
allows detection of about 2-3 logs reduction in CFU depending on the input number of bacteria in the assay. 
2x102 CFU/ml is the lower limit of detection, indicating zero colonies, therefore values lower than 2x102 CFU/
ml are not depicted. Error bars present intra-assay variation (SEM) and are based on CFU Experiments were 
performed at least twice. CFU = colony forming units.
As free cysteines of the cytoplasmic LCE proteins are likely to become oxidized once terminal 
differentiation has been completed and SC formation starts, we investigated the effect of oxidation 
and alkylation on the antimicrobial activity of LCE3 proteins. Previous studies on alpha- and beta-
(a)
(c)
(e)
(g)
(i)
(b)
(d)
(f)
(h)
(j)
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defensins have revealed differential effects of cysteine modification325,326. To study the requirement 
of free thiols for biological activity, we first reduced LCE protein with TCEP treatment and then 
irreversibly alkylated the thiols with iodoacetamide. As expected, oxidation increased the molecular 
mass of LCE3A as was revealed on SDS-PAGE (Supplemental Figure 4). The effects of these 
modifications on biological activity were moderate; protein oxidation caused increased antimicrobial 
activity of LCE3A protein against P. aeruginosa (Figure 4), whereas alkylation diminished the activity. 
As defensins can exert toxic effect on mammalian cells as well327 we tested LCE proteins effects 
up to 10 µM on submerged keratinocytes cultures for 4 or 20 hours and did not encounter any 
effect on cell viability or morphology (Supplemental Figure 5a-b). 
Figure 4. Effect of LCE3A protein oxidation status on antimicrobial activity. 
The original synthetic LCE3A protein was reduced with Dithiothreitol, reduced and alkylated with 
iodoacetamide, or oxidized with H2O2 to investigate the effect of oxidation status of the cysteines on its 
antimicrobial activity. Antimicrobial assay of a dilution series between 0.1 and 10 µM LCE3A protein on P. 
aeruginosa. Oxidized LCE3A is slightly more potent than reduced LCE3A, whereas alkylation considerably 
reduces its antimicrobial potency. CFU = colony forming units.
Transmission electron microscopy analysis of LCE3 mediated bacterial killing
We performed transmission electron microscopy (TEM) to obtain morphological information that 
may provide a clue on the mechanism of killing (Figure 5). In all cases, LCE3 proteins caused 
profound changes in the hydration level of the cell wall and cytoplasmic membrane of the 
Gram-positive S. epidermidis and also the outer membrane of the Gram-negative P. aeruginosa. 
The treated cells were extremely sensitive to the electron beam whereas the control cells were 
unaffected. We observed so called (membrane) “blistering” in addition to an electron-opaque 
halo around the treated cells which started to bubble under influence of the electron beam. From 
this we hypothesize that the LCE3 proteins affect the integrity and stability of the cytoplasmic 
membrane, eventually causing extrusion of cell content and cell lysis.
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Figure 5. Transmission electron microscopy images of bacteria exposed to LCE3 proteins. 
Photographs show transmission electron microscopy (TEM) images of untreated Gramneg P. aeruginosa and 
Grampos S. epidermidis (control) and of these bacterial strains after 1 hour incubation with 10 mM LCE3A, 
LCE3B or LCE3C protein. LCE proteins affect the integrity and stability of the bacterial membrane causing 
blistering, extrusion of bacterial content and eventually cell lysis. Scale bar = 500 nm.
Discussion 
Our study establishes two novel findings regarding functional genomics of the psoriasis risk 
factor LCE3B/C-del. Firstly, we show that LCE3B/C-del, a risk allele for psoriasis, is significantly 
associated with the elevated expression of the upstream LCE3A gene inhuman skin. Secondly, 
we have uncovered a hitherto unknown antibacterial function of the proteins encoded by these 
three genes of the LCE3 family.
LCE expression is largely restricted to skin and oral epithelial tissue, and is absent in cells of the 
immune system. This indicates that the biological mechanism conferring an increased psoriasis 
risk is linked to specific epithelial functions of these tissues. qPCR studies have shown that LCE3 
gene expression is low to undetectable in normal skin, but is readably detectable in oral epithelia15. 
Upon skin injury and inflammation, however, LCE3 genes are induced13,15 suggesting that LCE3 
proteins might be involved in skin barrier function or repair. The reported epistasis between the 
major risk factor HLA-C*06:02 and LCE3B/C-del103,106,328 supports the idea that an impaired barrier 
in LCE3B/C-deficient skin would facilitate the penetration of environmental antigens, which in turn 
could trigger an HLA-C*06:02 restricted immune response274. Based on this assumption, we 
performed detailed analysis of barrier properties of the del/del and wt/wt genotypes. However, 
for the molecules studied here, our in vitro models did not reveal an impairment of outside-in and 
inside-out barrier function in LCE3B/C-del epidermis. As the LCE3 baseline expression levels are 
higher in stratified oral epithelia (tonsil, gingiva, pharynx) than in normal skin231, we cannot exclude 
the possibility that the impact of LCE3B/C-loss could lead to leaky oral epithelia that are prone 
8167
to penetration of external antigens. The observation that many psoriasis patients have their first 
flare after streptococcal tonsillitis329,330 would be compatible with the oral cavity as site of entry of 
bacterial antigens. This potential mechanism clearly warrants further investigation.
An alternative explanation for increased penetration of external antigens in LCEB/C -deficient epidermis 
would point to a more direct antimicrobial role of these LCE proteins. Mammalian epidermis is known 
for its antimicrobial shield of keratinocyte-expressed antimicrobial peptides (AMPs)323. Alpha and 
beta-defensins AMPs are all very cysteine-rich, although the essentiality of the cysteines and resulting 
disulphide bridges varies among different members. LCE proteins do not require intact cysteines or 
disulphide bridges, a property also found for hBD3326 and alpha-defensin 6 (HD6)325. The observed 
sensitivity of LCE antimicrobial activity to high ionic strength is also in common with many defensins. 
We found a rather broad spectrum of antibacterial activity that includes Gram-positive and Gram-
negative species, and anaerobic as well as aerotolerant organisms. In view of their high homology, 
other LCE members have antimicrobial properties as well. It will be interesting to determine whether 
this activity extends to other organisms such as yeasts and fungi. 
A variety of AMP mechanisms that mediate bacterial killing or toxin inactivation have been 
described, including membrane permeabilization and depolarization331, peptide nanonets332 and 
local protein unfolding333. LCE3 proteins cause a rapid killing and probably lead to the extrusion 
of cellular components. This is reminiscent of the kinetics of killing by human neutrophil defensins 
where the outer and inner membrane of Escherichia coli are sequentially permeabilized within 
30-60 minutes334. Although our TEM study indeed points to such a permeabilizing effect, further 
analysis is needed to better understand the mechanism of bacterial killing and its relevance in 
the antimicrobial shield of the epidermis. 
How can we integrate these novel findings into a comprehensive picture of the pathogenesis of 
psoriasis? From an evolutionary perspective, the LCE3B/C indel is likely a derived rather than 
an ancestral allele, as the deletion has not been reported in non-human primate genomes. In 
addition, the frequency of the indel is only 37% in African populations but it is between 62-64% in 
East-Asian, South-Asian, American and European populations110,111,335. The increasing frequency 
of LCE3B/C-del in out-of-Africa populations may possibly indicate a selective advantage of this 
ancient mutation. In view of the antimicrobial activity of LCE3 proteins, the deletion could cause 
a different antimicrobial shield in the epidermis. In wt/wt individuals (AA genotype), LCE3A is not 
expressed in normal skin, and also the expression levels of LCE3B/C are also very low or absent. 
LCE3B/C-del thus causes the LCE3A gene to be expressed at significant levels in normal skin 
of these individuals (Fig 1b). The loss of LCE3B/C would not have a noticeable effect in normal 
skin, as they were not expressed anyway. The net result of the indel would be a quantitatively 
(and possibly qualitatively) different epidermal host defense repertoire. Speculatively, this could 
provide an evolutionary benefit, and hence favour the spread of LCE3B/C-del. An increased 
risk to develop psoriasis could be regarded as the evolutionary cost of having this stronger 
antimicrobial shield in the epidermis and oral cavity. 
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As there is an epistatic interaction with HLA-C*06:02103,301, LCE3B/C-del could alter the self-
peptide profile of the skin by altering the balance of LCE3A self-peptides, compared to LCE3B 
and LCE3C. It could also alter the cutaneous microbiome in such a way as to promote the survival 
and colonization of taxa that elicit an HLA-C*06:02 restricted response. A precedent comes from 
a recent microbiome study showing that filaggrin deficiency in ichthyosis vulgaris patients causes 
marked changes in the bacterial species composition336. Microbiome studies on psoriasis have 
been performed, and shifts in microbiome composition have been reported, but unfortunately 
none of these studies have included the host HLA-C*06:02and LCE3B/C-del genotype. Clearly, 
future studies should aim to establish the effects of LCE3B/C-del on the tissue microbiome, and 
their potential effects on HLA*C06:02 dependent immune processes that lead to disease.
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Supplemental Figures
Supplemental Figure 1. General morphology, epidermal proliferation and expression of 
differentiation markers in LCE3B/C wt/wt and del/del 3D reconstructed epidermis. 
LCE3B/C wt/wt and del/del 3D reconstructed epidermis models show equal stratification and morphology 
(H&E staining). Early (keratin 10, K10), late differentiation proteins (involucrin, IVL; loricrin, LOR; late cornified 
envelope 2, LCE2; late cornified envelope 3, LCE3, transglutaminase 1, TGM1) and the proliferation marker 
(Ki67) are expressed equally in both LCE3B/C genotype groups. Pictures are representative for N= 5 
keratinocyte donors per LCE3B/C genotype group. Scale bar = 100 µm.
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Supplemental Figure 2. Expression levels of DEFB4 and CXCL10 in LCE3B/C wt/wt and del/del 
reconstructed epidermis. 
(a) mRNA expression levels of DEFB4 and CXCL10 measured with qPCR comparing LCE3B/C wt/wt and del/
del reconstructed epidermis under unstimulated, Th1 cytokine and Th17 cytokine stimulated conditions. N=6 
keratinocyte donors per LCE3B/C genotype group. (b) DEFB4 and CXCL10 are differentially induced upon 
Th1 or Th17 stimulation. N=12 keratinocyte donors of both LCE3B/C genotypes. Error bars represent SEM. 
* indicates statistical significant difference to control (LCE3B/C wt/wt genotype or unstimulated keratinocyte 
culture). ***P<0.0005. Repeated measures ANOVA, followed by Bonferroni post hoc testing was performed 
P < 0.05 was considered statistically significant.
(a)
(b)
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Supplemental Figure 3. P. aeruginosa antimicrobial assays comparing the influence of salt 
concentration in the assay buffer and activity of LCE proteins compared to hBD2. 
(a) Dilution series between concentrations of 170 and 10 mM sodium phosphate buffer with 10 µM LCE3 
protein in an antimicrobial assay against P. aeruginosa. b) Antimicrobial activity of a dilution series between 
10 and 0.1 µM hBD2 or LCE3A protein against P. aeruginosa. Note that the assay allows detection of about 
2-3 logs reduction in CFU depending on the input number of bacteria in the assay. 2x102 CFU/ml is the lower 
limit of detection, indicating zero colonies. Error bars present SEM and are based on CFU counts of several 
experiments. CFU = colony forming units; PB= sodium phosphate buffer.
(a)
(b)
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Supplemental Figure 4. SDS-page gel with LCE3A protein in different conformations. 
Coomassie-blue stained SDS-page gel of reduced synthetic LCE3A protein indicating the change of 
molecular mass by alkylation or oxidation. a) Reducing SDS-page gel showing increase molecule mass 
of alkylated LCE3A protein. b) Non-reducing SDS-page gel showing protein bands of different molecular 
masses of oxidized LCE3A protein, indicating protein multimerization. Arrow heads indicate LCE3A protein 
bands. 
(a) (b)
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Supplemental Figure 5. In vitro toxicology of LCE protein on monolayer cultures of normal human 
epidermal keratinocytes. 
Measurement of lactate dehydrogenase (LDH) release of keratinocytes exposed to the indicated doses of 
either reduced or oxidized LCE3A, LCE3B or LCE3C protein. The graph shows the fold change of optical 
density (OD) of lactate dehydrogenase amount after (a) 4 or (b) 20 hours incubation compared to control. As 
positive control cells were treated with Triton X-100. Fold increase of OD values of dead cells (cells treated 
with Triton X-100 as positive control) were >15. N=3 keratinocyte donors. Error bars represent SEM.
(a)
(b)
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AG 0,00 NN
AG 4,93 NN
AG 72,68 NN
AG 4,63 NN
AG 10,36 NN
AG 0,00 NN
AG 8,24 NN
AG 0,00 NN
AG 8,72 NN
AG 20,44 NN
AG 0,00 NN
AG 8,06 NN
AG 0,00 NN
AG 0,00 NN
GG 4,81 NN
GG 80,15 NN
GG 9,15 NN
GG 4,80 NN
GG 21,75 NN
GG 0,00 NN
GG 0,00 NN
GG 11,90 NN
GG 5,38 NN
GG 15,56 NN
GG 4,82 NN
GG 12,73 NN
GG 40,88 NN
GG 0,00 NN
GG 0,00 NN
GG 4,59 NN
GG 0,00 NN
Genotype LCE3A  
expression
Skin biopsy
AA 0,00 NN
AA 0,00 NN
AA 0,00 NN
AA 0,00 NN
AA 0,00 NN
AA 0,00 NN
AA 0,00 NN
AA 0,00 NN
AA 0,00 NN
AA 0,00 NN
AA 0,00 NN
AG 0,00 NN
AG 0,00 NN
AG 0,00 NN
AG 0,00 NN
AG 0,00 NN
AG 0,00 NN
AG 0,00 NN
AG 16,61 NN
AG 4,48 NN
AG 8,71 NN
AG 17,38 NN
AG 0,00 NN
AG 118,46 NN
AG 0,00 NN
AG 0,00 NN
AG 4,52 NN
AG 69,89 NN
AG 0,00 NN
AG 0,00 NN
AG 5,34 NN
Supplemental Tables 
Supplemental Table 1. Normalized RNA-seq data LCE3A. 
NN, normal skin; PN, non-lesional psoriatic skin; PP, lesionsoriatic skin
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GG 12,15 NN
GG 9,48 NN
GG 0,00 NN
GG 5,49 NN
GG 9,95 NN
GG 0,00 NN
GG 9,92 NN
GG 5,15 NN
GG 752,98 NN
GG 29,00 NN
GG 10,62 NN
GG 11,24 NN
GG 50,26 NN
GG 24,38 NN
GG 0,00 NN
GG 3,80 NN
GG 39,39 NN
GG 23,16 NN
AA 4,48 PN
AG 0,00 PN
AG 4,85 PN
AG 0,00 PN
AG 9,90 PN
AG 0,00 PN
AG 5,04 PN
AG 0,00 PN
AG 41,14 PN
AG 0,00 PN
AG 15,70 PN
AG 33,64 PN
AG 28,41 PN
GG 0,00 PN
GG 0,00 PN
GG 4,60 PN
GG 4,82 PN
GG 8,41 PN
GG 9,60 PN
GG 0,00 PN
GG 3,82 PN
GG 0,00 PN
GG 0,00 PN
GG 25,34 PN
GG 3,77 PN
GG 7,15 PN
GG 0,00 PN
AA 5677,02 PP
AA 670,77 PP
AG 1493,48 PP
AG 8815,45 PP
AG 7407,41 PP
AG 4675,72 PP
AG 1838,64 PP
AG 2971,84 PP
AG 5132,50 PP
AG 1931,08 PP
AG 2316,66 PP
AG 8386,70 PP
AG 2869,79 PP
AG 2226,71 PP
AG 5031,46 PP
AG 5592,58 PP
AG 4651,03 PP
AG 9980,45 PP
AG 2148,35 PP
AG 1553,08 PP
AG 8352,87 PP
AG 6081,59 PP
AG 6104,10 PP
AG 9155,74 PP
AG 1668,54 PP
AG 2642,16 PP
AG 5533,04 PP
AG 4639,93 PP
AG 5714,95 PP
AG 10954,90 PP
AG 2987,94 PP
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AG 7227,05 PP
AG 5752,85 PP
AG 5964,11 PP
AG 7566,92 PP
AG 825,91 PP
AG 8159,48 PP
AG 8004,48 PP
AG 1287,24 PP
AG 3457,02 PP
AG 8130,71 PP
AG 4751,90 PP
AG 3637,48 PP
AG 844,86 PP
AG 5185,24 PP
AG 3542,62 PP
AG 4311,81 PP
AG 11703,40 PP
AG 7345,77 PP
GG 807,67 PP
GG 7280,85 PP
GG 4580,75 PP
GG 10160,30 PP
GG 1961,26 PP
GG 3346,75 PP
GG 2021,33 PP
GG 5700,67 PP
GG 3506,51 PP
GG 5762,86 PP
GG 2311,29 PP
GG 4672,68 PP
GG 9581,99 PP
GG 6797,14 PP
GG 4833,38 PP
GG 5902,34 PP
GG 8994,04 PP
GG 9869,43 PP
GG 8178,39 PP
GG 16039,20 PP
GG 760,47 PP
GG 9591,75 PP
GG 7518,39 PP
GG 11580,70 PP
GG 12066,00 PP
GG 4953,80 PP
GG 1153,26 PP
GG 34269,50 PP
GG 288,02 PP
GG 2978,19 PP
GG 3327,11 PP
GG 4667,82 PP
GG 6975,69 PP
GG 4468,85 PP
GG 4580,29 PP
GG 7528,51 PP
GG 3025,30 PP
GG 6404,29 PP
GG 3617,84 PP
GG 12694,30 PP
GG 3756,76 PP
GG 9882,30 PP
GG 9697,93 PP
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Supplemental Table 2. Primers used for qPCR analysis.
HUGO 
gene 
symbol
Alias gene name Forward primer 5’-3’ Reverse primer 3’-5’ *E
CXCL10 Chemokine (C-X-C motif)  
ligand 10
ttcctgcaagccaattttgtc tcttctcacccttctttttcattgt 2.01
DEFB4 Human beta defensin 2 gatgcctcttccaggtgttttt ggatgacatatggctccactctt 1.99
LCE1A Late cornified envelope 1A tgcaagagtggctgagatgc agacaacacagttggtgtcagg 2.18
LCE2A Late cornified envelope 2A ggacctgtcccagagtgatg gatccaggatgggctcttg 2.10
LCE3A Late cornified envelope 3A gagtcaccacagatgcc cttgctgaccacttccc 2.02
LCE4A Late cornified envelope 4A cccccaaaatgtccctcaaagt ggagccacagcaggaagagat 1.88
LCE5A Late cornified envelope 5A ccctctttatcctgccc acaacacctagttctccaa 1.87
LCE6A Late cornified envelope 6A agaagcagcaatcttgga cctttgggaactggaatg 2.05
RPLP0 hARP, 60S acidic ribosomal  
protein P0
caccattgaaatcctgagtgat-
gt
tgaccagcccaaaggagaag 2.02
*E is efficiency as fold increase in fluorescence per PCR cycle.
Supplemental Table 3. Antibodies and their dilutions used for immunohistochemistry.
Target protein Animal, code, manufacturer dilution
Cytokeratin-10 Mouse-monoclonal, DE-K10, Euro Diagnostics 1:100
Involucrin Mouse-monoclonal, MON-150149 1:20
Ki67 Mouse-monoclonal, MIB-1, DAKO 1:50
Late cornified envelope protein 2 By M. Narita (Cambridge Cancer Centre) 1:1000
Late cornified envelope protein 3 Mouse-monoclonal, clone-7231 1:5000
Loricrin Rabbit-polyclonal, 145P, Convance 1:2000
Transglutaminase-1 Rabbit-polyclonal, H-87, Santa-Cruz 1:100
LCE3 proteins are antibacterial
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Summary 
In chapter 1 of my thesis I describe the general structure and function of human skin. One of the 
main functions of epithelial tissues, such as the epidermis, is to provide a barrier between the inside 
and outside of our body. This barrier is accomplished by different epithelial proteins and structures 
that contribute to physical, chemical, immunological and microbial skin barrier. The majority of skin 
barrier mechanisms are present in or on the terminally differentiated corneocytes that make up the 
stratum corneum. There, differentiation proteins like filaggrin or the late cornified envelope proteins 
are present. Mutations in the filaggrin gene and the LCE3B/C locus are known genetic risk factors 
for atopic dermatitis and psoriasis, respectively. The goal of this thesis was to study the biology that 
underlies the risk conferred by these genetic signals. As these genetic risk factors are not single-
nucleotide polymorphimsms in non-coding regions, but directly affect protein expression, we could 
address their function in a hypothesis-driven approach. To analyse the relation between genotype 
and phenotype, which could involve morphological as well as functional alterations, a suitable model 
system is needed. For ethical and practical reasons, in vivo human skin tissue is not suitable to 
study the biology of these skin diseases. Alternatively, submerged as well as three-dimensional in 
vitro cultures of primary human keratinocytes are well-established model systems for dermatological 
research. In chapter 2 we showed that these keratinocyte models are vulnerable to the exposure of 
widely used antibiotics. Cell growth and differentiation of keratinocytes appeared to be hampered by 
the use of preventive application of antibiotics, which is quite common practice in cell research. This 
was the starting point of antibiotics-free cell culture practice as the gold standard at our department. 
Using our 3D epidermal equivalent model, we analysed the effect of different soluble factors on 
stratification and differentiation on epidermal keratinocytes. In chapter 3 we tested whether interleukin-9 
(IL-9), which was recently described as a novel player in atopic dermatitis pathophysiology, is involved 
in the alteration of skin differentiation and barrier function. We have shown that in both healthy and 
atopic dermatitis-like epidermis, IL-9 does not affect keratinocyte morphology nor expression of 
keratinocyte-derived structural proteins, chemokines and cytokines. We therefore proposed that 
IL-9 is likely to play another role in atopic dermatitis rather than disturbing epidermal differentiation 
and skin barrier formation. Two other soluble factors, of which increased levels are linked to atopic 
dermatitis, are HMGB1 and IL-33. As their exact role in the epidermal alterations of atopic dermatitis 
skin was yet unknown, we also tested these compounds in the 3D equivalent model (chapter 4). 
We found that IL-33 and more strongly HMGB1, downregulated the expression of epidermal late 
differentiation markers. We therefore hypothesized these “alarmins” to contribute to the dysregulated 
epidermal differentiation which is part of the typical atopic dermatitis pathophysiology.
Part 2 of my thesis focused on filaggrin mutations and atopic dermatitis. Loss-of--function mutations 
of the filaggrin gene were shown to be causative for the development of ichthyosis vulgaris and 
predisposing to atopic dermatitis. Although this gene mutation was discovered about ten years 
ago, its exact mechanism leading to disease remained unknown. One of the hallmarks of atopic 
dermatitis is the impaired skin barrier function in lesional but also non-lesional skin. A widely 
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accepted idea, or even dogma, was that filaggrin mutations might be the underlying factor for this 
phenomenon, although conclusive evidence was lacking. In chapter 5 we have tested genetically 
defined, completely filaggrin-deficient primary keratinocytes of ichthyosis vulgaris patients in our 
3D epidermal equivalent model. We investigated epidermal stratification and differentiation and the 
expression of epidermal barrier proteins. In addition, we analysed if there were any alterations in 
barrier function compared to filaggrin wild type keratinocytes. Intriguingly, we found that the loss of 
filaggrin alone does not relate to any of the keratinocyte-dependent hallmarks of atopic dermatitis. 
However, using microbiome analysis, we have shown that loss of filaggrin protein causes significant 
alterations of the skin microbiome composition. Gram-positive anaerobic cocci, bacteria that feed on 
filaggrin breakdown products, were less abundant in filaggrin-deficient patients compared to healthy 
controls. Moreover, we found that these bacteria are able to quickly induce antimicrobial peptides in 
keratinocytes. Together, we showed that the loss of filaggrin can influence the human microbiome 
and that this might lead to alterations in epidermal host defense, which, speculatively could contribute 
to the link between filaggrin deficiency and AD prevalence (chapter 6). 
The final part of this thesis presents the studies that we have performed focusing on the late cornified 
envelope proteins. Deletion of LCE3B and 3C (LCE3B/C-del) has been identified as one of the 
genetic risk factors for psoriasis. The underlying mechanism between loss of these proteins and 
psoriasis, and the general biologic function of these and the other 16 LCE family members, however, 
was yet unknown. Using specific antibodies, we have analysed the expression profiles of LCE2 and 
LCE3 proteins in the skin and a broad range of other human epithelial tissues (chapter 7). We have 
shown that despite the high sequence homology of LCE family members, their baseline expression 
as well as their expression regulation in disease is different. Whereas LCE2 proteins are expressed 
in the uppermost granular keratinocytes of normal skin and are downregulated in psoriasis, LCE3 
proteins are expressed in the higher spinal and lower granular cells and are highly increased in 
psoriatic skin. These data suggested a nonredundant role of the different LCE proteins. In chapter 
8 we further investigated the link between the LCE3B/C-del and psoriasis and aimed to identify the 
biological function of the psoriasis-associated LCE3 proteins. First, we have found that expression 
of LCE3A, the gene directly adjacent to the LCE3B/C-del locus, was highly increased in normal, 
non-psoriatic, LCE3B/C-deleted skin compared to wild type skin. These findings were made in skin 
biopsies comparing normal healthy and psoriatic skin, as well as in vitro in 3D epidermal equivalents 
that were either unstimulated or cytokine stimulated to mimic psoriasis. For the first time, we revealed 
a function for members of the LCE protein family. We show that LCE3A, LCE3B and LCE3C are 
broad range antimicrobial peptides in vitro, suggesting that they function as host defense molecules 
in the epidermis. Together, alterations in expression of LCE3 proteins as well as their antibacterial 
function implicate that the deletion of LCE3B/C might affect the homeostasis of our skin host defense 
repertoire and consequently the commensal bacterial composition. Future research therefore needs 
to focus on the here discovered function of the LCE proteins as this might be the missing link between 
the deletion of LCE3B/C and psoriasis. 
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General discussion and future outlook
As the title of this thesis already implies, “from sequence to function”, was the main approach 
of my research. But why did we choose to do it this way? Due to the advances in molecular 
genetic technologies over the past decades, numerous studies have been performed to analyse 
the human genome in health and disease. Since the first successful genome-wide association 
(GWAS) study about 10 years ago337 numerous studies were published showing certain single-
nucleotide polymorphism (SNPs) to be associated with disease. Most GWAS studies compare 
cases to controls, to search for any genetic traits that are significantly associated with a 
particular phenotype, e.g. a certain disease. In dermatological research, several GWAS studies 
have been performed and they have come up with numerous SNPs and other genetic variants 
being associated with a certain skin disorder. For example, until today there are more than 40 
loci described to be associated with psoriasis103,276,301,338-347. Certainly, this technical development 
is one of the bigger steps in scientific research and offers great opportunities to understand the 
code of the human (and non-human) genome. I believe that these new candidate loci are very 
valuable starting points for further research, but disease-associated SNPs alone do not explain a 
disease. We need to better understand how a certain genetic trait can lead to disease. Therefore, 
those variants located within coding regions of our genome are particularly useful. Knowing the 
affected gene can already suggest biological mechanisms which might be disturbed by the 
mutation. Hypothesis-driven experiments can then be designed to test this, which is the basic 
approach of the research described in this thesis. For both psoriasis and atopic dermatitis (AD), 
we tested the impact of one of the major genetic risk factors, LCE3B/C-del and FLG null mutations 
respectively, to investigate their functional consequences in the skin. As these mutations are 
within genes that encode for keratinocyte proteins expressed during the later stages of epidermal 
differentiation, we hypothesized that both may interfere with epidermal functions in the more 
differentiated layers of the epidermis. This assumption is very useful to narrow the amount of 
experiments needed to test your hypothesis. Before digging deeper into both the FLG-and LCE-
related studies, I want to emphasize the value of the in vitro models that we have used for this 
research. To study proteins expressed in differentiating keratinocytes, a suitable model system is 
needed. Keratinocyte monolayers are useful high-throughput models348,349, however they do not 
faithfully mimic the in vivo keratinocyte environment. Although longer differentiation periods for 
monolayer keratinocytes can induce the expression of late differentiation markers, this is still not 
sufficient to adequately mimic and investigate keratinocyte interactions as present in stratified 
skin. For both practical and ethical reasons, human donor skin is not readily available. For this 
reason, there is a great demand for high-quality three-dimensional (3D) stratified skin models. In 
my studies, I used a 3D epidermal equivalent model, meaning that we solely rebuild the skin’s 
epidermal compartment. We favoured this model to initially focus on only the keratinocytes. 
Furthermore, we experienced this model to be highly reproducible. In literature, many 3D models 
have been described and many of them use keratinocyte cell lines, e.g. HaCat or N/TERT 
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cell lines349,350. We aimed to use primary adult keratinocytes instead as they nicely represent 
in vivo keratinocytes. Moreover, we aimed to use keratinocytes of various donors to include 
biological variation and replicates in our studies. Techniques for genetic modification have also 
been improved during the last years; applying these in our 3D model would of course be an 
interesting approach. Unfortunately, primary human keratinocytes are not the most favourable 
cells for genetic interference. Non-viral transient transfection is efficient in short-term monolayer 
cultures351 but the knockdown or transgene expression is not stable in 3D models as they require 
much longer cultivation periods. Therefore, (lenti)viral delivery methods are more favourable for 
keratinocytes in 3D cell cultures. In this system, transduction of DNA is stable as it is permanently 
integrated into the host genome352. However, this technique still has a major drawback. Efficiency 
of gene silencing or induction is often low and off-target effects need to be taken into account. 
An elegant way to overcome these difficulties is to use primary cells that already have the 
genotype that is aimed to investigate, which is, however, admittedly not always possible. We 
used this approach to study the effect of the LCE3B/C-del or FLG null-mutations in vitro. We 
isolated keratinocytes from genotyped donors (e.g. FLG-null keratinocytes from ichthyosis 
vulgaris patients) and screened our keratinocyte bank for cells carrying the genotype of interest. 
In our 3D epidermal equivalent model, we could then study the impact of these genetic variants 
on epidermal development, differentiation, gene and protein expression as well as functional 
assays. This approach also takes into account the possible adaptation or compensation, e.g. 
for the loss of filaggrin protein, that might occur on the long term, which actually nicely reflects 
in vivo circumstances. Moreover, we can exclude that there is any remaining wild type transcript 
or protein in these models. Besides these psoriasis or atopic dermatitis associated gene 
polymorphisms one could investigate the impact of genetic variants in keratinocyte-expressed 
genes other than FLG or LCE3B/C on the epidermis.
Filaggrin mutations in atopic dermatitis and ichthyosis vulgaris
The discovery of the strong genetic association of filaggrin (FLG) mutations with ichthyosis 
vulgaris and AD, about ten years ago, has been a milestone in the study of these diseases69,73,273. 
Until then, AD research had been dominated by immunological theories, and the contribution of 
the skin, or specifically the epidermis, was rather neglected. Since these discoveries, numerous 
studies have investigated the relation between FLG mutations and AD. The fact that AD and 
ichthyosis vulgaris both are associated with skin barrier impairment and that FLG has a skin-
restricted expression has fostered the idea that FLG loss is the underlying factor responsible 
for skin barrier impairment in those patients. Until today, this hypothesis has become a widely 
accepted dogma. However, as summarized and discussed in this thesis, solid experimental 
evidence for this was lacking. In our study, we have shown that there is no evidence that FLG 
loss leads to the disease-associated skin barrier impairment using complete FLG deficient 
patient-derived keratinocytes cultured in our 3D epidermal model. There is no doubt about the 
association of FLG mutations and AD or ichthyosis vulgaris, as this has been replicated in large 
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cohorts and is replicated worldwide, as summarized in a recent review353. The same holds true 
for the finding that AD skin is affected by a leakier epidermal barrier212,224,354-356. In my thesis, I 
question that the loss of FLG alone is probably not the sole underlying factor responsible for 
barrier impairment in AD. As FLG mutations only explain a subgroup of AD patients, whereas all 
AD patients suffer from barrier impairment, there must be other factors involved rather than FLG 
alone. However, it is true that the exact experimental conditions that are used to test the impact 
of FLG loss on barrier function might be of crucial importance. Besides the increased risk for 
developing AD, FLG mutations generally lead to a dry skin, and disease flares are also more 
prevalent in dry conditions, like during the cold season. In vitro models, including ours, are grown 
in laboratory incubators at ambient temperatures and a high humidity, not exactly mimicking 
the circumstances of in vivo skin. Presumably, these and other specific conditions might be 
crucial to test the importance for FLG protein in the epidermis. Nevertheless, our model, is the 
only to date that completely rules out the risk for off-target gene effects and incomplete protein 
loss, and moreover was shown to have a functional epidermal barrier. Therefore, we do have 
enough evidence to state that the barrier alterations as shown in earlier studies, under the same 
experimental conditions, might be due to spurious results other than FLG loss. However, in the 
future it might be interesting to test whether factors like humidity and temperature do play a 
role on FLG-dependent skin barrier function. Moreover, it could well be that not FLG loss alone, 
but an additional trigger (e.g. allergen sensitization or until now unknown mutations in FLG-like 
genes like filaggrin-2 or hornerin) leads to the typical AD barrier dysfunction and subsequent 
skin inflammation. I believe that our 3D models in which we use FLG deficient keratinocytes are 
a valuable system to test this in the future.
Additionally, it is very intriguing that next to the contribution of the immune system and the 
epidermis, another compartment appears to play a role in AD and potentially other (inflammatory) 
skin diseases, namely: the skin microbiome. Since the start of the Human Microbiome Project 
which was launched in 2008, many studies have shown how microbes in and on our body, 
can contribute to health and disease. Also in dermatological research, studies have suggested 
a relation between microbiome composition and skin disease. However, the chicken and egg 
causality has yet to be discovered. It can either be that the skin disease causes disturbance of 
the normal microbiome, or that alterations of the microbiome leads to a skin disease. AD patients 
often suffer from skin infections with Staphylococcus aureus (S. aureus)88,357,358. Moreover, it has 
been shown that the non-lesional skin of AD patients is more often colonized with S. aureus when 
compared to skin of healthy controls359. We have tested whether the FLG genotype is correlated 
to a specific microbiome composition. We found that not the AD related pathogen S. aureus, 
but other skin colonizers were differentially present on FLG deficient skin, namely Gram-positive 
anaerobic cocci (GPAC) like Finegoldia magna. These bacteria use specific nutrients that can be 
derived from epidermal proteins, like breakdown products of FLG. So, interestingly it appears 
that our genetic background is important for the colonization by certain microbiota. Moreover, 
we have shown that keratinocytes react differently to specific types of microbiota. Therefore, 
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the host defense response of our epidermis appears not be a random response to any kind 
of exogenous trigger, but is specific to the type of trigger, e.g. certain microbe. We do not yet 
understand this host-microbe interaction exactly but the crucial role in the balance of health and 
disease of our skin and other epithelia is undeniable. We have evidence suggesting that FLG-
dependent reduction of F. magna can cause a delayed host defense response and we believe 
this might play a role in AD. It would be very interesting to study the interactions of F. magna, 
S. aureus and other skin bacteria, commensals as well as pathogens, with keratinocytes and 
immune cells to learn more about the mechanisms of bacteria recognition and other microbes 
like fungi and viruses. Furthermore, I would like to investigate whether the genetic background 
influences the abovementioned processes. More precisely, does FLG loss, besides the altered 
amounts of NMF breakdown products, also play a role in host-microbe interactions? For this we 
need to add microbiota to our 3D epidermal model, which would be a very valuable tool to better 
understand the interaction of human epithelia and our skin microbiome in health and disease. 
Finally, to make our model even more complete we could combine this 3D skin microbiome 
model with the addition of immune-cells (e.g. patient-derived T-cells). The incorporation of T-cells 
in a 3D skin model is feasible as we have demonstrated before121. Only then we would be able 
to analyse the cross-talk of the epidermis, immune cells and the microbiome. The use of patient-
derived cells and microbiota, would allow us to closely mimic the patients in vivo epidermal 
microenvironment and enables us to find an answer to the chicken and the egg question in the 
pathogenesis of AD. Figure 1 illustrates the possible causality between FLG and AD based on 
the results of this research.
LCE proteins psoriasis
Since the discovery of the first LCE family members in 19978 these genes and encoded proteins 
have not been extensively studied. After the deletion of LCE3B/C was discovered as a risk factor 
for psoriasis103 more studies have been performed investigating this gene locus, though the 
function of the LCE proteins and their exact mechanistic role for psoriasis remained unexplored. 
The development of specific anti-LCE2 and anti-LCE3 antibodies, however, gave us valuable 
information about the expression of these LCE subgroups in the epidermis but also in other 
epithelia. Distinct amounts and locations of expression strongly implicate separate regulation 
and different roles of individual LCE proteins, or LCE subgroups. From an evolutionary point 
of view this also makes sense, as it would be difficult to explain why 18 very similar proteins 
are highly conserved and are all present if they all have the same function. Whereas most LCE 
subgroups, particularly LCE1 and 2, are always present at substantial levels in the epidermis, the 
LCE3 subgroup is low to absent in normal skin and is only induced upon skin insults, like injury or 
inflammation. This implicates the LCE3 proteins are either upregulated as part of the process of 
e.g. skin inflammation or that they might be induced as an epidermal reaction to inflammation and 
that they might contribute to response or clearance of this event. Moreover, there are differences 
in expression patterns between diverse epithelia, e.g. the skin versus internal epithelia13,15. To 
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accomplish differential gene expression, these genes need to be regulated separately or at least 
group-wise. It has been shown that there are three amino acid loop extensions (TALES) that are 
abundant in the epidermis and bind LCE promotors. Interestingly, LCE1 and LCE2 promotors 
are bound more strongly by TALE transcription factors than LCE3 promotors278. Likely, these and 
other DNA regulation mechanisms are present to specifically determine the LCE composition of 
the different keratinized epithelia and to make those being responsive to certain circumstances 
(e.g. injury, inflammation).
Figure 1. Schematic illustration of the (hypothetic) relation between filaggrin mutations and 
atopic dermatitis. 
In healthy FLG wild type skin NMF molecules are present, derived from FLG and other epidermal proteins. 
These are nutrients for microbes that colonize our skin. Specific species of commensal skin bacteria (GPACs) 
are able to induce keratinocyte antimicrobial peptide expression and thereby contribute to host defense 
reaction of our skin. The epidermal immune system is adapted to the presence of these skin commensals 
and therefore there is no inflammatory response. FLG mutations lead to deficiency of FLG-derived NMF. 
The lack of nutrients for GPAC bacteria can reduce their numbers on the skin, which may be advantageous 
for other e.g. non-commensal bacteria like S. aureus. Both the lower numbers of commensal, as well as 
the increased proportion of pathogenic bacteria, may induce pro-inflammatory activation of the epidermis. 
This might either occur via immune cell activation as well the host defense response of the keratinocytes. 
This scenario might explain the causality between FLG mutations and the typical hallmarks of AD like skin 
inflammation and S. aureus infection.
In this thesis, we for the first time show a hitherto unknown protein function of the LCEs, namely 
the strong antimicrobial activity of the LCE3 proteins LCE3A, LCE3B and LCE3C. Before this 
discovery we could only hypothesize about the protein function of the LCEs based on their 
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location and pattern of expression. Currently, we have proven this antimicrobial activity in vitro 
and therefore we can only speculate about the exact implication of this function for in vivo 
epidermis. It is known that our epidermis itself can express a pallet of antimicrobial peptides 
(AMPs) like SKALP/Elafin or beta-defensins. The expression of LCE3 proteins is very similar to 
that of SKALP/Elafin, hBD2 or SLPI150,280-282, as all these proteins are present in the granular layer 
in the so-called “sunny-side” of the cells. Moreover, alike the LCE3s, the expression of AMPs 
is low in normal healthy skin but induced in inflammatory and damaged skin. These features 
all suggested the LCE3 proteins to be antimicrobial. Concerning the expression patterns, one 
might then suggest that the other LCE proteins, which have not yet been tested, would not have 
this function. However, the high amino acid sequence homology makes it very likely that all LCE 
proteins might have the same function. It therefore is very interesting to find out more about the 
mechanism and specificity of bacterial killing, and if the whole protein is needed or that only 
specific parts of the LCE peptides are important for this antimicrobial feature. Knowing which 
part of the LCE3 proteins is responsible for antimicrobial activity allows us to better predict which 
other LCE proteins might also be antimicrobial based on the sequence homology. LCE3 proteins 
appeared to be very broad antimicrobial peptides that can kill commensal as well as pathogenic 
bacteria of both Gram-positive and Gram-negative type. In case other LCE proteins are also 
antimicrobial, do they kill the same type of microorganisms or is there specificity between the 
different LCE members? One could hypothesize that the LCEs (e.g. LCE1 and LCE2 proteins) 
that are expressed at substantial levels in healthy skin are not antimicrobial, or to a lesser extent, 
and that only when needed, for example after skin barrier disruption when there is danger of 
infection, LCE3 proteins possessing a broad antimicrobial spectrum to form an antibacterial 
shield are upregulated. The mechanism of bacterial damage by the LCEs is very interesting 
to be further investigated. As both Gram-positive and Gram-negative bacteria are sensitive we 
can assume that not the outer membrane, which is only present in Gram-positive bacteria360, 
is the target for LCE-mediated killing. Like other AMPs, the LCE proteins are very cationic. This 
characteristic is important for the antibacterial function. The positive charge, defined by the 
amino acid composition, can interact with the negatively charged bacterial membranes361,362. 
Membrane depolarization and disturbance like pore-formation, phase separation and disruption 
of the lamellar bilayer that can cause leakage of bacterial content leading to cell death363. Our 
initial transmission electron microscopy (TEM) analysis indicates that the cytoplasmic membrane 
is affected, but we need more extensive imaging techniques for a more detailed investigation. 
Immuno-electron microscopy could be valuable to see if the LCE proteins are located around 
or even within the bacterial cells. Moreover, we could investigate if LCE proteins are not only 
antibacterial but also antifungal, antiparasitic, or antiviral and if so, study if there is a common 
mechanism for neutralizing these microorganisms.
Beyond antimicrobial activity, LCE proteins may also have other functions in the epidermis. We 
have performed protein interaction studies with yeast-two-hybrid and co-immunoprecipitation 
techniques to find interaction partners of LCE proteins (data not shown). Amongst some 
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interesting non-LCE candidate proteins, we have evidence that all LCEs, despite LCE6A, can 
bind each other. This suggest that the LCEs, probably together with other epidermal proteins, 
can form a network in the epidermis. In view of the LCE3 proteins’ antimicrobial activity this 
protein network might serve as an antibacterial shield, but it could also well be contributing to 
cell or tissue stiffness of the cornified layer. More detailed investigations on the LCEs protein 
interaction partners will give new insights on the role of these proteins and their function in the 
epidermis.
Regarding the high cysteine content of the LCE proteins, they do have a common feature with 
the small proline-rich (SPRR) proteins. These keratinocyte-expressed proteins are encoded in 
the epidermal differentiation complex (EDC) on chromosome 1 and are expressed during late 
keratinocyte differentiation. Interestingly, these proteins are capable to protect against reactive 
oxygen species (ROS). ROS are chemicals released from neutrophils and macrophages to 
combat bacterial infection after wounding. However, ROS are also toxic to the host cells and 
therefore need to be cleared from the tissue. Another reason for ROS occurrence is UV radiation 
from sunlight. SPRRs can quench ROS molecules to prevent epidermal damage. It has been 
shown that this is due to the high cysteine content of these proteins54,364. Hypothetically, LCE 
proteins might also have anti-ROS function. We will investigate this in the future.
ROS-neutralization would implicate the LCE to contribute to chemical skin barrier function. 
However, earlier studies have already postulated that they might also be part of the physical skin 
barrier13,103. Based on their expression patterns in psoriasis and after skin injury, non-LCE3 family 
member proteins might be involved in skin barrier homeostasis, whereas LCE3 proteins would 
rather be involved in skin barrier repair13. In this thesis, we do not have tested the exact roles of 
all LCE groups on skin barrier function, but we have shown that loss of LCE3B and LCE3C, does 
not cause barrier impairment. With qualitative as well as quantitative techniques, we showed 
that LCE3B/C-del 3D epidermal equivalents have similar in vitro epidermal barrier properties as 
LCE3B/C wild type keratinocytes, both in normal and in psoriasis-like equivalents. Of course, it 
might be that loss of LCE3B and C is compensated by other LCEs, as we have shown increased 
expression of mainly LCE3A in LCE3B/C-del skin. This would then also be true in vivo, meaning 
that LCE3B/C-deleted skin does not suffer from skin barrier impairment. Suggesting that LCE3 
proteins are rather involved in skin barrier repair than homeostasis, it would be interesting to 
test this in our in vitro model as well. One method to test barrier repair would be to damage the 
epidermal barrier in vitro with chemicals (e.g. SDS) or mechanically (e.g. liquid nitrogen) and 
then analyse duration and quality of epidermal barrier repair in LCE3B/C wild type and deleted 
equivalents.
As mentioned before, the strength of using defined primary keratinocytes of a certain genotype 
is that we elegantly avoid inefficient, incomplete genetic modification (e.g. knockdown or 
overexpression) that often bears the risk of off-target effects. However, the obvious great 
limitation of primary cells is that we can only use naturally occurring genotypes. For the LCEs, 
and especially with regard to its association with psoriasis, the use of LCE3B/C-deleted 
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keratinocytes was of great value for this research. Actually, to better understand the role 
and function of other LCE subgroups or individual members, the use of genetically modified 
keratinocytes e.g. missing or overexpressing these genes would be a fantastic tool for further 
research. The recently discovered and quickly developing ‘clustered, regularly interspaced, 
short palindromic repeat’-Cas9 (CRISPR-Cas9)365 system would be a great tool to selectively 
modify the LCE locus. We could delete different LCEs and then analyse epidermal development, 
stratification, differentiation, barrier function in our 3D epidermal equivalents to better define 
the role of the specific genes in the epidermis. As we have shown that LCE3A is increased in 
LCE3B/C deleted skin I suggest to investigate the loss of LCE3A in LCE3B/C wild type but also 
LCE3B/C-deleted keratinocytes. This would elucidate whether LCE3A in particular is needed 
for compensation of the loss of LCE3B and C and whether this individual LCE member has a 
crucial role in the epidermis. Therefore, in my future studies I aim to apply the CRISPR-Cas9 
system in our keratinocyte cultures. Due to the short culture and passaging capacity of primary 
keratinocytes, we will need to switch to an alternative cell source. At the moment, we are testing 
and validating the quality and similarity of N/TERT keratinocyte cell lines compared to in vivo skin 
and our primary keratinocyte-based monolayer and 3D epidermal equivalent model (data not 
shown). The N/TERT cell lines have a LCE3B/C wild type genotype, so this cell line is suitable for 
my intended LCE gene editing purposes.
Taking all new findings into account, I would now like to address the causality between the deletion 
of LCE3B/C and the increased risk for psoriasis. We found that the deletion of LCE3B/C causes 
the flanking LCE3A gene to be significantly induced in normal skin. Yet, we can only speculate 
about how this is happening. We know that there are DNA regulatory elements within the 32 kB 
of DNA that are lost with the deletion293,366. This not only comprises LCE3B and LCE3C but also 
additional flanking and intermediate DNA. It would be very interesting to be able to genetically 
modify these elements, e.g. with CRISPR-Cas9 to determine if the loss of such elements is 
responsible for the altered expression of LCE3A. This would suggest that the risk factor for 
psoriasis LCE3B/C-del is not only a risk factor due to the loss of these two genes, and encoded 
proteins, but also comprise a dysregulated expression of LCE3A, which will be discussed below. 
Moreover, altered genetic architecture due to the loss of this DNA locus could interfere with 
expression regulation. Chromatin conformation is tightly regulated and might well be affected by 
the loss of this amount of DNA. Techniques like chromosome conformation capture could give 
valuable information on the LCE3B/C genotype dependent modifications. 
In our research, we have also unravelled the yet unknown function of the LCE proteins 3A, 
3B and 3C (the rest is still under investigation) and identified a broad-spectrum antimicrobial 
activity of these LCEs. We therefore see the LCE proteins as a novel class of cutaneous host 
defense molecules. LCE3A protein showed the strongest activity as it killed bacteria at low 
concentrations. When we combine these two major findings: increased expression of LCE3A in 
healthy LCE3B/C deleted skin, and the antimicrobial function of the LCE proteins, and especially 
LCE3A, we believe to have found a clue to the causality between this genetic risk factor and 
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psoriasis. Carriers of the homozygous deletion express high amounts of LCE3A mRNA. In 
normal skin, the gene expression of LCE3A, LCE3B and LCE3C is very low to absent, therefore 
the induction of LCE3A in LCE3B/C-deleted carriers causes an overcompensating amount of 
these LCE3 genes. Presuming that expressed mRNA is translated into protein, which obviously 
needs to be validated, normal skin of the LCE3B/C-del genotype would express higher levels of 
LCE3(A) antimicrobial protein. However, we do not know yet the function of LCE3D and LCE3E, 
the other two members of the LCE3 subgroup. These are expressed to a higher extent in normal 
wild type skin. It needs to be investigated if LCE3D and LCE3E are also antimicrobial and to 
the same extent and specificity as LCE3A protein. We now know that LCE3A protein can kill a 
very broad range of bacteria, not only pathogenic but also commensal ones. Consequently, we 
hypothesize that carriers of LCE3B/C-del might have alterations of their cutaneous microbiome 
due to an altered LCE3 expression profile compared to wild type. Future research will show 
whether this is true. We aim to perform microbiome analysis of healthy skin of all three LCE3B/C 
genotypes to investigate if there is a correlation between the loss of LCE3B and LCE3C and the 
diversity and composition of skin microbiota. Obviously, this phenomenon is present in normal 
skin and does not yet explain the causality to psoriasis. We believe that a dysregulated microbiome 
does not necessarily leads to psoriasis, but that it is a predisposing factor that increases the risk for 
psoriasis. This is also apparent from the Odds Ratios (OR) for the LCE3B/C deletion on psoriasis, 
which is 1.4 and definitely is not explaining all psoriasis carriers. Psoriasis is a multifactorial, 
polygenic disease, meaning not one trigger can explain all cases. We think that additional triggers 
can cause psoriasis onset in LCE3B/C deleted carriers. Different studies have shown the epistatic 
link between LCE3B/C-del and the strongest risk factor for psoriasis HLA-C*06:02103,105,301,328,347,348. 
First of all, it will therefore be interesting to see whether we also see microbiome profiles dependent 
of not only the LCE3B/C but also the HLA-C*06:02 genotype, and especially the combination 
of both. The main question is what might be the link between these two genetic risk factors, 
contributing to a significant proportion of the population, and the risk for psoriasis? Speculatively, 
LCE3B/C-del dependent shifts in the microbiome could favour a HLA-C*06:02 restricted immune 
response towards certain microbiological epitopes. So far, HLA-C*06:02-binding peptides have 
not been identified in psoriasis patients. It would be intriguing to see whether any bacterial, or 
other microorganism-derived, peptides are differentially present in the microbiome of LCE3B/C 
deleted individuals, and fit into this specific HLA molecule. Alternatively, these peptides could be 
homologous to any keratinocyte, or skin-expressed, proteins. This hypothesis is supported by 
the finding that psoriatic T-cells primed against streptococcal M protein antigens can cross-react 
with keratinocyte-expressed keratin proteins367,368. This molecular mimicry can cause an auto-
inflammatory response in healthy skin, which in turn might be the onset for psoriasis. Moreover, 
it has been shown that psoriasis onset and disease exacerbation often follows a streptococcal 
throat infection93,94. With regard to the higher baseline expression levels of LCE3 members in the 
oral cavity this is a very interesting observation. We have seen that the LCE3B/C deletion increases 
LCE3A in the epidermis, but we do not know if this holds true in oral epithelia. If this increase is due 
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to DNA regulatory changes, this could be true for oral epithelia as well. It would be interesting to 
determine the expression levels of LCE genes of LCE3B/C wild type and deleted oral epithelia and 
to investigate whether LCE3B/C mediated changes do affect the overall expression levels of LCE3 
proteins. Consequently, not only the cutaneous, but also the oral microbiome would be interesting 
to analyse for LCE3B/C genotype dependent alterations, as this is one of the favourable body 
regions for bacteria like the psoriasis-associated streptococci.
Figure 2. Schematic illustration of the (hypothetic) relation between the LCE3B/C deletion and 
psoriasis risk. 
Carriers of the LCE3B/C wild type genotype express only low levels of the LCE3 antimicrobial peptides. 
The composition of their microbiome is in a healthy homeostasis and therefore there is no activation of 
immune cells in the epidermis. Deletion of LCE3B/C induces the presence of LCE3A in the epidermis and 
due to its antimicrobial activity, this might lead to a slight alteration of the cutaneous microbiome. As the 
deletion of LCE3B/C has rapidly spread among the population, this alteration may in itself be associated 
with an evolutionary advantage. The other side of the coin may be an increased susceptibility to psoriasis. 
Hypothetically, specifi c microbe-expressed peptides are recognized by the psoriasis-associated MHC variant 
HLA-C*06:02 and presented to T-cells to induce a specifi c immune response. Th1 and Th17 cytokines are 
secreted and these in turn will lead to even higher levels of LCE3 proteins in particular. Thereby the LCE3B/C 
deletion alone, or even stronger in combination with HLA-C*06:02, will lead to the characteristic psoriatic 
skin infl ammation. 
Earlier research speculated that the LCE3B/C deletion leads to impaired skin barrier repair. We 
have shown that the loss of LCE3B/C at least does not lead to barrier impairment. It yet remains 
to be investigated whether barrier repair, and not barrier function as such, is altered due to the 
deletion of LCE3B/C. This would be an interesting question for future research.
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Altogether, I believe that we have valuable knowledge to the understanding of the role of the late 
cornified envelope proteins in the epidermis and that we now have a glimpse on the underlying 
mechanistic link between the LCE3B/C deletion and psoriasis (Figure 2). Future research, as 
described here in my thesis, will add to this knowledge and contribute to the understanding of 
the biology and genetics of psoriasis.
Final considerations
In this thesis, I have shown that high quality 3D epidermal models of primary keratinocytes are a 
valuable tool for experimental dermatological research. These models are well suited to study the 
morphology, stratification, proliferation, differentiation and barrier function of the human epidermis. 
The opportunity to use patient-derived and genotypically defined keratinocytes makes this model 
especially useful to study the impact of genetic polymorphisms of keratinocyte-expressed proteins. 
We have demonstrated that these models can contribute to a better understanding of the genetics, 
biology and mechanisms of atopic dermatitis and psoriasis, the two model diseases we have used 
in this research. We were able to perform our experiments with a sufficient number of biological 
replicates and thereby limiting/avoiding the use of patient/animal material, which is clearly an 
advantage of our approach. 
With regard to the new insights that we have obtained in the biology of these two inflammatory 
skin diseases, we have shown that there appears to be a very specific balance and cross-talk 
between all skin compartments: the keratinocyte, the skin immune cells and the microbiome. 
They all together determine health or disease of our skin and we have shown here that defects 
in one of those compartments, in our case the keratinocytes, can disturb this balance leading to 
disease or at least higher disease susceptibility. Future research of the interactions between skin 
and its microbiome holds great promise for a better understanding of this interaction in human 
disease. 
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In hoofdstuk 1 van mijn proefschrift beschrijf ik de algemene opbouw en functie van de 
menselijke huid. Eén van de meest belangrijke functies van ons huidepitheel is het vormen van 
een barrière tussen de binnenkant van ons lichaam en onze omgeving. Deze barrière wordt 
gevormd door verschillende eiwitten en cel- of weefselstructuren die in deze epithelia aanwezig 
zijn. Deze dragen bij aan de fysieke, chemische, immunologische en microbiële huidbarrière. 
De meeste bestanddelen die bijdragen aan de huidbarrière bevinden zich in de volledig 
gedifferentieerde huidcellen, genaamd corneocyten. Meerdere lagen van deze cellen vormen 
samen het zogenaamde stratum corneum, ofwel de hoornlaag van de huid. In deze laag zijn 
onder andere filaggrine en de late cornified envelope (LCE) eiwitten aanwezig. Eerdere studies 
hebben gevonden dat mutaties in het filaggrine gen kunnen leiden tot een verhoogde kans op 
eczeem en dat een veel voorkomende afwijking in het LCE-gen locus is geassocieerd met het 
krijgen van psoriasis. 
Het onderzoeksdoel van dit proefschrift was om de onderliggende biologische mechanismen te 
onderzoeken die ervoor zorgen dat mutaties in de hierboven genoemde genen kunnen leiden 
tot het ontstaan van de huidziekten eczeem en psoriasis. De door ons onderzochte mutaties zijn 
niet slechts zogenaamde single-nucleotide polymorphisms (SNPs), in een niet-coderende regio 
van ons genoom, maar het zijn mutaties in een coderend deel van een gen die direct gevolgen 
hebben op de expressie en/of kwaliteit van het desbetreffende eiwit.  Daarom hebben wij in een 
hypothese-gerichte studie gekeken naar veranderingen in de werking van deze eiwitten om zo 
meer te leren over hun functie in de huid en hun bijdrage aan ziekte. Om de relatie tussen het 
genotype (de aan- of afwezigheid van een bepaalde mutatie), en het fenotype (de eventuele 
structurele of functionele veranderingen van de huid ten gevolge van de genmutatie), vast te 
stellen is een geschikt modelsysteem nodig. Om zowel praktische als ook ethische redenen is 
het uiteraard niet mogelijk om de analyses direct op humane huid van vrijwilligers of patiënten 
te doen. Daarom is het gebruik van laboratorium-modellen een waardevol alternatief. In de 
experimentele dermatologie maakt men hiervoor gebruik van huidkweken in een petrischaal 
(2D) of gelaagde (3D) huidmodellen. In hoofdstuk 2 hebben wij getest wat het effect is van 
het gebruik van antibiotica op deze huidmodellen. We hebben gevonden dat antibiotica, welke 
vaak standaard ter preventie van infectie worden toegevoegd aan celkweken, ervoor zorgen dat 
de groeisnelheid en kwaliteit van de huidmodellen worden verminderd. Sindsdien is het kweken 
zonder antibiotica de gouden standaard geworden op onze afdeling. 
Met behulp van ons 3D huidmodel hebben we de effecten van verschillende stoffen op 
epidermale uitrijping en differentiatie getest. Allereerst hebben wij in hoofdstuk 3 onderzocht 
of interleukine-9 (IL-9) invloed heeft op epidermale differentiatie en expressie van belangrijke 
huidbarrière-eiwitten. Deze interleukine werd namelijk recentelijk beschreven als additionele 
speler in de pathofysiologie van eczeem. We vonden dat IL-9 geen invloed heeft op de expressie 
van structurele huideiwitten, chemokines of cytokines in zowel normale 3D huid als in een 3D 
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huidmodel voor eczeem. Hieruit concludeerden wij dat de rol van IL-9 in eczeem een andere zal 
zijn dan de voor eczeem typische verstoorde epidermale differentiatie en barrièrefunctie. Twee 
andere factoren die geassocieerd zijn met eczeem, namelijk HMGB1 en IL-33 hebben wij ook 
getest in ons model (hoofdstuk 4). Ook hun effect op keratinocyten en epidermale uitrijping 
waren tot heden nog onbekend. Wij vonden dat IL-33, maar sterker nog HMGB1, de verminderde 
expressie van epidermale differentiatie genen en eiwitten veroorzaakt. Dit duidt erop dat deze 
moleculen betrokken kunnen zijn bij de verstoorde epidermale differentiatie in eczeem. 
Het tweede gedeelte van mijn proefschrift behandelt het verband tussen filaggrine mutaties en 
eczeem. Eerder is aangetoond dat zogenaamde “loss-of-function” mutaties in het filaggrine gen 
leiden tot het ontstaan van ichthyosis vulgaris en bovendien het risico verhogen voor het ontstaan 
van eczeem. Hoewel deze ontdekkingen al meer dan 10 jaar geleden zijn gedaan was tot heden 
niet bekend hoe deze genmutatie leidt tot ziekte. Eén van de typische kenmerken van eczeem is 
de verminderde huidbarrièrefunctie, in zowel de aangedane als ook de niet aangedane huid. Een 
algemeen geaccepteerd dogma, waarvoor echter nog geen goed bewijs bestond, was dan ook 
dat deze verstoorde huidbarrière wordt veroorzaakt door de filaggrine mutaties. In hoofdstuk 5 en 
6 hebben wij gebruik gemaakt van volledig filaggrine-deficiënte primaire keratinocyten afkomstig 
van ichthyosis vulgaris patiënten. In 3D huidmodellen, gemaakt van deze patiënten cellen, 
hebben wij onderzocht of er veranderingen zijn in de morfologie en expressie van differentiatie 
eiwitten. Verder hebben wij geanalyseerd of er veranderingen zijn in de huidbarrièrefunctie van 
deze 3D huidmodellen in vergelijking met 3D huidmodellen gemaakt van normale “gezonde” 
cellen. We vonden dat het missen van filaggrine op zichzelf geen enkel typisch eczeemkenmerk 
tot gevolg had, met betrekking tot de morfologie en functie van de epidermis. We vonden 
echter dat door het gemis van filaggrine de samenstelling van het huidmicrobioom, oftewel 
de populatie micro-organismen die voorkomt op onze huid veranderd. Het bleek dat bepaalde 
bacteriën, de zogenaamde Gram-positieve anaerobe cocci (GPAC), verminderd voorkomen op 
de huid van ichthyosis vulgaris patiënten die drager zijn van homozygote filaggrine mutaties, in 
vergelijking met de bacteriële samenstelling van gezonde vrijwilligers. Van deze GPAC-bacteriën 
is bekend dat zij afbraakproducten van onder andere filaggrine gebruiken als voedingsbron. 
Verder vonden wij dat deze bacteriën in staat zijn om keratinocyten aan te zetten tot een snelle 
afweerreactie, namelijk het aanmaken van antimicrobiële huideiwitten. Mogelijk draagt dit bij 
aan het verhoogde risico op eczeem en kolonisatie van huidpathogenen, zoals Staphylococcus 
aureus, voor dragers van filaggrine mutaties. 
In het laatste deel van dit proefschrift beschrijf ik het onderzoek naar de LCE eiwitten. De 
gendeletie, het verlies van DNA, van de twee genen LCE3B en LCE3C, is geassocieerd met 
een verhoogd risico op het ontwikkelen van psoriasis. Het hieraan ten grondslag liggende 
mechanisme, en in het algemeen de functie van deze en de overige 16 LCE eiwitten, is echter 
tot op heden niet bekend. Met specifieke antilichamen tegen twee subgroepen van de LCE 
eiwit familie, LCE2 en LCE3, hebben wij de expressie van deze eiwitten in kaart gebracht. In 
hoofdstuk 7 laat ik zien in welke lagen van de epidermis en andere gekeratiniseerde humane 
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epithelia deze LCE eiwitten tot expressie worden gebracht. Ondanks de zeer grote gelijkenis 
van de LCE eiwitten wat betreft hun aminozuurvolgorde, vonden wij dat de normale expressie 
en de regulatie van de verschillende LCE eiwitgroepen, bv in aangedane huid, verschillend 
is. LCE2 eiwitten bevinden zich uitsluitend in de bovenste nog levende huidlaag, het stratum 
granulosum, en de expressie is hier verlaagd in lesionale psoriasis huid vergeleken met normale 
huid. In tegenstelling tot LCE2, worden LCE3 eiwitten juist verhoogd tot expressie gebracht in 
aangedane psoriasis huid waar deze zich bevinden in het stratum spinosum tot aan de laatste 
laag van het stratum granulosum. Deze resultaten impliceren dat de verschillende LCE eiwitten 
in de huid waarschijnlijk ook verschillende functies hebben. In hoofdstuk 8 bestudeerden wij de 
relatie tussen de LCE3B/C-deletie en psoriasis en gingen op zoek naar de biologische functie 
van de LCE3 eiwitten in de huid. Een interessante bevinding was de sterk verhoogde expressie 
van het LCE3A gen, dat direct grenst aan het gedeleteerde stukje DNA, in de normale huid van 
individuen die drager zijn van een of twee LCE3B/C deleties, vergeleken met individuen die geen 
drager zijn van deze deletie. Wij vonden dit eerst in huidbiopten van gezonde vrijwilligers en 
psoriasispatiënten en hebben dit later bevestigd in normale en psoriasis 3D huidmodellen met 
keratinocyten van beide LCE3B/C genotypes. Voor het eerst sinds de ontdekking van de LCE 
eiwitten, hebben wij een functie voor deze huideiwitten gevonden. We toonden aan dat in vitro, 
LCE3A, LCE3B en LCE3C sterke antimicrobiële werking hebben tegen een breed scala aan 
bacteriën. Dit suggereert dat de LCE eiwitten belangrijk zijn in de antimicrobiële afweer van de 
huid. De veranderde expressie van met name LCE3A en de antibacteriële werking van de LCE 
eiwitten samen duiden er op dat de LCE3B/C deletie zorgt voor een veranderde antimicrobiële 
afweer en daardoor misschien een verstoring van het huidmicrobioom veroorzaakt. Toekomstig 
onderzoek moet zich daarom richten op deze nieuw ontdekte functie van de LCE eiwitten 
aangezien dit de tot heden onbekende link kan zijn tussen de LCE3B/C deletie en psoriasis. 
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In Kapitel 1 dieser Doktorarbeit beschreibe ich den generellen Aufbau und die Funktion der 
menschlichen Haut. Eine der wichtigsten Funktionen von Epithelgeweben, wie der Lederhaut, 
auch Epidermis genannt, ist dass sie die Barriere zwischen dem Körper und dessen Umgebung 
formt. Diese Barriere setzt sich aus den verschiedensten Proteinen und Strukturen der Epidermis 
zusammen und wird in die physische, die chemische, die immunologische und die mikrobielle 
Barriere unterteilt. Hauptsächlich befinden sich diese in oder auf den Korneocyten der obersten 
Hornschicht, das sogenannte Stratum Corneum. In dieser Hautschicht befinden sich auch 
Filaggrin und die Late Cornified Envelope (LCE) Proteine. Es ist bekannt, dass Mutationen 
in den Genen die diese Proteine codieren, zu entweder Ekzem (auch bekannt als Atopische 
Dermatitis) oder Schuppenflechte (auch bekannt als Psoriasis) führen können. Das Ziel dieser 
Forschungsarbeit war es, den Zusammenhang zwischen den oben genannten Gendefekten und 
dem Auftreten beider genannter Hautkrankheiten, besser zu verstehen. Die Mutationen betreffen 
keine SNPs (single-nucleotide polymorphims), in nicht-codierenden Bereichen der menschlichen 
DNA, sondern liegen in der codierenden DNA Sequenz und beeinflussen deshalb direkt das 
hieraus abgeleitete Protein. Aus diesem Grund haben wir die funktionalen Konsequenzen dieser 
Mutationen in Hypothese-gerichteten Experimenten erforscht. 
Um den Zusammenhang zwischen dem spezifischen Genotyp, und dem Haut-Phenotyp, die 
Morphologie und Funktion der Haut, zu bestimmen, benötigt man zunächst ein geeignetes 
Modell. Aus sowohl praktischen als auch ethischen Gründen können die dazu notwendigen 
Experimente nicht direkt an menschlicher Haut ausgeführt werden. Als Alternative werden für die 
experimentelle Hautforschung oft in vitro, also im Labor erzeugte, Hautmodelle verwendet. Es 
geht hierbei sowohl um konventionelle einlagige Zellkulturen (2D) als auch um mehrschichtige 
Modelle (3D), wobei aus Keratinozyten eine vollständige Epidermis kultiviert werden kann. In 
Kapitel 2 beschreibe ich, dass sich die Zugabe von Antibiotika, welche oft standardmäßig 
zur Infektionsprävention angewendet wird, nachteilig auf Wachstum und die Qualität der 3D 
Hautmodelle auswirken kann.
Mit Hilfe der 3D Hautmodelle können wir den Effekt bestimmter Stoffe auf die Entwicklung und 
Reifung der Epidermis analysieren. In Kapitel 3 erläutere ich den Einfluss von Interleukin-9 (IL-
9) auf die Reifung und das Vorkommen von epidermalen Proteinen, welche für die terminale 
Differenzierung und die Barriere Funktion wichtig sind. IL-9 wurde kürzlich als ein Faktor 
beschrieben, der eine zusätzliche Rolle in der Pathophysiologie von Ekzem spielt. Wir haben 
gezeigt, dass in sowohl normalen als auch Ekzem-ähnlichen Hautmodellen, IL-9 weder einen 
Effekt auf die Entwicklung und Morphologie der Haut, noch auf die Expression von Proteinen, 
Zytokinen oder Chemokinen hat. Wir gehen daher davon aus, dass IL-9 in Ekzem eine andere 
Funktion als die Beeinträchtigung der Differenzierung der Epidermis hat. Zwei weitere Stoffe 
die eine Rolle in Ekzem spielen, von denen jedoch der genaue Zusammenhang zwischen 
einem erhöhten Expressionslevel und dieser Hautkrankheit nicht bekannt ist, sind Interleukin-33 
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und HMGB1. Diese Stoffe haben wir ebenfalls in unserem 3D Hautmodell getestet (Kapitel 
4). Wir konnten feststellen, dass beide Faktoren, vor allem HMGB1, dafür sorgen, dass 
Hautdifferenzierungsproteine verringert werden und vermuten daher, dass diese Stoffe zur 
beeinträchtigten epidermalen Reifung bei Ekzem beitragen.
Der zweite Teil dieser Doktorarbeit behandelt hauptsächlich Filaggrin-Mutationen und Ekzem. 
Studien haben gezeigt, dass Mutationen im Filaggrin-Gen verantwortlich sind für die Hautkrankheit 
Ichthyosis vulgaris, und dass diese das Risiko für Ekzem erhöhen. Obwohl diese Erkenntnisse 
bereits vor etwa 10 Jahren gewonnen wurden, ist der kausale Zusammenhang zwischen 
diesen Mutationen und der Krankheit bisher nicht bekannt. Eines der wichtigsten Merkmale von 
Ekzem Patienten ist die verschlechterte Hautbarriere Funktion in entzündeter, sowohl aus auch 
gesunder Haut. Ein weit verbreitetes Dogma ist daher, dass Filaggrin-Mutationen der Grund 
dafür sind. Eindeutige Erkenntnisse fehlten jedoch bislang. In Kapitel 5 haben wir in unserem 3D 
Hautmodell primäre Keratinozyten von Ichtyosis vulgaris Patienten getestet, die einen genetisch 
definierten vollständigen Fillagrin-Defizit aufweisen. Wir haben die Ergebnisse mit Modellen von 
normaler Haut, ohne Mangel von Fillagrin, verglichen und analysiert ob Veränderungen in der 
Reifung und vor allem in der funktionellen Hautbarriere vorliegen. Interessanterweise konnte 
gezeigt werden, dass das Fehlen von Fillagrin Protein keinen Einfluss auf die Keratinozyt-
betreffenden Merkmale von Ekzem, und diese Modelle sogar eine vergleichbare Hautbarriere 
aufweisen. Daraus konnten wir schließen das Filaggrin-Mutationen, und damit der Verlust von 
Filaggrin, nicht die alleinige Ursache der verminderten Hautbarriere von Ekzem Patienten sein 
kann. Zudem konnten wir mit Hilfe der Mikrobiomanalyse herausfinden, dass Menschen mit 
Filaggrin-Mutationen eine veränderte Zusammenstellung der Bakterien haben die auf ihrer Haut 
leben. Unsere Analysen haben gezeigt, dass die Anzahl an gram-positiven, anaeroben Kokken 
(GPAC’s) auf der Haut von Trägern der Filaggrin-Mutation geringer ist als in der Kontrollgruppe. 
Diese Art von Bakterien ernährt sich von Stoffen die beim Abbau von Filaggrin und anderen 
Proteinen entstehen. Darüber hinaus konnten wir feststellen, dass genau diese Bakterien in 
der Lage sind in Keratinozyten eine schnelle Reaktion hervor zu rufen, bei der antimikrobielle 
Abwehrstoffe produziert werden. Zusammengefasst deuten diese Ergebnisse darauf hin, dass 
Filaggrin-Mutationen zu einem veränderten Haut-Mikrobiom führen und Folge dessen eine 
verminderte antibakterielle Abwehrreaktion in der Haut stattfindet. Möglicherweise ist dies der 
kausale Zusammenhang zwischen Filaggrin- Mutationen und Ekzem. 
Im letzten Abschnitt dieser Doktorarbeit behandele ich die Late Cornified Envelope (LCE) 
Proteine. Die Deletion von LCE3B und LCE3C wird mit einem erhöhten Risiko für Schuppenflechte 
assoziiert. Sowohl der genaue Zusammenhang, als auch die generelle biologische Funktion 
dieser, und der anderen 16 LCE Proteine, ist jedoch bis heute nicht bekannt. Mit spezifischen 
Antikörpern gegen LCE2 und LCE3 Proteine haben wir die Expression in der Epidermis und in 
anderen humanen keratinisierenden Epithelen getestet (Kapitel 7). Wir konnten zeigen, dass 
diese Proteine, trotz ihrer besonders hohen Homologie, verschieden exprimiert werden. LCE2 
Proteine befinden sich ausschließlich in der letzten Zellschicht des Stratum Granulosum und 
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werden in psoriatischer Haut verringert exprimiert. LCE3 Proteine werden dahingegen auch in 
tieferen Lagen der Epidermis exprimiert (vom Stratum Spinosum bis zum Stratum Granulosum) 
und kommen gerade in der psoriatischen Haut vermehrt vor. Hieraus lässt sich ableiten, dass 
die verschiedenen LCE Proteine trotz sehr ähnlichem Aufbau, unterschiedliche Funktionen in 
der Epidermis aufweisen. In Kapitel 8 haben wir darüber hinaus versucht den Link zwischen 
der LCE3B/C Deletion und der Entstehung von Schuppenflechte zu finden. Zudem wurde die 
biologische Funktion dieser Proteine in der Epidermis untersucht. Eine überraschende Erkenntnis 
war, dass die mRNA Expression von LCE3A, dem Gen welches direkt an den LCE3B/C DNA-Lokus 
angrenzt, bei gesunden Menschen, die die LCE3B/C Deletion aufweisen, stark erhöht ist. Wir 
haben diese Ergebnisse nach dem in vivo Befund zusätzlich in vitro in unseren 3D Hautmodellen 
bestätigen können. Zudem konnten wir als erste überhaupt eine Funktion der bisher noch wenig 
erforschten LCE Proteine herausfinden. Wir haben festgestellt, dass LCE3A, LCE3B und LCE3C 
stark antibakteriell gegen eine Vielzahl verschiedener Bakterien wirken und somit in unserer 
Haut wahrscheinlich eine wichtige Rolle zur Abwehr gegen Bakterien spielen. Zusammengefasst 
lässt sich sagen, dass eine hohe Wahrscheinlichkeit besteht, dass die LCE3B/C Deletion durch 
veränderte Expression von LCE3A dafür sorgt, dass das Haut-Mikrobiom verändert wird. Dies 
ist möglicherweise der Zusammenhang zwischen dieser Genmutation und dem erhöhten Risiko 
für Schuppenflechte.
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en gestructureerd werkt als jij, en die zo tot in de details elke dubbele spatie en andere tikfouten uit 
manuscripten kan halen als jij. Dus naast de waardevolle inhoudelijke inbreng bij besprekingen 
etc. heb jij er ook mede voor gezorgd dat de hoofdstukken van dit boekje zo strak er uit zijn 
komen te zien . Maar buiten jouw vaardigheden als onderzoeker en begeleider ben je vooral 
ook een fijne, hele directe, bijzonder humorvolle en supergezellige collega. Ellen en ik hebben 
ons (bijna altijd 😊) graag laten afleiden door jouw bezoekjes aan onze kamer, op de maandag 
ochtend voor het bespreken van het weekend, of tegen het einde van de dag als jouw batterijen 
soms begonnen op te raken. Vooral dan was jouw humor en jouw grappen (exclusief die over 
Duitsers 😊) een leuke aanvulling op een lange werkdag op het lab. 
Lieve Ellen, we hebben inmiddels al een lange weg hier samen afgelegd. Je werd mijn stage 
begeleidster, daarna mede-OIO en nu ben je ook mijn co-promotor. Van begin af aan heb ik jou 
bewonderd om jouw inzet, enthousiasme en enorme passie voor het onderzoek. Niet alleen voor 
mij, maar voor menig andere jonge onderzoeker zal jij een voorbeeld zijn. Tijdens mijn stage 
heb jij me enthousiast en nieuwsgierig gemaakt naar het onderzoek en heb ik al veel geleerd 
van jou. Ik was apetrots dat ik daarna hier aan mijn PhD traject mocht beginnen. Sindsdien zijn 
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wij collega’s en kamergenootjes. Dat is niet alleen handig omdat ik jou altijd om advies en hulp 
kan vragen, maar vooral supergezellig. Bedankt voor alles wat ik van jou heb mogen leren en de 
kansen die je mij hebt gegeven. Ik wens je veel succes met jouw verdere carrière, ik weet zeker 
dat jij het nog ver gaat schoppen.
Prof. van de Kerkhof, als hoofd van onze afdeling mag u zeker niet ontbreken. Hoewel wij voor 
mijn promotie maar weinig directe raakvlakken hebben gehad, bent u toch op belangrijk geweest 
voor mijn onderzoek. Als afdelingshoofd besteedt u niet alleen aandacht aan de patiëntenzorg, 
maar heeft u ook het wetenschappelijke onderzoek hoog in het vaandel staan. De combinatie 
hiervan op onze afdeling is bijzonder waardevol. Bedankt dat ik hier deel van heb mogen zijn. 
Diana en Ivonne, mijn lieve paranimfen, ik wil jullie van harte bedanken dat jullie op de grote 
dag naast me staan. Dat ik jullie zou vragen om mijn paranimfen te worden dat weet ik al heel 
lang. Ik will jullie van harte bedanken voor al die inzet, werkuren, bloed, zweet en soms tranen 
die ook jullie in het onderzoek voor dit proefschrift hebben gestoken. Diana, wat hebben wij 
vele uren samen in de kweek gezeten…we hebben ontelbare uren cellen opgewerkt, gezaaid 
en weer geoogst. Met niemand anders heb ik zo veel samen gewerkt tijdens mijn promotie als 
met jou en ik heb ervan genoten. We hebben onze ups en downs gehad, en zijn af en toe door 
problemen in de kweek fors op de proef gesteld. Gelukkig hebben we elke horde uiteindelijk 
genomen en hebben we samen veel mooie resultaten geboekt. Jij staat altijd klaar om te helpen 
en dat waardeer ik enorm.  Ivonne, ook jij hebt mij ontzettend veel werk uit handen genomen en 
daarvoor wil ik jou bedanken. Jij verzet moeiteloos de grootste bergen aan kleuringen en andere 
klussen en niks is jou te veel. Ik heb je nooit twee keer om hulp hoeven vragen of je stond al 
klaar om te beginnen. Jouw ervaring en expertise op het gebied van histologie hebben ook bij 
dit boekje bijgedragen om prachtige plaatjes te kunnen maken van hetgeen waar we onderzoek 
naar doen. Samenwerken met jou was niet alleen bijzonder productief maar ook vooral heel erg 
leuk en gezellig. Wij gaan er samen een mooie dag van maken en ik kijk er al naar uit om met 
jullie beide ook de komende jaren nauw te blijven samenwerken. 
Lieve labmaatjes, Patrick, Jos, Danique, Gijs en Malou ook jullie wil ik van harte bedanken! Ik 
ben blij dat wij als groep met z’n allen zo fijn samenwerken. Iedereen heeft zijn eigen project, 
maar toch helpen we elkaar waar nodig en profiteren wij van elkaars expertise. En bovendien 
is het altijd reuze gezellig samen op het lab, in de koffiekamer en op congressen… Eigenlijk 
bij elke gelegenheid die we samen hebben. Patrick, jouw kennis, kunde en oplossingsgericht 
denken zijn goud waard en daarom gebruik ik je maar al te graag als vraagbaak bij lastige 
labzaken. Een ander talent waar jij bekend om staat zijn jouw woordgrappen, ook die zou ik 
niet willen missen bij ons op werk. Jos, leuk dat je ons team als mede-OIO kwam versterken. Jij 
bent rustig en hardwerkend je en laat je nooit gek maken, niet door drukte of tegenslag binnen 
jouw project en ook zeker niet door al het vrouwelijke geklets en gegiechel in de koffiekamer. 
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Ik wens je veel succes met het afronden van jouw proefschrift, het wordt vast een masterpiece. 
Danique, onze one-of-the-guys girl. Jij bent inmiddels ook al een hele poos deel van ons lab 
en bent de expert voor ons bacteriën-werk. Moeiteloos en met enorme precisie verricht je grote 
hoeveelheden assays en analyses en dat was zeker ook voor het laatste hoofdstuk van mijn 
proefschrift bijzonder waardevol. Bedankt voor jouw inzet, altijd bereidwillige hulp. Ook jou 
wens ik veel succes met het afronden van jouw promotie. Gijs, jouw eerste promotie heb je al 
behaald, je promoveerde van analist naar PhD. Dat je gevraagd bent om dit te gaan doen zegt 
al hoe goed je bent in wat je doet. Als mede-kweker werken we geregeld samen en dat is altijd 
gezellig. Leuk dat je de komende jaren bij ons blijft en ook jou wens ik heel veel succes met je 
promotietraject. Lieve Malou, ja ook hier was weer de vraag, hoort ze bij het lab of hoort ze meer 
bij de klinische onderzoekers…maar je weet dat ik je altijd als een deel van ons heb gezien, 
dus vandaar ook deze plek in het dankwoord. Ik begon mijn PhD onderzoek naast jou in ons 
“studentenhokje” en vond dat van begin af aan heel erg gezellig. Je bent een harde werker, weet 
wat je wilt en hoe je dat kunt bereiken, daar mag je trots op zijn. Jouw expertise en inzet in de 
beeldvormende technieken zijn een aanwinst voor de dermatologie. Ik wens jou van harte dat je 
hier nog veel mee zult bereiken en je jouw visies werkelijkheid kunt laten worden. En ik kijk al uit 
naar de komende NVED’s met jou als kamergenootje. 
Piet, ook jij hebt me in de afgelopen jaren menigmaal geholpen, met betrekking tot mijn 
onderzoek, en daarnaast vaak ook met technische zaken. Jij was er altijd om te helpen als ik 
er weer niet uit kwam met de computer, de microscoop of om te adviseren op het gebied van 
biofysische metingen aan de huid en de nieuwste ontwikkelingen hiervan. Dankjewel.
Esther, officieel hoor je niet bij onze afdeling, maar inofficieel maak je zeker wel deel uit van 
ons lab. Je komt altijd goed gemutst het lab op en daardoor is het steeds gezellig om met 
jou een praatje te maken tijdens de kleuringen. Ik hoop dat er ook in de toekomst nog veel 
immunohistochemie op jouw to-do lijst staat, zodat je nog heel lang gezellig bij ons komt 
aanschuiven.
Wiljan, ook voor jou geldt mijn grote dank. Jij hebt met jouw (moleculaire) expertise bijgedragen 
aan het onderzoek van dit proefschrift. Ik sta altijd weer versteld van de schat aan de kennis die 
jij hebt en heb enorm veel van jou geleerd. Onze maandelijkse besprekingen zijn een verrijking 
voor ons onderzoek en ik zou dat graag ook in de toekomst willen voortzetten. 
Denise, thank you for helping me with the different physical measurements on our 3D skin 
models and the time you spend here with me during the weekend to analyse a bunch of samples 
with the Raman. I wish you all the best with finishing your thesis and your future career. 
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Judith, Ferry en Merel, jullie zou ik kunnen omschrijven als mede-LCE-onderzoekers. Judith, van 
jou heb ik het stokje overgenomen toen ik begon aan mijn promotie. Niet voor niets zijn jouw 
prachtige artikelen in dit proefschrift misschien wel het meest geciteerd. Jouw onderzoek was 
de basis voor de projectaanvraag die geschreven en toegekend is waardoor ik, naast Ferry en 
later Merel, het onderzoek naar de LCE eiwitten hebben kunnen voortzetten. Ik vond het een 
feest om met jou samen te werken en jou te leren kennen als een energieke, vrolijke en lieve 
collega en ik vond het daarom ook erg jammer dat jij ons een aantal jaar geleden hebt verlaten. 
Des te leuker dat we elkaar niet helemaal uit het oog zijn verloren. Ferry, jij kwam ons lab, en dan 
met name het LCE-onderzoek, versterken met veel moleculaire kennis en daadkracht. Wat heb 
jij in relatief korte tijd een hoop werk verzet. Jammer dat ook jij ons weer hebt verlaten, maar ik 
wens je heel veel succes en geluk in jouw carrière. Merel, toen kwam jij op Ferry’s plek in ons 
project werken aan de LCE’s. je paste gelijk goed in onze groep en was al snel een vertrouwde 
collega waarmee ik in de afgelopen jaren samen heb gewerkt en overlegd in onze talrijke LCE-
meetings. Ook jou wens ik een succesvolle en gelukkige toekomst toe. Kortom, ik wil jullie alle 
3 bedanken voor de inzet en bijdrage die jullie aan dit proefschrift en mijn passie voor de LCE’s 
hebben geleverd. 
Elkie, wat hebben wij, samen met Ellen, op onze kamer zitten lachen en lol gemaakt. Vanaf de 
eerste dag dat je bij ons kwam was het gezellig…zo gezellig dat we af en toe maar even de deur 
dicht hebben gedaan 😊. Het was een feest om jou als collega en roomie te hebben en ik vind het 
leuk dat je straks weer onze groep komt versterken. 
Uffe, you also joined our office for some months, and as with Elkie, it was fun right from the 
beginning. It was a fruitful collaboration for the short time that you visited us. Two papers included 
in this thesis are based on these few months of collaboration. Moreover, it was lots of fun and a 
pleasure to have you around. All the best for you and your career and it would be great to meet 
again.
Lieve Heleen, in het begin van mijn promotietraject hebben wij nog maar een korte tijd echt 
samengewerkt op het lab voordat jij begon aan de opleiding tot dermatoloog. Maar in die 
tijd heb ik jou leren kennen als ambitieuze en professionele onderzoeker en daarnaast als 
een lieve en betrokken collega. Bedankt voor de inspiratie die ik ook uit jouw proefschrift en 
promotieonderzoek heb kunnen halen. Ik wens jou heel veel succes en geluk als dermatoloog 
in de patiëntenzorg. 
Beste klinische onderzoekers, liefdevol ook onze bieb-collega’s genoemd, ook jullie hebben een 
belangrijke bijdrage gehad tijdens mijn promotie. Van jullie heb ik tijdens de talloze LOTTO’s en 
journal clubs de meer klinische en patiëntgerichte kant van het dermatologische onderzoek leren 
kennen. Ik leerde veel over o.a. psoriasis en eczeem, maar dan door de ogen van de patiënt en 
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de behandelaar. De combinatie van klinisch en lab-onderzoek is bijzonder waardevol en het was 
leuk dat ik beiden heb mogen mee maken. Bovendien was het steeds zeer gezellig met jullie, 
bv tijdens onze kerstborrel, paasbrunch, bierproeverijen en bij de jaarlijkse NVED meeting in 
Lunteren. Jullie zijn er te veel om op te noemen, maar ik wil iedereen van harte bedanken die ik 
de afgelopen jaren hier heb mogen mee maken.
Naast mijn directe collega’s en mensen waar ik mee samen op het lab heb gewerkt wil ik hier ook 
graag nog alle andere derma medewerkers bedanken voor de leuke tijd op de afdeling. Collega’s 
van de klinische staf, het secretariaat, de verpleging, de administratie, de arts-assistenten en de 
fotografie, ook jullie bedankt voor de fijne samenwerking, gezelligheid tijdens dagjes-Uit of leuke 
praatjes in de koffiekamer. Und Anja, danke für die deutsche Unterstützung wenn mal wieder die 
Witzbücher über unser schönes Nachbarland aufgeschlagen wurden 😉. 
Tijdens mijn promotie heb ik ook een aantal studenten mogen begeleiden en hun het werk als 
onderzoeker op het lab laten proeven. Philip, Marye, Emma, Ieke en Ellen, bedankt voor jullie 
inzet en bijdrage aan mijn onderzoek. Ik hoop dat jullie het net als ik ook als een mooie en 
leerzame tijd hebben ervaren. Ik wens jullie allemaal in elk veel succes voor de toekomst, zij het 
in de wetenschap of met heel een andere loopbaan. 
Ik wil hier ook graag nog iedereen bedanken die verder op enige manier heeft bijgedragen 
aan dit proefschrift. Elke collaborator, helpende hand, inspiratiebron of kritische stem heeft op 
zijn manier ervoor gezorgd dat dit proefschrift is geworden wat het nu is. Onderzoek doe je 
samen, dus zowel binnen als buiten onze groep zijn er mensen die mij hebben geholpen bij 
het experimenteren, analyseren en interpreteren van data en dat waardeer ik zeer. Een aantal 
mensen wil ik hier in het bijzonder noemen: Jo, Evelyn en Martin, Johanna und Ewa, Laura 
en Rob, Alex and JT, Tom en Sacha, Joke en Richard. Bedankt voor jullie fijne en productieve 
samenwerking. En wie weet zijn er nog gelegenheden voor meer gemeenschappelijke projecten 
in de toekomst. 
Hans en Sander, ook jullie wil ik hier bedanken. Ik kwam bij jullie terecht voor mijn eerste master 
stage, en heb toen voor het eerst écht mogen proeven wat onderzoek doen betekent. Daarna 
wist ik het zeker, onderzoek doen, en dan het liefst werken met cel- en weefselkweek, is wat ik 
in de toekomst wil gaan doen…en zo is het uiteindelijk ook gekomen. Bedankt voor jullie hulp 
en begeleiding en bovendien ook voor de gezelligheid. Naast het werken op een lab heb ik 
namelijk ook al bij jullie op het lab mogen mee maken hoe fijn de sfeer en collegialiteit op een 
onderzoeksafdeling kan zijn. Hans, ik ben blij dat jij mijn mentor wilde zijn tijdens mijn promotie, 
maar ik hoop dat jij niet teleurgesteld bent dat ik je hiervoor niet één keer nodig heb gehad. 
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Corien, wij leerden elkaar kennen tijdens mijn stage bij Orale Biologie en bleken uiteindelijk 
nog meer gemeenschappelijke raakvlakken te hebben. Ik ging voor mijn tweede stage naar 
Dermatologie, waar jij eerder ook al stage had gelopen. Daarna ging ik op zoek naar een OIO 
plek en kwam ik in eerste instantie ook uit waar jij later jouw promotie traject bent ingegaan. 
Uiteindelijk werkten wij allebei in het dermatologisch onderzoek. Ik vond het altijd heel gezellig 
om samen te lunchen en fijn om te kunnen sparren over de ervaringen en uitdagingen die zich 
voordoen tijdens een promotie. Ik wens je veel succes en vooral heel veel plezier met je nieuwe 
loopbaan en ik zou het leuk vinden als we ook in de toekomst onze lunchafspraken blijven 
aanhouden. 
So, jetzt zu euch meine Mädels…. Chris, Inga, Meike, Sarah, Tanja, Tina, Vera, Vroni und Wiebke 
(damit es keinen Streit gibt in alphabetischer Reihenfolge 😊). Ihr seid einfach die Besten und es 
ist jetzt mal an der Zeit euch Danke zu sagen für alles was ihr für mich gemacht habt und was 
ihr mir bedeutet. Wir kennen uns jetzt schon so lange, und haben schon so einiges zusammen 
erlebt (wenn man das alles aufschreiben würde, wäre das Buch sicher viel dicker als dieses hier 
😊). Ihr seid einfach immer für mich da, in guten und in schlechten Zeiten. Egal wie verstreut wir 
alle wohnen, wenn ich bei euch bin dann ist es immer wie zu Hause sein und egal wie lange 
wir uns mal nicht sehen, es fühlt sich jedes Mal an als ob es gestern gewesen wäre, dass wir 
uns verabschiedet haben. Unsere Freundschaft ist etwas ganz Besonderes und ich bin sehr 
glücklich, dass es euch gibt. Auch wenn ich euch nicht immer so gut erklären konnte was ich 
da im Labor eigentlich mach, wart ihr immer interessiert und habt meine kleinen und großen 
Erfolgserlebnisse mit mir gefeiert. Danke für eure Unterstützung und dass es euch gibt. Inga, 
danke dass du mir bei den Deutschen Texten geholfen hast. Ich muss zugeben da waren mehr 
Verbesserungen nötig als nur fehlende Punkte und Kommas. Wie ihr ja schon öfter festgestellt 
habt, ist es bei mir nach mittlerweile 10 Jahren hier in den Niederlanden manchmal so eine 
Sache mit der Deutschen Sprache. Aber wir verstehen uns ja zur Not irgendwann auch ohne 
Worte.
Judith, auch dir möchte ich hier Danke sagen. Wir kennen uns jetzt auch schon einige Jahre 
und haben viel zusammen erlebt. In den Jahren während meiner Doktorarbeit haben wir viel Zeit 
zusammen verbracht und ich habe mich immer gerne bei dir  von der Arbeit abgelenkt, mich bei 
dir ausgeheult und einfach gerne Zeit mit dir, und mit Rik, verbracht. Im letzten Jahr hatte ich mit 
der Fertigstellung  dieser Arbeit manchmal weniger Zeit für dich als ich es gerne gehabt hätte. 
Ich wünsche mir, dass wir das, auch wenn wir jetzt leider keine Nachbarinnen mehr sind, wieder 
öfter schaffen. Liebe Judith, en ook natuurlijk Rik (dat moet je maar even in het Duits lezen 😊), ich 
bin sehr froh, dass es euch gibt. 
Brenda, Martha, Vicky, Swinda, Judith, Viki, Christi, met jullie in de collegezalen begon eigenlijk 
mijn carrière in de wetenschap. Met jullie studeerde ik medische biologie en daar heb ik tot 
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vandaag nog geen seconde spijt van. Samen hebben we hard gewerkt, elkaar steeds geholpen 
en bovendien ook heel veel lol gehad. Als ik nu nog af en toe in het Huygensgebouw kom dan 
denk ik steeds met veel plezier terug aan deze tijd. Ik ben blij wij elkaar toen hebben leren 
kennen. Het afronden van mijn promotie voelt nu ook een beetje alsof ik heb behaald waar 
wij toen in 2007 samen aan zijn begon. Vanuit de biologie heeft iedereen van jullie uiteindelijk 
zijn eigen weg gekozen. Ik wens jullie allemaal veel succes met jullie loopbaan en net zo veel 
plezier uit jullie werk te halen als ik dat heb mogen hebben de afgelopen jaren. En vooral ook 
buiten het werk wens ik jullie heel veel geluk. Lieve Brenda, bijzonder dat jij het al die jaren hebt 
uitgehouden tussen ons Duitse dames 😊. Fijn dat jij als één van de weinigen nog hier in de 
buurt bent en wij elkaar nog regelmatig zien. Bedankt voor de fijne gesprekken en de leuke tijd 
die we steeds samen hebben. Jenny, du bist zwar keine von den „Bio-Mädels“, dennoch gehörst 
du auch an diese Stelle. Über deine damaligen Mitbewohnerinnen habe ich dich kennen gelernt 
und da bin ich ganz froh drüber. Auch dir wünsche ich ganz viel Erfolg für deine Karriere, aber so 
wie ich dich und deinen Enthusiasmus und Ehrgeiz kenne mache ich mir da gar keine Sorgen.
Ines, wir haben uns kennen gelernt bei einem Praktikum ganz am Anfang meines Studiums. Du 
warst eine der Praktikumsbegleiterinnen. Schnell danach haben wir uns dann aber nicht mehr 
nur an der Uni, sondern auch in unserer Freizeit getroffen. Wir haben seitdem schon so manche 
Abende zusammengesessen und über Studium, Bio, Forschung aber vor allem auch viele 
andere schöne Dinge gequatscht. Danke dafür. Schön, dass du auch deinen Weg gefunden 
hast und ich wünsche dir alles Gute für die Zukunft. 
Lieve Marianne en Arie, ook jullie wil ik van harte bedanken. Bij jullie en de rest van de familie 
voelde ik me vanaf de eerste dag heel erg welkom en ik ben blij dat ik hier deel van mag 
uitmaken. Het voelt alsof ik er naast jullie een hele boel ooms, tantes, neefjes en twee oma’s bij 
heb gekregen. Jullie twee wil ik bedanken voor het interesse in mijn werk en onderzoek, jullie 
steun en de heerlijke ontspannende weken bij jullie thuis op Aruba tijdens onze vakanties.
So, jetzt zu meinen großen Brüdern…Stefan und Christoph. Ich habe es endlich geschafft: der 
Dr. Titel ist in der Tasche und ich hoffe ihr seid ein bisschen stolz auf mich. Aber wie ich euch 
schon öfter gesagt habe, auch mit gelbem Nummernschild, holländischem Sprachfehler und 
jetzt auch mit dem Titel bleibe ich für euch immer eure kleine Schwester vom Brunnenweg, und 
das ist auch gut so. Schön, dass es euch gibt. 
Liebe Mama und Papa, bei euch möchte ich mich dafür bedanken, dass ihr mich mein ganzes 
Leben lang unterstützt habt. Ihr habt mich immer meinen Weg gehen lassen und mich wissen 
lassen, dass ihr hinter mir steht. Auch wenn meine Arbeit manchmal ziemlich kompliziert zu 
erklären war, und Mama oft mit dem Kopf geschüttelt hat, wenn ich ihr erzählt habe was ich 
während meines Arbeitstages so alles gemacht habe, habt ihr euch immer für meinen Job, und 
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mehr noch für wie es mir dabei geht, interessiert. Danke für eure Unterstützung und dafür, dass 
ihr einfach immer für mich da seid!
Oma, es hätte mir viel bedeutet, wenn du dies noch hättest miterleben dürfen. Ich bin mir sicher, 
du wärst stolz auf mich. 
Mijn lieve Martijn, na bijna 10 jaar ken jij mij als geen ander. Jij weet wat dit proefschrift voor 
mij betekent en dat ik met hart en ziel hieraan heb gewerkt. Je hebt naast me gestaan en me 
bijgestaan in goede en moeilijke tijden, wat betreft het werk maar ook daar buiten. Met heel mijn 
hart wil ik jou bedanken voor jouw steun en aanmoediging, en het eindeloze geduld dat jij altijd 
met mij hebt. Op momenten dat ik het even niet meer zag zitten wist jij me weer te motiveren en 
heb je mij met je aanstekelijke humor weer opgevrolijkt. Steeds heb je mij weer aangemoedigd 
en beloofd dat alles goed komt…en je had maar weer steeds gelijk. Ik ben trots en gelukkig dat 
jij bij mijn promotie naast me staat en dat wij de herinnering aan deze dag kunnen toevoegen 
aan alle mooie en bijzondere momenten die we al samen hebben beleefd en die er nog gaan 
komen. Dushi, ik kijk ontzettend uit naar de toekomst met jou!
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List of abbreviations
2D  two dimensional
3D   three dimensional 
AD  atopic dermatitis
AMP  antimicrobial peptide
CE  cornified envelope
CFU  colony forming unit
chr  chromosome
del  deletion
EDC   epidermal differentiation 
complex
eQTL    expression quantitative 
trait analysis
FLG  filaggrin
GPAC   gram-positive anaerobe 
cocci
GWAS   genome-wide association 
study
hBD  human beta defensin
HEE   human epidermal 
equivalent
H&E  haemtoxylin and eosin
HLA  human leukocyte antigen
IF  immunofluorescence
IL  interleukin
IV  ichthyosis vulgaris
LCE  late cornified envelope
LCE3B/C-del  deletion of 32 kB DNA 
including LCE3B and 
LCEC genes
LY  Lucifer yellow
NMF  natural moisturizing factor
NS  normal skin
OR   odds ratio
PS  psoriasis
qPCR    real-time quantitative 
polymerase chain reaction 
RNA-seq  RNA sequencing
SC  stratum corneum
SG  stratum granulosum
SNP    single nucleotide 
polymorphism
TEWL  transepidermal water loss
Th  T helper
TJ  tight junction 
wt  wild type
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